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Abstract 
Metal-based photoactivated chemotherapy (PACT) involves a class of metal-
based prodrugs, which may overcome the limitations and side effects of current 
metal-based chemotherapeutic agents on account of their novel mechanism(s) 
of action. In this thesis, a number of vibrational spectroscopic methods were 
developed and applied to study the mechanisms of metal-based PACT agents 
upon activation with light. 
A particularly promising PACT agent is the diazido Pt(IV) anticancer prodrug, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, py = pyrdine), in which photoinduced 
cleavage of ligands from platinum yields reactive species, which are likely 
implicated with the observed biological activity. However, monitoring the azido 
and hydroxido ligands, and the metal centre simultaneously remains 
challenging. Vibrational spectroscopy is a potentially powerful tool to study both 
metal and ligand vibrations without the requirement of labelling and is non-
destructive at the same time. The essential first step was the screening of 1 by 
a range of vibrational spectroscopic methods, including Attenuated Total 
Reflection Fourier Transform Infrared (ATR-FTIR), Raman and synchrotron 
radiation far-infrared (SR-FIR), aided by Density Functional Theory (DFT). This 
yielded an extensive vibrational fingerprint of 1 containing individual ligand 
(pyridine, hydroxide and azide) and platinum to ligand vibrations. The 
established methodologies provided the necessary basis for elucidating further 
photodecomposition and photoreaction pathways. 
Successive ATR-FTIR studies allowed for examinations of the 
photodecomposition of 1 complemented by transient electronic absorption and 
UV-Vis spectroscopy under 420 nm or 310 nm irradiation. Chemometric data 
evaluation using Principal Component Analysis (PCA) and Multi Curve 
Resolution Alternating Least Squares (MCR-ALS) on the steady state UV-Vis 
and ATR-FTIR spectra captured the formation of a Pt(II) intermediate, 
trans-[Pt(N3)(py)2(OH/H2O)] and a final product, trans-[Pt(py)2(OH/H2O)2], in 
which the trans pyridine scaffolds were retained. Upon irradiation, the rapid 
removal of the hydroxido stretching vibration was found to correlate to a shift in 
the anti-symmetric azido vibration, indicative of a possible second intermediate.
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Experimental evidence of subsequent azido dissociation from platinum 
suggests that at least one hydroxyl radical is formed in the reduction of Pt(IV) to 
Pt(II) under such conditions. Additionally, photoproducts formed upon irradiation 
of 1 in the presence of the DNA nucleotide 5’-guanosine monophosphate (5’-
GMP) could be systematically studied using ATR-FTIR, mass spectrometry and 
DFT calculations. 
Underpinning methodologies were subsequently applied to study a series of 
photoactivatable ruthenium-based CO releasing complexes of the formula 
[RuLCl2(CO)2] (L = 2,2’-bipyridine with 4’ methyl and/or carboxyl substituents). A 
three-step mechanism involving the sequential formation of 
[RuL(CO)(CH3CN)Cl2], [RuL(CH3CN)2Cl2] and [RuL(CH3CN)3Cl]+ was deduced 
upon 350 nm irradiation in acetonitrile. Rapid removal of the first CO ligand (k1 ≫ 3 min−1) and a modest rate for the second CO ligand (k2  = 0.099 – 0.17 
min−1) was observed, with slowest rates found for the electron-withdrawing 
carboxyl substituents. Aqueous media considerably slowed down the 
photodecarbonylation (k1  = 0.46 – 1.3 min−1 and k2  = 0.026 – 0.035 min−1) and 
the carboxyl groups were shown to have a less pronounced effect on the rate 
constants, revealing the possible implications for the design of such candidates 
intended for clinical application. 
State-of-the-art synchrotron based infrared spectroscopy was utilised with 
continued focus on the mechanism of action of 1. ATR-FTIR and synchrotron 
radiation far-infrared were combined (SR-ATR-FIR) to enable the rapid 
screening of samples, exposing changes to the metal to ligand vibrations of 1. 
Additionally, in situ irradiation using liquid transmission SR-FIR revealed the 
removal of in the platinum to oxygen (hydroxide) and platinum to nitrogen 
(azide) vibrations simultaneously. Moreover, a mid-infrared live single cell study 
of 1 on acute myeloid leukaemia cells (K562) by Synchrotron Radiation Infrared 
Microspectroscopy revealed significant changes to DNA base stacking and lipid 
vibrations after only four hours of low dose irradiation at 350 nm (2.58 J cm-2). 
Lastly, the low wavelength excitation of the earlier described photoactivatable 
metal-based anticancer prodrug candidates was considered, which commonly 
hamper their clinical feasibility. A range of lanthanide-doped upconverting 
nanoparticles (UCNPs) were synthesised, allowing for near-infrared light 
excitation and visible light emission as a potential platform for wavelength 
activation of PACT agents in a clinically-relevant window. 
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Chapter 1 
Scientific Introduction 
A general scientific introduction is provided in Chapter 1. Cancer is outlined first 
as this is the ultimate driving force behind this research. Chemotherapy, a 
principal form of treatment, is discussed next with a focus on the widely used 
metal-based anticancer drug, cisplatin (cis-[PtCl2(NH3)2], CDDP). The 
mechanism of action of cisplatin is explored in order to demonstrate the need to 
develop more effective drugs with significantly fewer side effects. Metal-based 
photoactivated chemotherapeutic agents, derived from cisplatin, may provide a 
solution, based on their novel mechanisms of action and an overview of the 
current understanding of a particularly potent diazido Pt(IV) prodrug follows, 
around which this thesis is centred. Subsequently, the use of vibrational 
spectroscopy as a potential powerful tool to deepen our understanding of the 
photophysical and photochemical properties of such photoactivatable metal-
based prodrugs is considered. Vibrational spectroscopy allows for direct 
observation of oscillating nuclei without the requirement of labelling and is non-
destructive at the same time. Approaches to measure both metal and ligand 
vibrations complemented by theoretical calculations and use of high intensity 
synchrotron radiation provide a broad platform to study the metal coordination 
environment of such drugs in great detail. Lastly, the practical boundary of 
requiring a light source to activate these drugs is discussed, in particular the 
potential use of upconverting nanoparticles as a platform for wavelength 
activation in a clinically-relevant window. 
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1.1 Cancer 
Cancer, in a broad consensus, is a genetic disease caused by an accumulation 
of mutations in the genome of somatic cells (all except reproductive cells).[1] 
Whilst the cellular origin of cancer was first deduced in 1863, it was only in 2005 
when the first decrease in the total number of deaths caused by cancer was 
reported.[2] Nevertheless, the global burden of cancer is estimated to rise 
rapidly, from an estimated amount 14.1 million new cases (and 8.2 million 
deaths) in 2012 to 21.7 million new cases (and 13 million deaths) in 2030.[3] A 
short overview is given below on our current understanding of the disease to 
give the reader a better comprehension of why it is so difficult to treat cancer. 
 
The near complete identification (~99%) of the human genome (i.e. the 
complete set of human DNA) was accomplished in 2004, capturing over 3 billion 
DNA basepairs.[4] This, and the advances of DNA sequencing technologies, 
facilitated the rapid systematic analysis of mutations fundamentally responsible 
for the origin and evolution of cancer tumours.[5] Shortly after, a census carried 
out by Wellcome Trust Sanger Institute in 2004, already revealed 291 human 
genes that are causally implicated with the development of cancer 
(oncogenesis).[6] To date, this census has extended to 567 human genes with 
over 540,000 different genetic mutations underlying human oncogenesis.[7] 
While the rapid extension of our knowledge of the underlying gene mutations is 
still on going, one can imagine the limitlessness of possibilities leading to 
different types of cancer. 
A multitude of mutations can cause cancerous cells to appear and take shape in 
the form of tumours. The crude view of a tumour would be to imagine multiple 
identical cancer cells clustered together (Figure 1.1A), which could in turn 
become invasive cancer cells by being released from this cluster and re-
entering the body’s blood stream where they can form distant metastasis 
(secondary malignant tumour growth away from the primary tumour). This is not 
entirely incorrect, however, as the biology of a cancerous tumour is more 
complicated to rationalise. Figure 1.1B shows a better representation of the 
tumour microenvironment. This microenvironment consists of cancer cells and 
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recruited normal cells corrupted by the cancer, which as a whole is responsible 
for tumour growth and progression.[8]  
 
Figure 1.1. (A) Schematic view of a cancerous tumour. (B) Tumour 
microenvironment with recruited and corrupted normal cells. Adapted from D. 
Hanahan and R. Weinberg. [8a,9 ] Reprinted with permission from Elsevier. 
 
Hanahan and Weinberg proposed the hallmarks of cancer in an effort to provide 
a coherent framework to understand the complicated diversity of tumour 
microenvironments and what they are capable of, underlying the disease cancer 
(Figure 1.2).[8a,9]  
In short, cancer cells can sustain their proliferative signalling pathways leading 
to chronic proliferation, whilst normal cells carefully regulate themselves to 
control their cell numbers. Human cells are capable of responding to 
unregulated growth by activation of growth suppressor genes. However, 
cancers are known to sufficiently stall or inactivate these growth suppression 
pathways, which would otherwise lead to growth arrest, senescence (aging) or 
apoptosis (cell suicide program).  
Additionally, obstruction or inactivation of the apoptotic cell program is often 
found to occur during cancer development, therefore making cancer capable of 
resisting cell death.[10] Enabling replicative immortality allows the cell to continue 
to grow and divide, whereas normal cells are only able to cycle through a limited 
amount of growth and division phases. In order to sustain this growth and 
multiplication of cells, angiogenesis (branching of blood and lymphatic vessels) 
is almost always induced to allow for the supply and evacuation of increasing 
demand of nutrients and metabolic waste. At the same time, reprogramming of 
the energy metabolism allows cancer to function under aerobic (like normal 
human cells), anaerobic or both conditions.[11]  
One might expect the human body’s immune system to reject cancer cells as a 
foreign entity, given its many mutations. The fact that there are clinically 
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detectable cancers that have avoided, evaded and/or supressed it, is the basis 
of the long standing theory of the interactions of cancer with the immune 
system.[12] Recent years have shown that, in many cases, there is a complex 
interaction between the immune system and the development of cancer, which 
can ultimately lead to either to eradication or evasion.[13] In line with the above is 
the incorporation of immune inflammatory cells in the tumour environment, 
capable of supplying bioactive molecules, which can supplement the 
progression of other hallmarks, such as growth and survival factors as well as 
reactive oxygen species that can accelerate the genetic evolution of cancer.[14] 
Furthermore, genome instability and mutation are the obvious, yet not to be 
forgotten hallmark, continuously driving cancer progression. 
Lastly, the invasion and development of metastasis can occur throughout the 
progression of the cancer, whereby detached cancer cells enter the lymphatic 
or blood system, spreading throughout the body and settling in distant tissues 
(the start of possibly another/secondary tumour).  
Most forms of human cancer develop these hallmarks to a certain degree and 
naturally vary between the different types of cancer. This makes them incredibly 
difficult to treat and while surgery and/or radiotherapy may successfully remove 
primary lesions of cancer, it often cannot treat the distant metastases. In such 
conditions, drug therapy (universally called chemotherapy) is usually 
considered. 
 
Figure 1.2. The hallmarks of cancer, providing a structured overview of acquired 
capabil it ies by developing cancers. Adapted from D. Hanahan and R. Weinberg.[8a] 
Reprinted with permission from Elsevier. 
New materials for anticancer imaging and therapy 
Chapter 1 Robbin R Vernooij 4 
 
1.2 Chemotherapy 
The application of chemotherapy in conjunction with surgery and radiotherapy 
started to develop between the 1940s and 1960s.[5,15] To date, there are over 
100 different chemotherapeutic agents approved in the US alone, which can be 
administered in multiple combinations, depending on the type of cancer, stage 
and conditions of the patient.[16] The shortcomings of most chemotherapeutic 
agents are unfortunately undeniable, whereby toxicity towards normal tissues of 
the body and inherent as well as acquired drug resistance hamper the clinical 
efficacy of chemotherapy. Therefore, there is on going effort to develop new 
and improve on long-standing chemotherapeutic agents. 
One particular field of chemotherapy is metal-based anticancer agents, which 
was stimulated by the discovery of the antiproliferative properties of cisplatin 
(CDDP, cis-[PtCl2(NH3)2]) in 1965.[17] Metal-based anticancer agents have a 
broad-spectrum of application in the clinics, with approximately 50% of all 
patients receiving a platinum based compound.[18] 
1.2.1 Metal-based Chemotherapy 
Prior to the discovery of the anticancer properties of cisplatin, the field of 
chemotherapy development consisted almost solely of organic and natural-
product chemistry.[19] One of the last remarks published in a paper by professor 
Barnett Rosenberg in 1971, the principal investigator on cisplatin as a 
chemotherapeutic agent, was: ‘Without hesitancy I suggest it is now appropriate 
for inorganic chemists to join their organic brothers in submitting samples of 
their syntheses to appropriate Cancer Institutes for screening for anti-tumour 
activities’.[20] This paper and his work are largely responsible for opening up the 
field of chemotherapy to metal-based agents and its rapid development. 
Continuous explorations of transition metal complexes have led to a range of 
clinically globally approved platinum complexes to date (Figure 1.3) and 
complexes based on other transition metals such as ruthenium undergoing 
clinical trials.[21] 
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Figure 1.3. Structures of clinically approved platinum anticancer drugs.  
 
Nevertheless, the efficacy of these drugs is limited by acquired and/or inherent 
resistance by cancer, restricting the applicable spectrum of chemotherapeutic 
agents, and the indiscriminate toxicity of drugs towards normal healthy cells, 
leading to severe long and short term side effects on patients.[5,15,22] 
It would be irrational to assume that each of these approved drugs has the 
same mechanism of action, although, one of the commonalities between them 
is that they rely on chemical activation. The mechanism of action of cisplatin will 
be used as the example below to provide a clear image, working towards new 
generations of anticancer drugs. 
Starting with cisplatin, the mechanism of action has been studied in detail over 
the past decades, whereby hydrolysis of one or two chlorido ligands results in 
the active species of cisplatin thought to induce the observed toxicity.[20,22b,23]  
Following Figure 1.4, intravenous injection or infusion of cisplatin into the 
bloodstream is stabilised by the high inherent chloride concentration (~100 mM) 
and can be co-administered with sodium chloride solutions at adjusted pH 
values between 3.5 – 4.5 (Figure 1.4).[16,19] This allows for the distribution of the 
relatively inactive cisplatin throughout the body, whereupon entry into the cell is 
attained by both active and passive uptake.[24] Cisplatin becomes susceptible to 
hydrolysis inside the cytoplasm due to the relative low intracellular 
concentration of chloride anions (4 – 20 mM) (Figure 1.4).[24d,25]  
Stepwise hydrolysis of cisplatin yields active charged Pt(II) species capable of 
binding to DNA base pairs, such as the most nucleophilic position of DNA, the 
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N7 position of the guanine base.[24d] The structural distortion caused by the 
formation of multiple intra- and interstrand DNA adducts sets in motion cell 
death pathways and hinders the transcription and replication of the cell (Figure 
1.4).[23l,24c,25] Typically, the cell cycle is halted in the G2 stage as a response to 
cisplatin-DNA adducts in an effort to repair the induced DNA damage by 
nucleotide excision repair (NER, replacement of 30-mer oligonucleotides 
containing cisplatin adducts with new oligonucleotides templated from the 
leftover single-stranded DNA).[22b] In the event of failed repair, for instance by 
the binding of high mobility group (HMG) proteins to 1,2 intrastrand (GpG) 
crosslinks of cisplatin blocking the NER, the cell initiates the cell death pathway 
referred to as apoptosis.[26] 
 
Figure 1.4. Simplif ied representation of the mechanism of action of cisplatin. 
Cellular uptake followed by stepwise hydrolysis/activation, binding of cisplatin to 
DNA and cellular processing leading to cell death (apoptosis).  
 
Unfortunately, besides the unselective uptake by healthy cells leading to severe 
short term and long term side effects, there are also many points between the 
bloodstream and the nucleus were cisplatin can be deactivated, i.e. chlorido 
ligand release and binding of platinum to other biological targets than DNA 
causing unwanted side effects (Figure 1.5). First, cisplatin (and Pt(II) in general) 
exhibits high affinity towards sulphur containing compounds. The most 
abundant protein in the human bloodstream, human serum albumin, can 
interact with cisplatin through thiols and thioethers from cysteine and 
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methionine residues respectively, even though the high concentration of 
chloride in the bloodstream reduces reactivity by suppressing hydrolysis (Figure 
1.5). [27]  
Second, the down-regulation of proteins associated with the active uptake (via 
copper or organic cation transportersors) and up regulation of efflux by copper 
transports, such as ATP7B, in response to high plasma concentrations of 
cisplatin can lead to decreased uptake or increase efflux of (activated) cisplatin 
(Figure 1.5).[24a,28] 
Third, increase in DNA repair or replicative bypassing of cisplatin-DNA adducts 
as a response to DNA damage recognition in cancer cells leads to decrease in 
cell death responses.[29] 
Last, and based on the same principle of the first point, is the elevated amounts 
of sulphur containing compounds inside the cancer cells, such as glutathione, 
methionine, metallothionein and proteins. The interaction of platinum 
compounds with proteins is not completely understood.[30] However, binding of 
the hydrolysed cisplatin to such compounds before reaching DNA causes 
cytoplasmic inactivation and is one of the biggest factors limiting the efficacy.[29]  
 
While the chemical activation by relative changes in chemical gradient is the 
underlying origin of the efficacy of metal-based agents like cisplatin, it is also 
this unselective activation that hampers the efficacy by dose limiting side 
effects.[31] 
Different research strategies to overcome these limitations have been 
formulated throughout the last decades, including exploration of metal 
complexes targeting intracellular proteins and biomolecular molecules outside 
of the nucleus, developing more kinetically inert, d6 low-spin, metal complexes 
and using carriers such as polymers and nanoparticles to improve 
delivery.[21,24d,32] 
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Figure 1.5. Schematic representation of possible deactivation pathways of 
cisplatin by intra- and extracellular conditions. Abbreviations used: CTR = copper 
transporters, GSH = glutathione, MT = metallothionein and OCT = organic cation 
transporter. Adapted with permission from Johnstone et al. [24d] Copyright 2013 
American Chemical Society. 
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1.3 Photoactivatable Anticancer Complexes 
One particular field of research has been focussing on replacing the chlorido 
ligands of metal complexes (responsible for biological selectivity) with ligands to 
yield metal complexes that are stable and inert in the dark, but can be released 
locally (replaced with physical selectivity) in selected areas where cancer is 
located in effort to address the severe side effects and resistance on account of 
their novel mechanism(s) of action. Metal complexes that utilise electromagnetic 
radiation to induce ligand release and the subsequent formation of active 
species to target cancer are commonly referred to as photoactivatable 
anticancer complexes and give rise to the field of inorganic photoactivated 
chemotherapy (PACT).[33] The temporal and spatial control over the activation of 
the drug has the advantages of only affecting the cancerous areas and builds 
on the clinically established field of photodynamic therapy (PDT), which has 
been used in the clinics for nearly three decades.[34] Photosensitizers are used 
in PDT to transfer the energy from light to ground state triplet oxygen (3O2), 
subsequently producing highly reactive singlet oxygen species (1O2), which are 
one of the main contributors to cell death from PDT treatment.[35] However, 
many malignant and most aggressive tumours are hypoxic by nature, which is a 
major drawback for PDT as it relies on the presence of oxygen.[36] PACT 
potentially offers an advantage over PDT in hypoxic conditions, as it exploits 
different mechanisms to induce cell death by active binding of metal- and 
ligand-based species formed upon light activation. 
 
1.3.1 Photoactivatable Anticancer Prodrug Cancidates 
A large variety of metal-based photoactivatable anticancer prodrugs (Co(II, III), 
Cu(II), Mn(I), Fe (II, III), Ir(III), Pt(II, IV), Re(I), Ru(II), Rh(III), V(IV) have been 
reported to date.[33,37] 
Selected examples are shown in Figure 1.6, underlining the different design 
approaches used for such complexes. Highlighted in red are potential leaving 
groups, which can be released upon photoactivation to yield metal-based and 
ligand species. These designs include photoreduction pathways from 
complexes such as the diodo Pt(IV) complex (Figure 1.6A) to yield active Pt(II) 
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species.[37d] Introduction of bulky conjugated ligands result in complexes, such 
as the biquinoline Ru(II) complex (Figure 1.6D). This yields complexes with 
structural distortion to facilitate rapid photochemistry using visible or near-
infrared light to facilitate biquinoline release and Ru(II) species capable of 
binding to DNA.[37z] Alternatively, strategies to replace the chlorido ligands with 
thioether ligands to afford Ru(II) complexes such as the structure depicted in 
Figure 1.6E. These complexes are stable in the dark due to the strong 
preferential binding of sulphur (‘’soft’’ base, by Pearson’s HSAB principles) to 
Ru(II) (intermediate/soft acid) but can be released upon light activation.[38] 
Furthermore, strategies have been described using the release of toxic carbon 
monoxide to obtain biological activity in addition to metal-based species 
containing potential binding sites (Figure 1.6B, C).[37z,39] Such complexes are 
generally referred to as photoactivated metal-based CO-releasing complexes 
(photoCORMs). While there is a strong overlap in (photo)chemistry with PACT, 
the application of photoCORMs has not been limited to anti-tumour activity and 
they have also shown promising anti-inflammatory, vasodilatory and 
antimicrobial properties, building on the biological interactions of carbon 
monoxide.[37j,40] 
 
 
Figure 1.6 Chemical structures of PACT and photoCORMs complexes reported by 
the Bednarski, Mascharak, Glazer, Spiccia and Bonnet research groups 
(LHS).[37d,37z,38-39,41] Schematic representation of the photoactivation of PACT or 
photoCORMs complexes yielding active metal and/or l igand species to act as 
anticancer agents (RHS). 
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Providing a detailed review of PACT and photoCORM compounds to date is 
outside of the scope of this thesis and recent reviews capture the advances in 
these fields.[37k,42] Instead, the focus is placed on a potent photoactivatable 
diazido Pt(IV) anticancer prodrug candidate around which the majority of the 
work in this thesis is centred, after the brief introduction of photophysical and 
photochemical properties of PACT complexes and the underlying platinum 
chemistry of the diazido Pt(IV) complex. 
1.3.2 Photophysical and Photochemical Properties of PACT Complexes 
Metal-based PACT utilises the unique photochemical and photophysical 
properties of transition metal complexes. The photochemistry principles 
involving electronic transitions for organic and inorganic compounds are broadly 
identical. However, the unique interactions of the ligand orbitals with the metal 
orbitals result in the splitting of d-orbitals, as outlined by the crystal field theory 
(Figure 1.7A). Energy splitting (Δ) between d-orbitals gives rise to a variety of 
orbital energy levels, dependent on the ligands, electronic configuration of the 
metal and its oxidation state, and the geometry of the metal complex. These 
allow a range of electronic transitions to occur between or within metal, ligand 
and solvent orbitals, and typically fall within the visible light spectrum (Figure 
1.7B).  
The Beer-Lambert law, Laporte rule and spin selection rules have long helped 
to explain and benchmark (by extinction coefficient) the observed electronic 
transitions caused by the redistribution of electrons following the absorption of a 
photon.[43] The extinction coefficient, 𝜀 (M-1 cm-1), is a measure of the strength of 
the electronic transition and can be derived from the Beer-Lambert law 
(equation 1.1), which states that the monochromatic radiation absorbed (𝐴) by a 
homogenous solution is proportional to the path length (𝑙, cm) and 
concentration (𝑐, M).  
 
Equation 1.1 𝐴 =  𝜀𝑐𝑙  
 
The spin selection and Laporte rule govern the experimental probability of an 
electronic transition to occur, which is dependent on the transition dipole 
moment. Change in spin multiplicity (S) is not allowed according to the spin 
selection rule, whereas the Laporte rule states that transitions between states of 
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equal parity, such as ligand field (d-d) transitions, are not allowed in 
centrosymmetric molecules (Figure 1.7B). Nevertheless, relaxation of both 
these rules allows for forbidden transitions to be experimentally observed at low 
probability, hence low(er) extinction coefficients. Typically, the coupling between 
orbital and spin angular momenta (spin-orbit coupling) allows for spin forbidden 
transitions to be observed, which is more pronounced for heavier atoms. 
Furthermore, asymmetry or vibrational distortion in metal complexes breaks the 
centrosymmetry and subsequently Laporte forbidden transitions can be 
observed. The above translates to the general classification of the extinction 
coefficients by ligand field transitions (𝜀 = ~500 M-1 cm-1, Laporte forbidden), 
metal to ligand or ligand to metal charge transfer transitions (MLCT or LMCT,  𝜀 
= 103 – 106 M-1 cm-1), intraligand charge transfer transitions (ILCT, 𝜀 = 103 – 105 
M-1 cm-1) and charge transfer to solvent transitions (CTTS, 𝜀 = 10 – 103 M-1 
cm-1). 
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Figure 1.7. Metal-l igand orbital interactions and photochemistry of an octahedral 
transition metal complex. A) Crystal f ield splitt ing of the d-orbitals. B) Molecular 
orbital diagram outlining the possible electronic transitions between metal, l igand 
and solvent. C) Jablonski diagram defining the physical processes a ground state 
(S0) transition metal complex can undergo following light excitation. 
Photochemical reactions can occur at any stage after excitation, resulting in a 
photochemical product. D) Abbreviations used. 
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In recent decades, advances in theoretical calculations, Density Functional 
Theory (DFT) in particular, have had great influence on elucidating the nature of 
electronic transitions of transition metal complexes.[44] This allows extended 
elucidation to build on top of the benchmarks set for the extinction coefficients 
for each allowed or forbidden electronic transition, in an effort to explain the 
observed reactivity. This is covered in more detail in section 1.5.3. 
Excitation of a ground state (S0) transition metal complex into one or more of 
the electronic transition bands typically results in a singlet excited state, after 
which several physical processes can occur. Excited states can ultimately 
return to the S0 ground state complex through radiative or non-radiative decay 
as shown in Figure 1.7C. However, photochemical reactions can occur at any 
stage during the decay, which are intertwined with the physical processes and 
depend on the nature of the excited state, as well as the relative energy 
difference between other close-lying states.[33a] 
The photochemical reactions are initiated in the excited state, whereby the 
promotion of an electron has the potential to weaken specific bonds within the 
complex. Typically, complexes exhibiting ligand field transitions undergo light-
induced solvation, racemisation and isomerisation reactions, while complexes 
with LMCT transitions (Figure 1.7B) can undergo photoreduction at the metal 
centre through loss of ligands.[33a,b] 
These photochemical reactions are the foundations on which PACT relies. Intra- 
and intermolecular reactions such as photodissociation, photosubstitution and 
photoredox reactions are the favoured outcomes of such events by which active 
metal and/or ligand species are released to act as anticancer agents.[33a] 
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1.3.3 Platinum Redox Chemistry to Exploit in PACT 
The 5d8 Pt(II), square planar cisplatin complex owes its biological activity to the 
relatively slow substitution of chlorido ligands (section 1.2.1), which is a general 
feature in Pt(II) complexes.[45] Low-spin 5d6 octahedral Pt(IV) complexes are 
more kinetically inert than the 5d8 square planar Pt(II) complexes. This has led 
to the development of Pt(IV) prodrugs, based on cisplatin, by oxidative addition 
of two axial groups to Pt(II) complexes to retain the original coordination 
sphere.[46] The irreversible reduction of Pt(IV) back to Pt(II) gives the active 
square planar metal-based species, induced by intra- and extracellular reducing 
agents such as ascorbic acid, glutathione and cysteine or methionine containing 
proteins.[46a] Therefore, the rate of reduction plays a critical role in the biological 
activity of such Pt(IV) prodrugs.  
Diiodido Pt(IV) complexes were designed in an effort to eliminate the option of 
chemical reduction and introduce photoreduction, such as the trans,cis-
[PtI2(OAc)2(en)] (Figure 1.6 I, OAc = acetate, en = ethylenediamine).[37d,41a,47] 
The photoreduction was observed through the decrease in intensity of the 
LMCT transition of iodide to Pt(IV) upon light activation. However, in vitro 
toxicity of trans,cis-[PtI2(OAc)2(en)] was observed in both the dark and light 
conditions. This was later attributed to the potential ring opening of 
ethylenediamine in the presence of glutathione.[41a,47] 
This inspired the next generation of photoactivatable Pt(IV) prodrugs containing 
azides to overcome the instability of diiodido Pt(IV) complexes in the dark, 
building on the unique photochemical properties of metal-azides which can 
undergo reduction through concomitant azide radical release.[48]  
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1.4 Trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) 
The diazido dihydroxo diimine platinum (IV) complex, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, py = pyridine, Figure 1.8), is derived 
from a series of Pt(IV) diazido dihydroxo complexes, and has proven to be 
significantly more stable and potent than its predecessors and cisplatin (Figure 
1.8).[37s,37v,49] 
 
Figure 1.8. Molecular structure of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1). 
 
The azido ligand-containing series builds on a dual targeting strategy, with 
photoactive release of a potentially biologically-active Pt(II) species and 
biologically-active ligands (such as radical !N3 or the toxic N3- anion), while the 
Pt(IV) complexes remains inert in the dark.[50] 
Extensive screening of diazido compounds (Figure 1.9, Table 1.1) led to 1, 
which holds particular advantages over its predecessors, as well as increased 
phototoxicity. Namely: (a) increased solubility (for trans Pt(IV) diazido 
complexes in general vs. cis) of (up to) ~34 mM at 298 K in aqueous 
solution.[37v] (b) Pyridine ligands are retained upon irradiation whereas amine 
ligands were found to dissociate, which could potentially explain the reduced 
phototoxicity.[37v,51] (c) Phototoxicity could be attained with wavelengths up to 
500 ± 30 nm, providing a versatile range to work with.[37v] Whilst this compound 
has not yet reached clinical trials and is not commercially available yet, new 
strategies have already been shown to be capable of extenting the window of 
photoactivation to better suit current clinically available lasers wavelengths, 
whilst retaining the unique mechanism of action of 1 (section 1.6.1).[52]  
Pt
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N
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1
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Figure 1.9. Graphical representation of the history on photoactivatable Pt(IV) 
diazido complexes, including selected data underlying the scientif ic decisions 
going forward. A full l ist of publications to date is tabulated in Table 1.1. a 
Selected IC50 values after one hour of drug exposure, one hour of 365 nm 
irradiation (5 J cm-2) and 24 h recovery. Confidence intervals are omitted for 
clarity. [37s,37v,49a] IC50 values for cisplatin using a more common protocol of 24 h 
exposure and 24 h recovery without irradiation; A2780 = 1.2 µM and A2780cis = 
13.4 µM.[53] Notations used: A2780 = human ovarian carcinoma cells, ‘ ’CIS = 
A2780cis, cisplatin-resistant A2780 human ovarian carcinoma cells, HaCaT = 
human immortalised keratinocyte cells, IC50 = concentration at which the complex 
inhibits 50% of the dye uptake in the neutral red uptake phototoxicity assay, thus 
the lower the value the higher the toxicity towards the cell l ine. 
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Table 1.1. Scientif ic publications on photoactivatable Pt(IV) diazido complexes. 
Review articles are omitted unless new material has been added. Colour scheme 
correspond to compounds in Figure 1.9, no colour = new derivative. 
Title  Year Reference 
Nucleotide Cross-Linking Induced by Photoreactions of Platinum(IV)–Azide Complexes  2003 [54] 
Light-activated destruction of cancer cell nuclei by platinum diazide complexes  2006 [49b] 
A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin  2006 [49a] 
A potent cytotoxic photoactivated platinum complex  2007 [37s] 
Photoactivatable Platinum Complexes  2007 [55] 
Unprecedented carbon-carbon bond formation induced by photoactivation of a 
platinum(IV)-diazido complex 
 2008 [18a] 
Synthesis, characterisation and photochemistry of PtIV pyridyl azido acetato complexes  2009 [37t] 
Decomposition pathways for the photoactivated anticancer complex 
cis,trans,cis-[Pt(N3)2(OH)2(NH3)2]: insights from DFT calculations 
 2009 [51b] 
Photo-cytotoxic trans diam(m)ine platinum(IV) diazido complexes more potent than their 
cis isomers 
 2010 [56] 
A Potent Trans-Diimine Platinum Anticancer Complex Photoactivated by Visible Light  2010 [37v] 
Probing Platinum Azido Complexes by 14N and 15N NMR Spectroscopy  2011 [57] 
Insights into the Acid–Base Properties of PtIV–Diazidodiam(m)inedihyroxido Complexes 
from Multinuclear NMR Spectroscopy 
 2011 [58] 
Photoreaction pathways for the anticancer complex trans,trans,trans-[Pt(N3)2(OH)2(NH3)2]  2011 [51a] 
Ground and excited state properties of photoactive platinum(iv) diazido complexes: 
Theoretical considerations 
 2011 [59] 
Tryptophan Switch for a Photoactivated Platinum Anticancer Complex  2012 [37y] 
Interactions of DNA with a New Platinum(IV) Azide Dipyridine Complex Activated by UVA 
and Visible Light: Relationship to Toxicity in Tumor Cells 
 2012 [60] 
Combined Theoretical and Computational Study of Interstrand DNA Guanine–Guanine 
Cross-Linking by trans-[Pt(pyridine)2] Derived from the Photoactivated Prodrug 
trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] 
 2012 [61] 
A Computational Approach to Tuning the Photochemistry of Platinum(IV) Anticancer 
Agents 
 2012 [62] 
trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: a light-activated antitumor platinum complex 
that kills human cancer cells by an apoptosis-independent mechanism 
 2012 [63] 
Near-Infrared Light-Mediated Photoactivation of a Platinum Antitumor Prodrug and 
Simultaneous Cellular Apoptosis Imaging by Upconversion-Luminescent Nanoparticles 
 2013 [52a] 
De Novo Generation of Singlet Oxygen and Ammine Ligands by Photoactivation of a 
Platinum Anticancer Complex 
 2013 [37p] 
Diazido Mixed-Amine Platinum(IV) Anticancer Complexes Activatable by Visible-Light 
Form Novel DNA Adducts 
 2013 [37n] 
Cellular Accumulation, Lipophilicity and Photocytotoxicity of Diazido Platinum(IV) 
Anticancer Complexes 
 2014 [64] 
Targeted delivery of photoactive diazido PtIV complexes conjugated with fluorescent 
carbon dots 
 2015 [65] 
An integrin-targeted photoactivatable Pt(iv) complex as a selective anticancer pro-drug: 
synthesis and photoactivation studies 
 2015 [37u] 
A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand 
Guanidinoneomycin 
 2015 [37r] 
Multifunctional single-drug loaded nanoparticles for enhanced cancer treatment with low 
toxicity in vivo 
 2016 [66] 
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Spin-labelled photo-cytotoxic diazido platinum(iv) anticancer complex  2016 [37b] 
Comprehensive Vibrational Spectroscopic Investigation of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2], a Pt(IV) Diazido Anticancer Prodrug Candidate 
 2016 [67] 
Supramolecular Photoactivatable Anticancer Hydrogels  2017 [52b] 
Primary photochemical processes for Pt(iv) diazido complexes prospective in 
photodynamic therapy of tumors 
 2017 [68] 
 
1.4.1 DNA and In Vitro Work on 1 
The first report on 1 revealed its low micromolar doses of activity against 
keratinocyte (HaCaT), ovarian carcinoma (parental A2780 and cisplatin 
resistant A2780cis), oesophageal adenocarcinoma (OE19) and hepatoma 
(HepG2) cell lines, whilst only exposing them to 1 for one hour prior to light 
activation.[37v] This is in contrast with cisplatin, which requires 24 hours of 
exposure to attain similar antiproliferative activity given the active species 
formation is limited by the rate of hydrolysis.[53] 
DNA platination is one of the critical events responsible for cell death by 
cisplatin and the studies by Pracharova et al. revealed significant higher 
amounts of DNA platination by complex 1 compared to cisplatin, ~16-fold, in 
A2780 cells after one hour of drug exposure, irradiation and a further 24 hours 
of incubation.[60] This confirmed that 1 is capable of penetrating the nucleus and 
binding DNA after photoactivation. Importantly, no DNA platination was 
observed when 1 was exposed to A2780 cells when kept in the dark. Thus, the 
activity of 1 upon photoactivation is correlated to 1 penetrating the nucleus and 
binding to DNA, whilst there is no antiproliferative activity and no binding to 
DNA in the absence of irradiation. 
Distinct differences between DNA adducts of photoactivated 1 and cis- and 
trans-[PtCl2(NH3)2] were found, including large DNA unwinding angles, 
suggesting the importance of pyridine interactions with DNA-base residuals. 
Furthermore, using an in vitro model of RNA polymerase II (a RNA transcription 
protein inside the nucleus), it was shown that photoactivated adducts of 1 were 
markedly more effective at inhibiting RNA transcription.[60] This demonstrated 
the likelihood that DNA adducts of 1 lead to different downstream effects 
compared to those formed by cisplatin. 
In 2014, Pizarro et al. reported on the cellular accumulation, lipophilicity and 
photocytoxicity of 1 and other diazido Pt(IV) compounds (Figure 1.8).[64] 
Interestingly, after one hour in the dark, A2780 cells exposed to 1 exhibited the 
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highest platinum uptake (20 ± 1 ng Pt per 106 cells), over twice as much as 
cisplatin (8.1 ± 0.3 ng Pt per 106 cells). This supports the results of Paracharova 
et al. which indicated that 1 showed significantly higher amounts of DNA 
platination than cisplatin. Higher lipophilicty allegedly increases the passive 
diffusion of compounds into the cell, although, no correlation between the 
lipophilicity and photocytotoxicity or platinum uptake was observed between the 
diazido Pt(IV) compounds. This suggests that compounds such as 1 are 
(partially) involved in active transport into the cell. 
Both these studies suggest the involvement of the trans-pyridine scaffold of 1 
on the photocytoxicity are unique in this diazido Pt(IV) series. However, the 
effect of its photochemistry and resulting photoproducts (including released 
ligands) on the phototoxicity is yet to be fully elucidated. 
1.4.2 Photophysical and photochemical properties of 1 
Early efforts studying the photophysical and photochemical properties of 1 
involved the use of electronic absorption spectroscopy supported by Density 
Functional Theory (DFT), nuclear magnetic resonance (NMR) spectroscopy and 
mass spectrometry (MS) methods.[37v] 
The UV-Vis spectrum of 1 (Figure 1.10) revealed two absorption maximum at 
~260 nm and ~295 nm which were assigned as dissociative LMCT (N3, 
OH−>Pt) and mixed 1LMCT/1IL (OH−>Pt,N3 ; IL = interligand) transitions 
respectively, by time-dependent DFT.[37v] Furthermore, a weak shoulder in the 
visible region at ~414 nm can be gleaned, with a similar mixed 1LMCT/1IL 
character. The photodecomposition of 1 by UV-Vis features the loss of 294 nm 
absorption at different rates, depending on the excitation wavelength. 
Interestingly, evolution of gas bubbles was observed throughout irradiation of 1, 
although this was not further discussed at the time.[37v] Further studies on a 
close derivative of 1, trans,trans,trans-[Pt(N3)2(OH)2(py)(methylamine)], 
revealed a gas evolution consisting of N2 (likely recombination of two !N3) and 
O2 (from the complex, rather than solvent, verified by 18O-labeled water) by gas 
chromatography MS (GCMS).[37p] 
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Figure 1.10. The experimental (black) and predicted (red) UV-Vis spectra of 1  in 
water. Inset: expansion of the 350 – 450 nm region. Blue bars indicate the 
calculated excited states, with heights equal to extinction coefficients. Reprinted 
with permission from Farrer et al. [37v] Copyright 2010 WILEY-VCH Verlag GmbH & 
Co. KGaA, Weinheim. 
 
The photoinduced binding of 1 (9 mM) to a DNA-base model, 5’-guanosine 
monophosphate (5’-GMP, 2 mol equiv.), was studied by 195Pt NMR in D2O 
under 420 nm irradiation.[37v] Complete removal of 1 was observed within 45 
min of irradiation and led to two major Pt(II) NMR signals. Synthesis allowed for 
the elucidation of one of the formed compounds: trans-[Pt(py)2(5-GMP)2]2+ (A), 
whilst the other species was reasonably assigned to 
trans-[Pt(N3)(py)2(5-GMP)2]+ (B) (Figure 1.11). A third minor (PtIV) species was 
observed, which, after irradiation, increased in magnitude over time together 
with A, whilst B decreased. Subsequent monitoring of these species by electron 
spray ionization (ESI) MS matched this minor species to a molecular formula of: 
[Pt(N3)(OH)2(py)2(5’-GMP)]+ (C). 15N labelling of pyridine and azide allowed for 
further elucidation of the NMR spectra of 1, although, no photodecomposition 
studies by 14N or 15N NMR were reported. 
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Figure 1.11. Proposed molecular structures of the formed species by 
photoinduced binding of 1  with 5’-GMP under 420 nm irradiation, as observed by 
195Pt NMR and ESI-MS.[37v] 
 
A combination of electron paramagnetic resonance (EPR) and 14N NMR studies 
carried out by Butler et al. captured several important characteristic events of 
the azido ligands, upon irradiation of 1.[37y] Firstly, by using a spin trap, 5,5-
dimethylpyrroline N-oxide (DMPO), azidyl radicals (from 14N and 15N azido 
ligands) were captured in water, phosphate-buffered saline (PBS) and growth 
medium for cell culture (RPMI-1640). However, the azidyl radical binding to 
DMPO competes with the formation of N2 following radical dimerisation, 
depending on concentration and solvent, confirmed by 14N NMR. Whilst PBS 
yielded slightly higher concentrations of trapped radicals, RPMI-1640 yielded 
lower concentrations. The inclusion of various amino acids, vitamins, inorganic 
salts, and other growth-promoting substances in RPMI-1640 is likely to compete 
or influence the reaction of azidyl radicals with DMPO. Furthermore, the 
addition of a two molar equivalent of the DNA-base model, 5’-GMP, had little 
effect on the capture of azidyl radicals, but did prevent the precipitation of 
resulting platinum species otherwise formed at such high concentrations 
(4 mM), likely due to binding of 1 to 5’-GMP. 
Introducing known electron transfer mediators, present on the side chains of 
proteins, tyrosine (Tyr) and tryptophan (Trp), into the photoreactions was 
carried out to further investigate the possible effect of amino acids on the 
photocytotoxicity of 1. Tyr! and Trp! are weaker oxidising agents than !N3, thus 
Tyr and Trp could potentially quench the !N3 radical to N3-. 
The presence of L-Tyr, had little influence on the trapping of azidyl radicals, 
whilst L-Trp completely suppressed the capture of azidyl radicals by DMPO at 
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0.25 mol equiv., without substantially affecting the photodecompostion of 1. This 
interestingly translated similarly to the photocytotoxic effect of 1 on the A2780 
cancer cell line. Co-incubation of varying concentrations of L-Trp with 1 allowed 
for an increase in viability. At 500 µM L-Trp, the IC50 values (half maximal 
inhibitory concentrations) of 1 were increased by ~7 fold. Even at equal 
concentrations (~50 µM, L-Trp and 1), viable cells were observed after 24 
hours, whereas 50 µM of 1 alone resulted in no viable cells. 
This allowed for the first in vitro proof of the dual mechanism of 1, in which the 
released ligands upon irradiation are responsible for a part of the observed 
photocytotoxicity. Additionally, the relative depletion of Trp levels in the serum 
of some cancer patients (breast, lung and ovarian) could be an underlying factor 
of the effectiveness of 1 as a chemotherapeutic agent.[26,69] 
 
Significant advances have been made in effort to elucidate the mechanism of 
action, suggesting that the cleaved ligands and platinum centres following 
photoactivation, act in concert to elicit the observed multi-targeted biological 
activity. The potential use of NMR spectroscopy to monitor the azido release of 
1 was reported. However, it remains challenging to deduct significant 
information due to the broad resonances for quadrupolar I=1 14N and poorly 
sensitive I=1/2 15N resonances (due to lack the enhancement by polarisation 
transfer via coupled protons).[57]  
Further insights into the release of azide and, yet to be studied, hydroxido 
ligands as well as the changes around the platinum centre are of utmost 
importance to improve our understanding of these potential anticancer prodrugs 
in the field of chemotherapy. 
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1.5 Vibrational Spectroscopy 
Reflecting back on Rosenberg’s paper from 1971, the landscape of metal-based 
chemotherapy has undergone significant growth.[20] Interestingly to mention is 
the remark he included after the invitation to inorganic chemists to submit 
samples to Cancer Institutes for anticancer activity screening: ‘In addition to this 
chemical synthesis activity, it is desirable to know in more detail, and with 
greater security, the mechanisms of action of this new class of drugs, as well as 
their general toxicological and pharmacological properties in mammalian 
systems’.[20] Already then, emphasis was placed on scientists to investigate and 
progress techniques to study newly synthesised compounds in order to 
progress in this field. A new and improved chemotherapeutic agent is very 
rarely revealed in the first round of discovery. Studying the mechanism of action 
can provide invaluable information for the development of more potent drugs in 
the future and can provide direct insight on how to modify screened candidates. 
This mechanism of action of potential anticancer prodrugs is the broad theme of 
this thesis, where vibrational spectroscopic techniques are utilised in order to 
improve upon our knowledge and develop methods to study these compounds. 
 
Several non-invasive techniques exist to date that allow for the study of the 
mechanism of drug interactions with biological materials. These include 
radioactive and fluorescent labelling, nuclear magnetic resonance, X-ray 
spectroscopy and mass spectrometry.[70] Most of these techniques provide 
empirical information on the drugs and their mechanism of action. While 
vibrational spectroscopy was the foremost used analytical tool in research and 
industry on chemical structures, it was consigned to mainly a qualitative 
functional group analysis tool throughout the late 20th century.[71] However, 
recent decades have seen a resurgence of vibrational spectroscopic studies on 
biological specimens and biomolecular drug targets.[72] It is now a rapidly 
expanding research area because of the increased throughput, spatial 
resolution and means to process large data sets, while at the same time being 
label-free and non-destructive.[72b] Besides the fact that biomolecular changes 
and interactions can be examined using such techniques, another level of 
detection may be achieved when drugs containing distinct vibrational bands are 
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introduced; such as chloro (Cl), azido (N3), hydroxido (OH) and carbonyl (CO) 
ligands. Specifically for the case of metal containing drugs, vibrational 
spectroscopy allows for monitoring changes around the metal coordination 
environment. This makes vibrational spectroscopy a potentially powerful tool for 
gaining insights into the mechanism of action of the previously discussed metal-
based photoactivatable anticancer prodrug candidates (section 1.3, 1.4).  
1.5.1 Principles of Vibrational Spectroscopy 
Atoms are in constant motion, independent of phase, which depending on the 
temperature, increases or decreases in amplitude but never reaches zero. This 
constant motion within molecule, complex, ion etc. (further referred to as 
sample) can be broken down into normal modes of vibration, where all atoms 
oscillate at identical phase and frequency (constant translation and rotation) but 
with different amplitudes. All normal modes of vibration or fundamental 
vibrations of each sample can be deduced, which are determined by its 
symmetry (group theory). For example, the constant motion of a linear triatomic 
azide ion (D∞h) can be described by four normal modes of vibration (Figure 
1.12), namely, ν1 the symmetric stretching vibration, two deformations (ν2a&b) 
and ν3 the anti-symmetric stretching vibration. It is the frequency of these 
molecular vibrations that is measurable by vibrational spectroscopy.  
 
Figure 1.12. Normal modes of vibration of the triatomic l inear ion, N3-.  
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Both infrared and Raman spectroscopy can measure the vibrational transitions 
by excitation of the vibrational ground state (ν0) or vibrational excited states 
(vide infra). However, the physical origin of the two resulting spectra is distinctly 
different (exemplified by a normal of vibration in Figure 1.13). In infrared 
spectroscopy, the absorption of photons from the infrared source (λIR) causes 
transitions from the vibrational ground state (ν0) of a sample to a vibrationally 
excited state (ν1), and the energy of the photon (Ephoton) is equal to the ΔE of the 
sample after absorption.[73] In Raman spectroscopy, the excitation of a sample 
is the result of an incident photon (much higher in energy than in infrared 
spectroscopy) from a monochromatic radiation source (λ, usually an UV, Vis or 
near-infrared laser) inducing a transition into a virtual excited state (νv), followed 
by relaxation into either its ground vibrational state (Rayleigh scattering) or a 
vibrationally excited state (Stokes Raman scattering, νv-ν1).[74] Thus, Raman is a 
measure of loss in photon energy. Furthermore, a third scattering is possible 
(left out of the figure for clarity), whereby the incident photon excites the sample 
from ν1 to νv+1 and relaxes to the vibrational ground state ν0 (anti-Stokes 
Raman, νv+ν1). 
 
Figure 1.13. Simplif ied representation of infrared absorption and Raman 
scattering of a normal vibration. Notations used: ν0 = ground vibrational state, ν1 = 
excited vibrational state, νv = virtual state, λ IR = infrared l ight excitation, λ  = 
monochromatic laser excitation. 
 
Both Raman and Rayleigh scattering are very weak processes, thus Raman 
spectroscopy benefits from laser sources capable of producing sufficient 
photons (~1015–1018 s-1) in order to intensify the scattering and collect a 
(Stokes) Raman spectrum (Stokes Raman occurs with a likelihood of ~1 in 1010 
– 1012).[73b] In contrast, photon absorption by a sample in infrared spectroscopy 
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can occur with significantly higher probabilities, for instance, an one absorbance 
unit band absorbs ~90% of the photons.[73b] 
Not all normal vibrations are infrared and Raman active. A change in dipole 
moment of a normal vibration is required for the vibration to be infrared active, 
while a change in polarisation is required for a normal vibration to be Raman 
active. For example in Figure 1.12, the symmetric stretching vibration of the 
azide ion is not infrared active but Raman active and vice versa for the anti-
symmetric vibration. 
These principles are not straightforward and the quantum mechanical 
explanations are too extensive for this purpose. However, they can be 
visualised by imagining an infrared beam passing through one azide ion as a 
uniform electric field (left to right). It would be impossible to induce an 
symmetric stretch with any translation of the azide ion on the x,y,z coordinates. 
For Raman spectroscopy, the incident monochromatic laser light induces an 
electronic polarisation in the sample, which can couple to other existing 
polarisations of the sample, such as vibrational excited states. However, the 
polarisation of the anti-symmetric stretching vibration of an azide ion is isotropic 
and therefore only Rayleigh scattering will occur for this normal vibration. 
This gives rise to the mutual exclusion rule, whereby normal modes of vibration 
cannot be both infrared and Raman active if the sample has a centre of 
symmetry. However, in practice, the majority of samples with multiple different 
atoms have several symmetry elements in addition to the centre of symmetry, 
influencing whether or not a transition is infrared and/or Raman active. 
Furthermore, inter- and intramolecular interactions in the sample add another 
level of complexity on top of the symmetry elements. Therefore, many vibrations 
can be both infrared and Raman active. A general rule applies though, whereby 
strong Raman bands are typically weak infrared bands, resulting in vibrations 
being visible in both infrared and Raman spectra, which makes them highly 
useful complementary techniques. 
 
Group vibrations or characteristic vibrations are commonly identified as a 
particular localised vibration within a group of atoms that are dominant in a 
normal vibration, such as the anti-symmetric stretching vibration of azido 
ligands in the photoactivatable anticancer prodrug 1. However, it is important to 
keep in mind that, even though the characteristic vibration is dominant, all 
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atoms in the sample are vibrating and involved to a certain extent. Furthermore, 
vibrational spectroscopy is not limited to the observation of only normal modes 
of vibration. Multiples of normal modes (ν0 " νn ,n ≥ 2), the sum or difference of 
two or more normal modes and excitation of a vibrational excited state (ν1 " νn, 
n ≥ 2) can likewise be observed. These are referred to as overtones, 
combination bands and hot bands respectively. 
1.5.2 Vibrational Spectroscopic Techniques 
The main vibrational spectroscopic techniques or equipment used throughout 
this thesis are described briefly. 
 
Attenuated Total Reflection – Fourier Transform Infrared (ATR-FTIR) 
ATR-FTIR spectrometers are one of the most versatile infrared spectrometers, 
which are present in many active academic and industrial research labs. Their 
widespread use may be attributed to their increasing affordability, low 
maintenance, ease of use and ability to rapidly identify and classify any sample 
without prior sample preparation, so long as the sample can make physical 
contact with the ATR sample crystal. 
ATR-FTIR is a total internal reflection technique that measures the infrared 
absorption of the sample at the surface of the internal reflecting element (further 
referred to as ATR crystal, Figure 1.14).[75] Total internal reflection is obtained 
when the angle of infrared light reaching the ATR crystal surface is equal or 
larger than the critical angle (Equation 1.2) if the refractive index of the ATR 
crystal (𝑛2) is higher than the sample (𝑛1)  (Snell’s law). The electric field of the 
infrared beam under total internal reflection extends beyond the interface of 
reflection as it is polarised in the direction of the sample where infrared 
absorption can occur, which is known as the evanescent wave. The depth of 
penetration (dp) of this evanescent wave is related to the wavelength (λ) and 
incident angle (θi) of the infrared beam, and the refractive index of the ATR 
crystal (𝑛2) and sample (𝑛1) as shown in Equation 1.3. 
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Figure 1.14. Schematic representation of ATR at θ i  ≥  θc. Notations used: θ i / r  = 
angle of incidence/reflection, θc = crit ical angle, n1 = refractive index of the 
sample, n1 = refractive index of the ATR crystal, dp = penetration depth of 
resulting evanescent wave into sample, IR = infrared beam. 
 
Equation 1.2 sin𝜃! = 𝑛!𝑛!  
Equation 1.3 𝑑! =  𝜆2𝜋 sin!𝜃 −(𝑛! ÷ 𝑛!)!  
 
Two different ATR crystal materials are used throughout this thesis, diamond (𝑛 
= 2.4) and silicon (𝑛 = 3.42). Both of the ATR crystals are mounted into ATR 
accessories with the angle of incidence of the IR beam fixed to 45°. Assuming a 
typical refractive index of 1.5, the critical angle would be ~39° (diamond) or ~26° 
(silicon), meeting the requirements for ATR. The penetration depth can be 
calculated for the typical infrared wavenumber ranges as shown in Figure 1.15.  
 
Figure 1.15. Penetration depth of the evanescent IR wave into the sample at 
different wavenumbers including selected peak labels with a diamond or sil icon 
ATR crystal, IR beam incidence of 45° and a refractive index of the sample of 1.5.  
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Relatively low penetration depth is typically obtained in the mid-infrared region 
(~4000 – 400 cm-1) between ~0.5 – 6 µm, whereas the penetration depth starts 
to vary more significantly in the far-infrared region (~650 – 10 cm-1). The 
difference in penetration depth throughout the spectral region is why ATR 
spectra are not directly comparable to transmission spectra with fixed path 
lengths. The effective path length of ATR spectra can be calculated 
(approximately) for quantitative analysis as described by Griffiths et al., if 
desired.[75a] Nevertheless, ATR-FTIR allows for measurement of strongly 
absorbing samples, such as water, without having to work with short path length 
transmission cells.  
As outlined above, ATR-FTIR spectra are dependent on the refractive index of 
the sample. There are samples, such as solid and crystalline materials, that 
exhibit anomalous dispersion, which results in rapid changes to the refractive 
index of the sample whilst scanning through an absorption peak.[76] This results 
in asymmetric line shapes and shifts in absorption maxima to smaller 
wavenumber values and has to be accounted for. Such effects were observed 
throughout this thesis and corrections were carried out accordingly, which are 
outlined in Chapter 2.2. 
 
Raman Microspectroscopy 
Raman microspectroscopy is used to complement the infrared spectroscopic 
measurements. Raman microscopes are in general not limited to a lower 
wavenumber limit of ~400 cm-1 such as mid-infrared spectrometers due to the 
material of optics used, weak infrared sources and/or detector limits. 
This lower wavenumber region (~650 cm-1 – 10 cm-1) is of particular interest to 
inorganic materials as it is where metal to ligand vibrations occur.[77] Raman 
microspectroscopy allows one to collect spectra between ~4000 cm-1 – 50 cm-1, 
whereas far-infrared spectrometers have to be typically used in order to obtain 
spectra in the lower wavenumber region. Far-infrared spectrometers have their 
own limitations and restrictions, which are discussed further in Chapter 4.1. 
Raman scattering, as described above, is a weak process and the 
monochromatic lasers of different wavelengths and microscope lenses 
employed into the Raman microscopes allow one to minimise the unwanted 
scattering effects. Fluorescence can be a particular problem for many inorganic 
metal complexes.[77a] 
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Synchrotron Radiation as Infrared Sources 
Charged particle accelerators, i.e. synchrotrons, were originally used in the field 
of particle physics to allow the study of subatomic particle collisions. However, 
second and third generation synchrotrons were designed to store accelerated 
electrons created with strong magnetic and electric fields into electron storage 
rings. The electron storage ring utilises electromagnets to focus, steer and 
maintain the high-energy electrons in a vacuum, whereupon they emit 
extremely intense radiation, referred to as synchrotron radiation (SR). SR emits 
a wide range of electromagnetic radiation, including infrared radiation, which 
can be tuned by the electron energy. 
The brilliance of infrared SR of a 3 GeV SR source (such as the Diamond Light 
Source) shows at least two orders of magnitude advantage over a typical 
Globar infrared source (Figure 1.16).[78] Furthermore, this advantage increases 
more significantly in the far-infrared region. Apart from the high brilliance, SR is 
highly collimated, allowing for an effectively parallel source and its energy is 
intrinsically stable (directly proportional to the electron current), whereas 
thermal sources such as the Globar do not exhibit those properties.[79] 
This has resulted in the installation of infrared beamlines at synchrotrons, with 
at least 20 active infrared beamlines in 2016, continuously advancing their 
equipment and throughput to utilise SR.[80] Further discussion on the particular 
advantages of SR and application towards the research carried out in this thesis 
in the far- and mid-infrared regions can be found in Chapter 4. 
 
Figure 1.16. Calculated SR bril l iance of a 3 GeV SR source, a typical Globar 
infrared source and an ideal bending magnet SR diffraction l imited source. 
Adapted from Marcell i et al. [78] Reprinted with permission from Elsevier. 
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1.5.3 Computational Chemistry; Theory and Experimental Methods 
The last two decades have seen a vast increase in the amount of quantum 
mechanical approaches used to aid experimental observations, building on the 
improved reliability of models, affordable access to computational nodes and 
user-friendly computer codes.[81] Density functional theory (DFT, including time-
dependent DFT) is by far the most widely used method for transition metal 
complexes, allowing for accurate description of their ground state and excited 
state properties at moderate computational cost.[44b] 
DFT requires one, or several, basis set(s) and functional(s) to describe a 
sample, where the basis set is the set of functions describing the atomic orbitals 
and the functional is an approximation of the exchange-correlation energy of the 
overall system (sample). Multiple benchmarked basis sets and functionals 
(empirical and non-empirical) currently exist and have to be carefully selected to 
attain the appropriate ground state geometries of which the ground state and 
excited state properties are derived. 
A complete qualitative interpretation of vibrational spectra of multi-atom metal 
complexes from the basic physical principles is nearly, if not, impossible. DFT 
allows for the prediction of vibrational frequencies, derived from the overall 
energy of an optimised molecular system using a harmonic approximation. This 
means that stretching vibrations are typically overestimated by DFT calculations 
and uniform scaling factors are commonly used to address the lack of 
anharmonicity in the DFT calculations.[44d,82] Corresponding vibrational 
intensities are obtained through the description of the vibrational motion and 
electronic redistribution of electron density, yielding the dipole moments. Whilst 
accurate intensity descriptions can be obtained, the calculated intensities are 
largely reliant on the basis sets employed.[83] 
The DFT calculations used throughout this thesis are employed to aid the 
assignment of measured experimental frequencies. Likewise, time-dependent 
DFT (TD-DFT) calculations are used to predict the electronic absorption 
energies to rationalise the observed changes in the absorption spectrum upon 
irradiation of the photoactivatable metal complex. 
The DFT method can be a very powerful tool to elucidate experimental 
observations. However, it remains an ab initio method and care has to be taken 
not to over-interpret results. A complete description of the chemical environment 
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of the metal complex, i.e. crystal lattice, solvent molecules, intermolecular 
interactions is too computationally demanding. A conductor-like polarisable 
continuum model (CPCM) is used throughout this thesis to better describe the 
electrostatic interactions between metals and ligands.[84] This allows for better 
description of ground state geometries, further reflected in the better description 
of frequency and TD-DFT calculations, but is not to be confused with actual 
solvent molecules. 
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1.6 Addressing the Wavelength Activation of 
Photoactivatable Anticancer Prodrugs 
The activation of metal-based photoactivatable chemotherapeutic (PACT) 
agents requires a light source, thus there is a practical boundary that has to be 
addressed in order to introduce PACT agents into the clinic. Apart from 
introduction light sources into the clinics, the current excitation wavelengths 
(UVA – blue) of PACT candidates such as 1, is damaging to the skin (UV 
radiation) and does not allow for deep skin penetration due to the strong 
absorption of biomolecules such as haemoglobin and oxyhaemoglobin.[85] 
Optimum penetration depths can be achieved between ~650 – 900 nm (‘in vivo 
imaging window’) where the lowest extinction coefficients of haemoglobin, 
oxyhaemoglobin and water intersect.[85] 
Current clinical lasers are operational for the use in photodynamic therapy 
(PDT), the type of localised treatment of cancer with highly reactive singlet 
oxygen species in which the incident light energy is absorbed by a injected 
photosensitizer and subsequently transferred to ground state triplet oxygen 
(section 1.3). These PDT lasers are typically pulsed dye lasers (595 nm) and 
diode lasers (ranging from 630 nm to 670 nm).  
Several strategies exist to date in order to increase the absorption wavelengths 
of metal-based PACT candidates, such as changing the metal ion, extending 
aromatic ligand conjugation, conjugation to organic dyes or quantum dots and 
the use of upconverting nanoparticles.[42a,65-66,86] 
1.6.1 Upconverting Nanoparticles 
Upconverting nanoparticles (UCNPs) have received a vast amount of attention 
in recent years, which exhibit a unique type emission; anti-Stokes upconversion, 
capable of translating near-infrared light into UV/visible emission.[87] 
UCNPs are rare earth doped nanomaterials consisting of a host lattice (e.g. 
NaYF4, CaF2, LiYF4) doped with sensitizers and activators/emitters 
(lanthanides), which exhibit Stokes type downconversion and anti-Stokes type 
upconversion (Scheme 1.1). Photon excitation into a lanthanide (sensitizer) 
such as ytterbium (980 nm) and two or more subsequent Förster resonance 
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energy transfers (FRET) to other dopants, such as thulium (activator/emitter), 
allow for multiple excitations and thus multiple emission wavelengths depending 
on the dopants (Scheme 1.1B). Initial UCNP reports mainly consisted of 
ytterbium sensitizers. However, the biomedical downside of 980 nm irradiation 
is the strong absorption of water. Resulting thermal damage and reduced 
penetration depth transpired the introduction of neodymium ions into UCNPs, 
allowing for 800 nm excitation at which there is low absorption for both water 
and biomolecules.[85,88]  
 
Scheme 1.1. Graphical representation (A) and schematic (B) of the excitation of 
an UCNP by near-infrared l ight (800 nm or 980 nm) by two or more photons 
resulting in downconversion and upconversion. A) grey = host latt ice, coloured = 
sensitizer, bridge or activator/emitter. NIR = near-infrared l ight, Vis = visible l ight, 
UV = UVA/B light. B) Neodymium acts as a sensitizer, ytterbium acts as an 
sensitizer or subsequent bridge for neodymium to an activator such as thulium. 
Transition energies are obtained from Shen et al. and Mahalingam et al. [85,89] 
 
A variety of strategies exist to functionalise the surface of UCNPs, to render 
them water-dispersible whilst simultaneously having functional groups, such as 
carboxyl or amide groups, to allow covalent binding of pharmacokinetic 
modifiers, drugs, radionuclides, fluorescent tags, etc.[90] 
The first reports on photoactivation of metal-based PACT complexes by UCNPs 
were published between November – December 2013.[52a,91] 
Salassa et al. reported on the photolysis of [Ru(bpy)2(py)2]Cl2 (bpy = 2,2’-
bipyridine, py = pyridine) in aqueous solution by 980 nm irradiation of oleate-
capped NaYF4:Yb3+/Er3+ (20/2 mol%) UCNPs with an average size of ~80 
nm.[91a] The photolysis was monitored by UV-Vis and NMR spectroscopy and it 
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was suggested that covalent binding to the UCNPs surface would likely 
enhance the photolysis rate due to more efficient non-radiative energy transfer. 
 
Xing et al. were the first to report on the covalent binding of an axial derivative 
of 1, trans,trans,trans-[Pt(N3)2(OH)(O2CCH2CH2CO2H)(py)2] to silica-coated 
NaYF4: Yb3+/Tm3+ (30/0.5 mol%) UCNPs (~35 nm) with amino terminal 
groups.[52a] The UCNPs were further functionalised with a targeting peptide 
(polyethylene glycol derivative) with a flanking activatable FRET pair for specific 
recognition of apoptosis, consisting of a fluorescence donor Cy5 and a near-
infrared quencher Qsy21 cleavable by caspase-3 enzymes (Scheme 1.2). 
 
Scheme 1.2. Graphical representation of near-infrared (NIR) l ight activation of a 
diazido Pt(IV) prodrug by UCNPs and subsequent intracellular apoptosis imaging. 
Reprinted with permission from Xing et al. [52a] Copyright 2013 WILEY-VCH Verlag 
GmbH & Co. KGaA, Weinheim. 
 
In vitro studies of the UCNPs (10 µM) in A2780 and A2780cis ovarian cancer 
cells revealed the significant reduction in viability upon one hour of 980 nm (1.5 
W cm-2) irradiation, followed by 24 h incubation. The UCNPs exhibited equal 
toxicity to cisplatin in A2780 cells. However, significantly more potency was 
observed in A2780cis cells compared to both cisplatin and the free Pt(IV) 
New materials for anticancer imaging and therapy 
Chapter 1 Robbin R Vernooij 37 
complex. Important to note is that 25% of the Pt(IV) complex is cleaved from the 
UCNPs after five hours of NIR irradiation. Promising tumour activity was 
observed by irradiating treated cells for only one hour. Therefore, increased 
photo-release efficiency might substantially increase the potency of the UCNPs. 
Furthermore, live cell apoptosis imaging fluorescent studies by confocal laser 
scanning microscopy (Cy5, DAPI and Annexin V dyes), provided proof of 
concept with regards to real time imaging of photoactivated cytotoxicity arising 
from triggered apoptosis during localised drug release. Direct introduction of 
caspase-3 or near-infrared irradiation of the functionalised UCNPs in cells 
greatly enhanced the Cy5 fluorescence. 
 
Lastly, Lin et al. reported on the covalent bound diazido Pt(IV) complex, 
trans,trans,trans-[Pt(N3)2(O2CCH2CH2CO2H)2(NH3)(py)] (py = pyridine), to 
polyethylenimine coated UCNPs (NaYF4:Yb3+/Tm3+ (40/0.5 mol%) @ 
NaGdF4:Yb3+ (2 mol%), average size of ~65 nm). [91b] The second carboxyl 
terminus of the Pt(IV) complex was coupled to polyethylene glycol. The 
incorporation of both a metal-based PACT complex and gadolinium ions into the 
UCNPs allowed for upconversion luminescence, magnetic resonance, 
computed tomography (trimodal) imaging and near-infrared activated platinum 
delivery.  
In vitro studies in HeLa cervical cancer cells showed significant inhibition upon 
exposure to the UCNPs and 980 nm (2.5 W cm-2). Furthermore, significantly 
higher uptake of platinum was found after six hours of dark incubation when 
exposed to UCNPs compared to free complex. Tumour suppression in an in 
vivo model by intra-tumoural injection of the UCNPs exhibited more efficacy 
under 980 nm irradiation than 365 nm (UV) irradiation, despite the lower 
intensity of upconverted UV emission compared to the UV irradiation. 
 
Progress in the subsequent years after have led to a few other reports of metal-
based PACT complexes bound to UCNPs.[86a,92] However, the majority of work 
in the field of biomedical application of UCNPs has been focused on the 
optimisation of quantum yield and most importantly in terms of size, shape and 
coating in effort to prevent accumulation in the liver or spleen whilst allowing for 
renal excretion, which has been hampering the effectiveness of nanoparticles in 
vivo.[87c,93] 
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1.7 Research Objectives 
The main objective of the work in this thesis is to provide new insight into the 
mechanism of action of photoactivatable platinum anticancer prodrug 
candidates, along with the development of new vibrational spectroscopic 
strategies to approach this goal and exploration of an UCNP platform to extend 
the excitation wavelength of such complexes. Specifically, the aims are as 
follows: 
 
1. Explore the vibrational fingerprint of the photoactivatable Pt(IV) prodrug 
candidate, trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, py = pyridine), with a 
series of vibrational spectroscopic techniques as the essential first step 
towards monitoring the photoactivation pathways. 
 
2. Translate the vibrational signatures to support photodecomposition and 
photoinduced binding studies of 1 and subsequently apply these 
methods to other metal-based PACT candidates. 
 
3. Methodological plus instrumental development and utilisation of 
synchrotron based infrared techniques to study metal-based PACT 
candidates, outlined by 1, in an effort trying to overcome the limitations of 
bench-top infrared equipment. 
 
4. Synthesis and optimisation of UCNPs as a platform for addressing the 
wavelength activation of PACT candidates to a clinically-relevant 
window. 
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Chapter 2 
Comprehensive Vibrational 
Spectroscopic Investigation of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2], 
a Pt(IV) Diazido Anticancer Prodrug 
Candidate 
The potential of metal-based photoactivatable anticancer complexes as 
chemotherapeutic agents by local activation in selected cancerous areas to 
address the severe side effects of current clinical drugs have been discussed in 
Chapter 1.3. The promising candidate, trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, 
py = pyridine) shows biological activity resulting from its unique photophysical 
and photochemical properties, suggesting a multi-targeted biological activity 
originating from cleaved ligands and the platinum centre upon photoactivation 
(Chapter 1.4). Monitoring the reactive metal centre as well as the azido and 
hydroxido ligands of 1 remains challenging and the initial strategy, covered in 
Chapter 2, involved the vibrational spectroscopic screening of 1, towards 
utilisation of vibrational spectroscopy as a tool to study such metal-based 
anticancer prodrug candidates. Solid theoretical and experimental methods 
were established using Attenuated Total Reflection Fourier Transform Infrared 
(ATR-FTIR), Raman spectroscopy and synchrotron radiation far-infrared (SR-
FIR) complemented by density functional theory calculations to capture the 
vibrational fingerprint of 1. Chapter 2 includes of the main manuscript text 
(section 2.1), supporting information (section 2.2) and a link to the ACS 
LiveSlides recordings of this publication (section 2.3). 
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2.1 Main Manuscript 
 
Comprehensive Vibrational Spectroscopic Investigation of 
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Candidate 
 
Robbin R. Vernooij, Tanmaya Joshi, Evyenia Shaili, Manja Kubeil,  
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Figure 2.1 Table of contents graphic for the Comprehensive Vibrational 
Spectroscopic Investigation of trans,trans,trans-[Pt(N3)2(OH)2(py)2], a Pt(IV) 
Diazido Anticancer Prodrug Candidate.  
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Chapter 3 
Photoinduced Studies of Metal-
Based Anticancer Prodrug 
Candidates 
A more detailed understanding of the underpinning mechanism of photoinduced 
reactions by photoactivatable drugs is an essential component in the 
development of future biologically active metal complexes. The vibrational 
spectroscopic acquisition techniques outlined in Chapter 2 were subsequently 
applied to study the photodecomposition and photoreaction of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] by Attenuated Total Reflection Fourier 
Transform Infrared (ATR-FTIR), transient electronic absorption and UV-Vis 
spectroscopy, complemented by theoretical calculations. Building on the same 
methodologies, a range of ruthenium-based CO-releasing complexes (Chapter 
1.3.1) of the formula [RuLCl2(CO)2] (L = 4,4′-dimethyl-2,2′-bipyridine, 4′-methyl-
2,2′-bipyridine-4-carboxylic acid or 2,2′-bipyridine-4,4′-dicarboxylic acid) were 
studied on account of the electron-withdrawing/donating properties of the 
carboxyl/methyl substituents attached to the bipyridine ligand. In both studies, 
the steady state and chemometric analysis of the resulting spectra allowed for 
extraction of mechanistic and quantitative kinetic information, revealing new 
insights into photochemical and photophysical properties of the photoactivatable 
prodrug candidates. Chapter 3 comprises of two manuscript texts and their 
corresponding supporting information. First the submitted manuscript; 
Spectroscopic Studies on Photoinduced Reactions of the Anticancer Prodrug, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (section 3.1, 3.2 SI, 3.3 front cover, 3.4 
cover profile), followed by the published manuscript; Studies of Carbon 
Monoxide Release from Ruthenium(II) Bipyridine Carbonyl Complexes upon 
UV-Light Exposure (section 3.5 and 3.6 SI). 
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3.1 Main Manuscript: Spectroscopic Studies on 
Photoinduced Reactions of the Anticancer Prodrug, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
 
Spectroscopic Studies on Photoinduced Reactions of the Anticancer Prodrug, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] 
 
Robbin R. Vernooij, Tanmaya Joshi, Michael D. Horbury, Bim Graham, 
Ekaterina I. Izgorodina, Vasilios G. Stavros, Peter J. Sadler, Leone Spiccia† and 
Bayden R. Wood 
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Published online: 5 February 2018, awaiting issue assignment (front cover and 
cover profile) 
 
 
 
Figure 3.1 Table of contents graphic for the Spectroscopic Studies on 
Photoinduced Reactions of the Anticancer Prodrug, 
trans,trans,trans-[Pt(N3)2(OH)2(py)2].
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3.5 Main Manuscript: Studies of Carbon Monoxide 
Release from Ruthenium(II) Bipyridine Carbonyl 
Complexes upon UV-Light Exposure 
 
Studies of Carbon Monoxide Release from Ruthenium(II) Bipyridine Carbonyl 
Complexes upon UV-Light Exposure 
 
Manja Kubeil, Robbin R. Vernooij, Clemens Kubeil, Bayden R. Wood,  
Bim Graham, Holger Stephan, and Leone Spiccia 
 
Inorg. Chem. 2017, 56, 5941-5952 
 
American Chemical Society DOI: 10.1021/acs.inorgchem.7b00599 
 
 
Figure 3.2 Table of contents graphic for Studies of Carbon Monoxide Release 
from Ruthenium(II) Bipyridine Carbonyl Complexes upon UV-Light Exposure. 
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Chapter 4 
Synchrotron Infrared Beamline 
Studies 
In this chapter, the use of synchrotron based infrared techniques to study metal-
based anticancer complexes is discussed. At the heart of these studies is the 
photoactivatable anticancer prodrug candidate, trans,trans,trans-
[Pt(N3)2(OH)2(py)2] (1, py = pyridine), which has been comprehensively 
characterised and studied using laboratory-based infrared spectrometers in 
Chapter 2 and Chapter 3.1-2. The use of state-of-the-art infrared equipment 
coupled to the high brilliance and collimation of synchrotron radiation has 
advanced our understanding of the photophysical and photochemical properties 
of this anticancer prodrug candidate and enabled the development of (new) 
synchrotron techniques. All the results presented in this chapter were obtained 
at the THz/Far-IR and the Infrared Microspectroscopy beamlines at the 
Australian Synchrotron in Melbourne, Australia. This chapter describes the 
infrared transmission and reflection studies undertaken on 1, and consists of 
three parts: first, Synchrotron Radiation Far-Infrared (SR-FIR) transmission and 
Attenuated Total Reflection (ATR) studies to enable rapid screening of solid and 
evaporated liquid solutions of 1, exposing the changes occurring to the metal to 
ligand vibrations upon irradiation (section 4.2.1, 4.3.1); second, SR-FIR 
transmission measurements of the prodrug in solution under in situ irradiation 
exposed the decrease in the νPt-OH and νPt-N3 vibrations simultaneously 
(section 4.2.2, 4.3.2); the final part covers the mid-infrared single cell study of 1 
on live acute myeloid leukaemia cells (K562) by Synchrotron Radiation Infrared 
Microspectroscopy (SR-IRMS). Significant changes to the DNA base stacking 
and lipid vibrations were observed four hours after a low dose of 350 nm 
irradiation (2.58 J cm-2), whereas this was not observed or to a lesser extent in 
the control cells (section 4.2.3, 4.3.3). 
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Figure 4.1. Graphical abstract for the mid-infrared single cell study of 1  on l ive 
acute myeloid leukaemia cells (K562) by synchrotron radiation infrared 
microspectroscopy. 
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4.1 Introduction 
An introduction is provided below for the reader to familiarize themselves with 
the synchrotron based infrared techniques. The reader is kindly directed to 
Chapter 1.5.2 for a more detailed description of synchrotron light sources.  
Chapter 3.1 and 3.2 covered the use of mid-infrared to study the mechanism of 
action of 1 by monitoring its chemical environment on its own and in presence 
of a DNA-base nucleotide. Herein, state-of-the-art infrared equipment coupled 
with the high brilliance and collimation of the synchrotron beam enable studies 
to be carried out with unprecedented signal-to-noise ratios and resolution 
throughout the far-infrared to mid-infrared spectral region. 
4.1.1 Synchrotron Radiation Far-Infrared 
The use and further development of SR-FIR techniques to study the 
photoactivatable metal-based anticancer complex 1, studied throughout this 
thesis, is persued in this chapter to revisit far-infrared spectroscopy as a tool to 
study the characteristics of inorganic complexes. These include ATR and 
transmission experiments to study 1 in its crystalline, solvated and dissolved 
state. 
The usefulness of low-frequency spectra of inorganic and coordination 
compounds was already highlighted as early as the 1900’s by Randall.[1] The 
region below 650 cm-1 has vast amounts of metal to ligand vibrations and has 
been used throughout the years as a tool for structural analysis of such 
inorganic and coordination compounds. This, of course, is prior to the 
emergence of synchrotron radiation (SR) sources and Fourier transform 
interferometers as well as other analytical methods to carry out structural 
analysis of these compounds. Interestingly, the first use of Fourier transform 
interferometers in chemical applications was made in far-infrared 
spectroscopy.[2] One of the major limits in traditional far-infrared spectroscopy 
was the lack of energy in the low-frequency region of the infrared blackbody 
emission sources, such as the Globar or mercury arc lamps. These 
conventional infrared sources are still used as mid- and far-infrared sources, but 
typically emit over 500 times less energy at 200 cm-1 compared to 5000 cm-1.[1d] 
SR and FEL’s (free electron lasers) inspired the resurgence of far-infrared 
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studies with their unparalleled brilliance and collimation. This, together with 
more recent short pulse laser beam systems have led to the field of THz 
spectroscopy, covering the so called ‘THz gap’ (300 – 3 cm-1 or 10 – 0.1 THz) in 
the last decade or two, whereas acquiring significant intensity by infrared 
sources was difficult prior to this.[2]  
The use of water in far-infrared spectroscopy was avoided in the early stages, 
due to the strong broad absorbance in this region caused by intermolecular 
hydrogen stretching and libration modes of water, especially compared to the 
weak vibrations of the solute.[3] This is further reflected in the design of the 
interferometers, which are the typically in vacuum to reduce interference of 
water vapour. However, following the advancements in equipment and SR, 
more recent studies have shown that these vibrations of water can be exploited 
to investigate the higher-order structures of proteins and biological molecules by 
studying the hydration layers and/or hydrogen bonding networks.[4] 
To date, THz/far-infrared spectroscopy has been used for a variety of 
applications. These include but are not limited to, astrophysical and 
atmospheric research on gas phase molecules, potential surface studies of 
small molecules and atoms, morphology investigations of polymers and 
materials, studying low wavenumber vibrations of inorganic materials, 
phonon/lattice mode and optical constants determination of molecular crystals 
and biomolecular investigations of DNA, proteins, cells and tissue.[1d,2-5] 
4.1.2 Synchrotron Radiation Infrared Microspectroscopy 
The nature of vibrations in biological materials have been studied in great detail 
in the past decades leading to comprehensive descriptions of cellular vibration-
bands in the mid-infrared region (4000 – 400 cm-1).[6] A list of the main cellular, 
tissue and DNA related vibrations are tabulated in Table 4.1.  
Changes occurring to these described vibrations (in absolute or relative 
intensity, ratio and/or wavenumber) can be used to deduce mechanistic 
information of a factor applied to the cell, such as light irradiation, drug uptake 
or oxygen deprivation.[7] 
A prime example is the effect of cisplatin (cis-[PtCl2(NH3)2], CDDP) on cells, 
which is known to interact with DNA to form DNA adducts (primarily in the form 
of intra-strand crosslinking) leading to an extended signalling pathway cascade, 
usually leading to cell cycle arrest in its G2 phase and ultimately apoptosis 
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(Chapter 1.2.1).[8] Bambery et al. studied the effect of cisplatin uptake in single 
rat glioma cells by synchrotron radiation infrared microspectroscopy (SR-
IRMS).[9] Multivariate data analysis of the infrared spectra of treated versus non-
treated cells revealed a blue shift in the anti-symmetric phosphodiester 
stretching vibration (1241 – 1228 cm-1 region), which is characteristic of RNA 
(Table 4.1). These results were related to an increase of mRNA concentration 
inside the cell under these conditions. The indication of mRNA synthesis was 
assigned to a cellular response preceding protein synthesis in an apoptotic or 
repair event, in line with the mechanism of action of cisplatin. Interestingly, this 
shows that the largest effect of cisplatin on rat glioma cells, as monitored by 
infrared vibrations, is not related to nuclei condensation but rather a secondary 
response effect of the cell upon treatment with cisplatin. This technique proves 
to be an effective tool to study such drugs as cisplatin in cells on a single 
cellular basis, complementing the more conventional cytotoxicity assays. 
Fourier Transform Infrared (FTIR) spectroscopy and imaging techniques are 
rapidly developing in terms of resolution and acquisition time, whereby single 
cellular level of detection is now possible using Globar infrared sources.[10] The 
main reason FTIR has not seen wide application in the study of live biological 
systems is the strong mid-IR absorption of water overlapping with the vibrations 
outlined in Table 4.1 (the broad vibrations: ν(OH)  between 3700 – 2800 cm-1, 
centred at ~3300 cm-1 and δ(H2O) between 1700 – 1500 cm-1, centred at ~1640 
cm-1). Fixation methods, such as methanol or cryogenic fixation are commonly 
employed to circumvent this problem.  
However, Tobin et al. reported the development of a microfluidic sample slide 
allowing infrared transmission through cellular samples by limiting the path 
length to 12 µm or less whilst being in a hydrated state (e.g. cell medium).[11] 
This is where the high collimation and brilliance of SR offers advantage over the 
bench-top equipment. The aperture size of the SR can be reduced to ≥ 5x5 µm 
while maintaining high signal-to-noise ratio, thus allowing the infrared beam to 
pass through single cells without passing through the surrounding medium or 
solvent. Any remaining intracellular water/medium signal can be subtracted by 
acquisition of background spectra in the surrounding cellular environment.[11] 
Using a similar setup, Zobi et al. studied the uptake and cellular distribution of a 
metal-based photoactivatable carbon monoxide releasing complex 
(photoCORMs, Chapter 1.3.2) in fibroblasts (in growth medium) by SR-IRMS.[7d] 
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The CO stretching vibrations of the metal-carbonyl complex between 2100 – 
1800 cm-1, which are at least 100 cm-1 separated from the cellular vibrations 
(vide infra), were used to track the internalisation, accumulation and subsequent 
photoactivation of the compound without the need of exogenous labelling. This 
demonstrates the potential power of synchrotron-based infrared techniques. 
 
Table 4.1. Major infrared bands found in cells, t issues and nucleic acids. 
Reproduced from Ref. [12] with permission from the Royal Society of Chemistry. 
 
Notations used: ν  = stretch, δ  = in-plane angle bending, s = symmetric and as = 
anti-symmetric. 
 
The effect of the diazido Pt(IV) anticancer prodrug candidate 1 on live K562 
cells is investigated in this chapter and the corresponding infrared marker bands 
of K562 cells are listed below and a single cell infrared spectrum of K562 by 
SR-IRMS is shown in Figure 4.2. 
New materials for anticancer imaging and therapy 
Chapter 4 Robbin R Vernooij 192 
CH3 and CH2 stretching vibrations (3000 – 2800 cm-1) relate to all lipids inside 
the cell, as well as methyl containing parts of proteins and DNA. The weak 
carbonyl stretching vibrations (ν(C=O)) are related to phospholipids (~1740 
cm-1) and base stacking of purine and pyrimidine moieties (~1720 cm-1). The 
latter provide information about the ratio of alpha (A) and beta (B) sheet DNA. 
The amide I peak (1650 – 1635 cm-1) is the most intense absorption band. This 
is primarily governed by the in-plane carbonyl stretching vibration coupled to the 
carbon to nitrogen stretching vibration.[6,13] The amide II band is more complex, 
but mainly consists of the in-plane R2-N-H bending vibration with minor 
contributions (in potential energy terms) from carbon to nitrogen and carbon to 
carbon stretching vibrations.[6,14] Furthermore, the CH2 and CH3 bending modes 
(~1450 cm-1) from lipids and proteins, as well as the symmetric and anti-
symmetric phosphate stretching vibrations (~1180 cm-1 and ~1250 – 1215 cm-1, 
respectively) clearly stand out in the spectrum. Whilst these spectral features 
look very clear, changes occurring to these vibrations are relatively minor (small 
shifts of 3 – 10 cm-1 and minor peak ratio and/or peak intensity changes). 
Spectral and experimental replicates become highly essential in these cases 
and multivariate data analysis is almost a necessity to statistically verify 
observations. 
 
Figure 4.2. A synchrotron radiation infrared microspectroscopy spectrum of a 
single K562 cell including selected peak labels. Spectrum is background and 
rubberband baseline corrected. Notations used: ν  = stretch, sym = symmetric and 
asym = anti-symmetric. 
νsym(PO2-) 
νasym(CH3, CH2) 
νasym(PO2-) 
ν(C=O) 
amide I 
amide II 
νsym(CH3, CH2) 
Wavenumbers (cm-1) 
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Partial Least Squares-Discriminant Analysis (PLS-DA) models are used to 
investigate the data obtained from by SR-IRMS. PLS-DA is a statistical 
classification tool to capture variation in a data set, like the Principal Component 
Analysis (PCA) mentioned and used in Chapter 3.1. The main difference 
between the two is that PCA is an unsupervised method whilst PLS-DA is a 
supervised method, i.e. PLS-DA has predefined classes and looks to reduce 
dimension of the data set between these classes whilst PCA does not attempt 
to discriminate between classes directly. Thus, PLS-DA allows to breakdown 
data sets affected by several conditions (classes), such as the influence of time, 
irradiation and treatment with a drug on cellular spectra. An example data set is 
provided in order to further rationalise how PLS-DA operates and can be used 
to interpret data sets. 50 random spectra are generated and a distinct spectral 
feature is applied (green class) to half of them at 850 a.u. where no predefined 
band shapes were generated (Figure 4.3). While to the other half (red class), a 
spectral feature is added underlying the randomly generated bands at 1220 a.u. 
(Figure 4.3). The green feature at 850 a.u. results in an obvious distinction 
between the two sets, whereas the changes to the red class are less obvious 
due to overlapping bands and pre-existing features.  
 
Figure 4.3. 50 randomly generated spectra separated into two classes (green and 
red) by introducing a spectral feature for the green spectra at 850 a.u. (next to the 
generated peaks) and a spectral feature for the red spectra at 1220 a.u 
(underlying the generated peaks). 
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A PLS-DA model is created which contains two regression vectors (in the case 
of two classes) and cross validation is applied by checking the difference 
between each sample and the regression vectors. The cross validation value 
and/or error are measures of the classification performance and the regression 
vector is a measure of the direction (positive or negative) and intensity of the 
spectral bands in each classification (Figure 4.4). 
 
Figure 4.4. PLS-DA regression vectors (left) and Y cross validation error (right). 
 
The classification captures both manually applied spectral features in the 
regression vectors (850 a.u.; green = positive, red = negative,1220 a.u.; red = 
positive, green = negative). The separation of the green and red class by the 
cross validation error value (Ycv value) provides an approximation of how much 
the classes differ to each other and how well each sample performs in its class 
(green clusters around Ycv = 0 and red clusters around Ycv = 1). In a real time 
example, one would then investigate what changes to spectral features centred 
at 850 a.u. and 1220 a.u. could imply as described above. 
 
 
 
Variable (a.u.) Sample 
Y
cv
 v
al
ue
 
R
eg
re
ss
io
n 
ve
ct
or
s 
New materials for anticancer imaging and therapy 
Chapter 4 Robbin R Vernooij 195 
4.2 Results 
All studies were carried out at the Australian Synchrotron in Melbourne, 
Australia at the THz/Far-IR and Infrared Microspectroscopy beamlines. Beam 
time was acquired three times through the merit-based proposal scheme and 
once via an expert user application. A total of four days were spent at the 
Infrared Microspectroscopy beamline and twelve days at the THz/Far-IR 
beamline. In addition, the author has been involved with the development of the 
ATR technique for the THz/Far-IR beamline, which is now accessible for 
synchrotrons users as of application round 3, 2017.  
4.2.1 Synchrotron Radiation Attenuated Total Reflection Far-Infrared 
A feasibility study was carried out to test the potential application of attenuated 
total reflection in a synchrotron infrared setup, prior to the development and use 
of the Attenuated Total Reflection Synchrotron Radiation Far Infrared (SR-ATR-
FIR). 
Towards this end, a Specac golden gate diamond ATR accessory was used in 
both a bench top Bruker Equinox 55 FT-IR spectrometer (fixed beamspot size 
of ~30 mm) at Monash University and the IFS 125/HR Bruker FT spectrometer 
(variable beamspot size of 12.5 to 0.5 mm) at the Australian synchrotron. 
Different infrared sources, detectors and beamsplitters were used to test the 
capabilities of an ATR setup, which are listed in Table 4.2.  
The Specac ATR accessory contains ZnSe condensing optics to focus the 
infrared beam onto the 4 mm x 4 mm ATR crystal, which do not transmit 
infrared radiation below ~480 cm-1; this limited the spectral region to test. The 
entire IFS 125/HR Bruker FT spectrometer, including sample chamber, 
operates at   ≤ 10-4 mbar to minimise H2O and CO2 interference. Therefore, all 
spectra were obtained under vacuum, regardless of the infrared source.  
Solid polystyrene and Teflon™ samples (poly(1-phenylethene) and 
polytetrafluoroethylene) were used to carry out the spectral acquisitions and the 
reference spectra were obtained on the Bruker Equinox 55 FT-IR spectrometer. 
Infrared spectra of both materials at a resolution of 4 cm-1 using SR and the 
internal Globar source (12.5 mm beamspot size) at the Australian Synchrotron 
were compared to the spectra obtained at Monash University (Figure 4.5). 
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Identical peak positions and similar peak intensities confirmed the correct 
alignment of the setup. The feasibility of SR applied to ATR-FTIR was 
benchmarked vs. the internal Globar source by measuring the signal counts of 
the background (empty ATR), Telfon™ and polystyrene using the three different 
detectors (Figure 4.6). Figure 4.6A-C show, that in all cases, SR is superior to 
the Globar for beamspot sizes ≤ 2 mm. Figure 4.6D shows an example of the 
polystyrene ATR spectra obtained using the Si:B photodetector using different 
beamspot sizes for both the SR and Globar infrared sources. The high signal-
to-noise ratio for SR is maintained throughout each beamspot size, as shown by 
the polystyrene peaks at 694 cm-1 and 536 cm-1. The quality of the spectra 
recorded with the Globar source, however, clearly diminishes when the 
beamspot size is decreased (Figure 4.6D). This feasibility study of a SR-ATR-
FIR setup proved to be successful and enabled the following studies using a 
far-infrared capable ATR accessory. 
 
Table 4.2. Experimental setups used to test the potential of synchrotron radiation 
and ATR. A Specac golden gate diamond ATR accessory was used in all setups. 
Spectrophotometera Infrared 
sourceb 
Beamspot 
size 
(mm) 
Detectorc Beam 
splitter 
 Measurable 
spectral 
region (cm-1) 
 
IFS 125/HR Bruker  SR 
or 
Globar 
12.5 – 0.5 He-cooled Si 
bolometer 
6 µm 
multilayer 
Mylar 
 650 – 40d  
He-cooled 
Si:B 
photodetector 
KBr  750 – 450d  
N2-cooled 
MCTn 
KBr  5000 – 700  
Bruker Equinox 55 Globar ~30 N2-cooled 
MCT 
KBr  4000 – 600  
a Acquisit ion parameters: resolution =  4 cm-1, 50 interferograms coadded, 40 kHz. 
b SR = synchrotron radiation, Globar = internal infrared source. c MCTn = Mercury 
Cadmium Telluride narrow band, Si:B photodetector was not used for spectral 
acquisit ion, only for infrared signal counts. d Lower l imit restricted to 480 cm-1 due 
to ZnSe optics in the golden gate ATR accessory, ordinary lower l imits: Si 
bolometer = 10 cm-1 and Si:B photodetector = 300 cm-1. 
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Figure 4.5. ATR-FTIR spectra of Teflon™ and polystyrene, including selected 
peak labels. A & E) Molecular structures of Teflon™ and polystyrene. B & F) 
Spectra obtained with SR (12.5 mm) and MCTn detector. C & G) Spectra obtained 
with Globar (12.5 mm) and MCTn using the IFS125 at the THz/Far-IR beamline. D 
& H) Reference spectra obtained with Globar and MCT using the Equinox 55 at 
Monash University. Notations used: ν  = stretch, δ  = in-plane angle bending and γ  
= out-of-plane angle bending. The descriptions of phenyl modes are given in 
Wilson’s notations.[15] 
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Figure 4.6. Comparison of SR and Globar infrared source in the IFS 125/HR 
Bruker FT spectrometer equipped with a Specac golden gate diamond ATR 
accessory with three different detectors. Please refer to Table 4.2 for 
experimental conditions. A) MCTn detector counts using the Globar and SR 
infrared source at different beamspot sizes. B) Si:B photodetector counts using 
the globar and SR infrared source at different beamspot sizes. C) Si Bolometer 
detector counts using the Globar and SR infrared source at different beamspot 
sizes, please note that detector counts of Teflon™ and polystyrene could not be 
obtained due to l imited offl ine synchrotron time. D) Example ATR spectra of 
polystyrene, including peak labels, at different beamspot sizes using the Globar 
and SR infrared sources with the Si:B photodetector, highlighting the diminishing 
quality of the spectra using the Globar source when decreasing the beamspot size 
whilst the high signal-to-noise ratio of the SR remains the same. 
 
New materials for anticancer imaging and therapy 
Chapter 4 Robbin R Vernooij 199 
The above results allowed for a successful expert user time application at the 
Australian synchrotron to use a far-infrared capable ATR accessory for 48 hours 
to further test the capabilities of a SR-ATR-FIR setup. A Bruker platinum ATR 
accessory was kindly provided by Dr. Bobby Pejcic from CSIRO in Western 
Australia. The two days of beamtime was allocated to several potential SR-
ATR-FIR projects to support a funding application for a beamtime accessible 
SR-ATR-FIR setup. These included: 
1. Investigation of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) and its synthetic 
precursors trans-[Pt(N3)2(py)2] (2) and trans-[Pt(Cl)2(py)2] (3) using 
SR-ATR-FIR vs. SR-FIR (transmission infrared, as described in Chapter 
2). 
2. The photodecomposition of 1 by SR-ATR-FIR. 
3. Screening of solid DNA nucleobases for use in metal complex binding 
studies. 
4. Investigation of potential far-infrared marker bands of malaria infected 
red blood cells. 
 
Points 1 and 2 will be reported and discussed below. Points 3 and 4 can be 
found in section 4.8 at the end of this chapter to maintain focus of this work on 
complex 1. 
 
The Bruker platinum diamond ATR accessory was fitted into the IFS 125/HR 
Bruker FT spectrometer. This ATR accessory only contains gold-coated 
reflective mirrors and no condensing optics to obtain a spectral range of 8000 – 
10 cm-1. The synchrotron beamspot size was set to 2 mm, and no increase 
signal counts was observed beyond this diameter. Spectra were recorded at a 
resolution of 1 cm-1, 128 interferograms co-added. Samples were either 
measured as solids with the ATR anvil pressed down to ensure proper contact 
between the sample and the diamond (Figure 4.7A), or deposited onto the ATR 
diamond from solution followed by evaporation under a gentle N2 flow resulting 
in a thin layer of sample (Figure 4.7B). A custom built cover was placed over the 
ATR accessory to seal the spectrometer and allow for measurements in vacuo 
(Figure 4.7C).  
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Figure 4.7. A Bruker platinum ATR accessory inside an IFS 125/HR Bruker FT 
spectrometer with a custom built cover at the Australian Synchrotron. A) ATR 
anvil pressed down in a solid sample. B) A thin layer of sample (1) on the ATR 
diamond from solution after evaporation of solvent. C) Custom built l id to allow 
vacuum sealing inside the sample chamber whilst the ATR accessory is aligned. 
 
 
Figure 4.8. Structures of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1), trans-
[Pt(N3)2(py)2] (2) and trans-[PtCl2(py)2] (3). 
 
Initial comparison was made between the previously obtained transmission 
spectra at ~301 K of 1 and its synthetic precursors 2 and 3 (Figure 4.8), as 
reported in Chapter 2.[16] Figure 4.9 shows the ATR vs. transmission spectra, 
with peak labels and assignments in line. Extended ATR correction was carried 
out on the SR-ATR-FIR spectra of the solids of 1, 2 and 3 to correct for the 
artefacts caused by anomalous dispersion, as described previously in Chapter 
2.[16-17]  
A typical ATR spectra of solid samples took 5 – 10 min to acquire (majority of 
the time consists of pumping down the sample chamber to ≤ 10-4 mbar), 
whereas transmission spectra took ~30 min – 2 h to acquire (with sample 
preparation being the most time consuming step). 
Identical sample preparation as described in Chapter 3.1 was used to carry out 
the ATR measurements of the photodecomposition of 1 in water under 420 nm 
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irradiation (small quantities of solution were deposited onto the ATR crystal, 
followed by evaporation under a gentle N2 flow, prior to measurement). Figure 
4.10 depicts the SR-ATR-FIR spectra of crystalline 1 (Figure 4.10A), 1 from 
solution prior to irradiation (Figure 4.10B), 1 after 10 min of irradiation (Figure 
4.10C) and 1 completely photodecomposed after 22 h of irradiation (Figure 
4.10D).  
First, going from the crystalline solid of 1 to 1 evaporated from solution strongly 
effects the intermolecular interactions of 1 resulting in shifts of vibrational peaks 
mainly affecting the hydroxide and azide related vibrations, with less significant 
effects on the pyridine vibrations. The out-of-plane bending mode of azide, 
γ(N3), at 583 cm-1 and 574 cm-1 shifts to lower wavenumber values, merging 
together with the platinum to oxygen stretching vibration, ν(Pt-OH), shifting to 
higher energies from 540 cm-1 to the combination band at 574 cm-1, 569 cm-1 
and 559 cm-1. The out of plane pyridine bending mode, γ(py, 16b), shifts slightly 
from 476 cm-1 to 472 cm-1. Furthermore, the platinum to nitrogen (azido) 
stretching vibration, ν(Pt-N3), shows less splitting in bands with the two main 
vibrations at 411 cm-1 and 406 cm-1 (solid) remaining at 410 cm-1 and 406 cm-1. 
Platinum to oxygen bending modes, scr(HO-Pt-OH) at 299 cm-1 and 290 cm-1 
split up to 299 cm-1, 286 cm-1 and 278 cm-1. Lastly, the platinum to nitrogen 
(pyridine) stretching mode, ν(Pt-py), shifts to lower wavenumber values from 
257 cm-1 to 244 cm-1 with other combinational modes below 240 cm-1 effected 
slightly by the dissolution and evaporation of solvent of 1 (Figure 4.10A, B). 
Time restrictions only allowed for two time points to be investigated. 10 min was 
selected, at which time considerable changes were observed in the mid-infrared 
to the ν(OH) and νasym(N3) by ATR-FTIR without the complete removal of ν(OH). 
While at 22 h the spectrum of the final photoproduct is obtained, which only 
contained pyridine and water related vibrations. Upon 10 min of irradiation, the 
azido related vibrations show a reduction in wavenumber values and several 
shifts and splitting of bands (Figure 4.10B). Most importantly, the platinum to 
nitrogen (azido) stretching vibration, ν(Pt-N3), splits up into three main vibrations 
at 440 cm-1, 419 cm-1 and 384 cm-1, with γ(N3) still present at 578 cm-1. Further 
expanding on the hydroxido ligand vibrations, the broad platinum to oxygen 
(hydroxyl) stretching vibrations, ν(Pt-OH), peaking at 559 cm-1 prior to 
irradiation splits into two bands at 555 cm-1 and 507 cm-1, with the related 
platinum to oxygen bending modes reducing in intensity. The pyridine related 
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vibrations are mainly affected in terms of intensity. The γ(py, 16b) remains at 
473 cm-1 and the majority of vibrations below 230 cm-1 become too weak to 
observe apart from the vibrations at 222 cm-1 and 101 cm-1. Upon full 
photodecompositon of 1 after 22 h, the SR-ATR-FIR spectra consist solely of 
platinum to oxygen (OH/H2O) and pyridine vibrations as shown in Figure 4.10D. 
Namely, the broad platinum to oxygen stretching vibration, ν(Pt-OH/H2O), at 
545 cm-1, γ(py, 16b) at 468 cm-1, scr(HO-Pt-OH) at 295 cm-1 and ν(Pt-py) at 237 
cm-1. 
 
These results and those outlined in the Supporting Information were presented 
to the infrared beamline staff, which supported the successful internal 
synchrotron application by the THz/Far-IR beamline to purchase a custom built 
SR-ATR-FIR setup. This consisted of modifying a commercial ATR accessory to 
fit in the IFS 125/HR Bruker FT spectrometer, whereby the sample area above 
the ATR diamond would lie outside at ambient pressure while its optics 
remained in vacuum. A summary of the development of this ATR setup, which 
was finalised in June 2017 and is now available for beamtime applications, is 
shown in Figure 4.11. The SR-ATR accessory is a modified Pike GladiATR™ 
single reflection, heated (< 300 ⁰C), ATR accessory, with several optional 
adapters such as a digital high-pressure clamp and a liquid flow cell. 
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Figure 4.9. Transmission SR-FIR (black) and SR-ATR-FIR (red) spectra of 1  (A), 2  
(B) and 3  (C) including peak labels and selected peak assignments.[16] Resolution 
= 1 cm-1. Notations used: ν  = stretch, γ  = out-of-plane angle bending, scr = 
scissoring, wag = wagging. The descriptions of pyridine modes are given in 
Wilson’s notations, as described previously.[15-16] 
New materials for anticancer imaging and therapy 
Chapter 4 Robbin R Vernooij 204 
 
Figure 4.10. SR-ATR-FIR spectra of the photodecomposition of 1  (2 mM) under 
420 nm irradiation. A) 1  solid. B) 1  after dissolution in water followed by 
evaporation prior to measurement. C) 10 min of 420 nm irradiation. D) 22 h of 
irradiation. Resolution = 1 cm-1. Notations used: ν  = stretch, γ  = out-of-plane angle 
bending, scr = scissoring, wag = wagging. The descriptions of pyridine modes are 
given in Wilson’s notations, as described previously.[15-16] 
 
 
Figure 4.11. Timeline of the development of the SR-ATR-FIR accessory for the 
THz/Far-IR beamline at the Australian Synchrotron. Pike ATR accessory 
schematic and picture of the finalised setup (right) were kindly supplied by Dr. 
Dominique Appadoo. 
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4.2.2 Transmission Synchrotron Radiation Far-Infrared – Liquid cell in situ 
Irradiation 
The same spectrometer at the THz/Far-IR beamline at the Australian 
Synchrotron was used to work on a new transmission liquid cell far-infrared 
setup with a Surelite Nd:YAG pulsed laser (variable wavelength, beamsplitter 
set to 355 nm for these experiments in particular) aligned to the sample 
chamber to allow for in situ irradiation. Figure 4.12 shows a picture and a 
schematic representation of the setup. In short, the laser was aligned at a 90° 
angle to the SR, passing through a UV grade CaF2 window on the side of the 
sample chamber. By rotation of the sample holder, the sample can be exposed 
to irradiation and measured afterwards without breaking vacuum. The liquid 
cells are a custom design to be operated under vacuum, and are equipped with 
wedged diamond windows (1°) to attempt to minimise spectral artefacts caused 
by internal reflections from the window. These artefacts are further referred to 
as fringing, and will be considered in more detail below and in section 4.3.2.[18] 
Pictures of the diamond window liquid cells are shown in Figure 4.13. Different 
spacers can be used to achieve the desired path length (5 – 300 µm, Figure 
liquid 4.13A). One O-ring is used to seal the liquid from the vacuum (Figure 
4.13B) and allow for tight closure of the compressed windows (Figure 4.13C,D). 
The liquid cells allow for small excess sample volumes to be removed between 
the edge of the window and the O-ring upon tightening of the cell. Exact cell 
volumes and volumes used throughout the experiments are shown in Table 4.3. 
 
Table 4.3. Diamond window liquid cell volumes and volumes used according to 
spacer size. 
Spacer size (µm) Cell volume (µL) Volume used (µL) 
5 0.32 0.5 
10 0.64 - 
15 0.95 1.5 
20 1.27 1.5 
25 1.59 - 
50 3.18 4.0 
100 6.36 7.0 
200 12.72 - 
300 19.09 20.0 
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Figure 4.12. Picture (A) and simplif ied schematic representation (B) of the IFS 
125/HR Bruker FT spectrometer with a Surelite Nd:YAG pulsed laser aligned at a 
90° of the synchrotron radiation (SR). Rotation of the sample holder allows for 
sample exposure to irradiation without breaking vacuum. Please note that one 
sample compartment is left out for clarity. 
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Figure 4.13. Pictures of diamond window liquid infrared cells. A) Set holder with 
multiple spacers (5 - 300 µm) to vary the pathlength. B) Bottom and top window of 
a l iquid cell to hold the l iquid in between the O-ring. C/D) Assembled and sealed 
l iquid cell with a 100 µm spacer. 
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Initial tests of the liquid cells were carried out using different solvents: water, 
acetonitrile (MeCN) and dimethyl sulfoxide (DMSO). Fringing artefacts were 
found to be present, varying with solvent, sample, pathlength and within 
replicates (Figure 4.14A). Therefore, fringing corrections were carried out for 
each individual spectrum as reported previously.[18b,18c] The process provided 
below is supported by the example in Figure 4.14 of a 20 µm pathlength cell 
with MeCN: 
 
1. Inverse Fourier transformation of the single-channel sample spectrum 
(Figure 4.14B).  
2. Identify regions outside the centreburst in the interferogram that cause 
the fringing (Figure 4.14B, box 1 and 2). 
3. Straight line generation on those regions. 
4. Fourier transformation of the interferogram to the single-channel sample 
spectrum (Figure 4.14C). 
5. Single-channel sample spectrum divided by the single-channel reference 
spectrum (vacuum) gives the transmittance spectrum and is transformed 
to the absorbance spectrum (Figure 4.14D). 
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Figure 4.14. Processing schematic used to correct for fr inging artefacts. A) 
Single-channel sample spectra of vacuum (no fringes) and MeCN (sinusoidal 
fr inges observed). B) Resulting interferograms after inverse Fourier 
transformation, highlighting the artefacts of MeCN (box 1 and 2). C) Fourier 
transformed interferograms before (red), after one straight l ine generated on box 
1 (green) and after two straight l ine generations on box 1 and 2 (blue). D) 
Absorbance spectra (single-channel MeCN ÷ single-channel vacuum, transform 
transmission to absorbance) of corrected (blue) and uncorrected (red) MeCN 
single-channels. Notation used: δ  = in-plane angle bending. 
 
After this correction, depending on the sample, some artefacts still remained in 
the spectrum (Figure 4.14D, corrected MeCN) in the form of broader sinusoidal 
artefacts and non-smooth baselines. This prevented the use of water (strong 
far-infrared absorber) to study compounds at low concentration, at which one 
cannot distinguish between noise and signal with certainty. Therefore, DMSO 
was used as a solvent to study the in-situ photodecomposion of 1 to allow for 
elevated concentrations and longer pathlengths. 
The SR-FIR spectrum of DMSO using a 20 µm pathlength is shown in Figure 
4.15 with corresponding peak labels. Two methyl rocking modes are present at 
954 cm-1 and 933 cm-1, both in-plane and out-of-plane angle bending of CSO at 
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383 cm-1 and 334 cm-1, the out-of-plane CSC bending mode at 309 cm-1 and the 
broad peak at 97 cm-1 corresponding to intermolecular vibrations of several 
hundreds of DMSO molecules. These peaks are in line with previously reported 
results.[5n,19] Note that the CSC stretching vibrations cannot be observed, 
reported between 700 – 650 cm-1, due to absorption of the polyethylene window 
in the detector. 
 
 
Figure 4.15. SR-FIR spectrum of DMSO in a 20 µm pathlength diamond window 
liquid cell. Beamsplitter (Mylar) and detector (polyethylene window) are cut (~920 
– 870 cm-1 and ~740 – 650 cm-1, respectively) and the spectrum is smoothed (31 
points). Resolution = 1 cm-1. Notations used: rock = rocking mode, δ  = in-plane 
angle bending, γ  = out-of-plane angle bending. 
 
Elevated concentrations had to be used to observe clear absorption for 1 (76 
mM, 35.8 mg mL-1, 0.54 mol%) and its synthetic precursor 2 (54 mM, 23.6 mg 
mL-1, 0.38 mol%). The spectra of 1 and 2 in a 100 µm pathlength cell are shown 
in Figure 4.16. The pyridine bending mode, γ(py, 4), is located at 777 cm-1 and 
772 cm-1 for 1 and 2 respectively. The platinum to oxygen stretching vibration, 
ν(Pt-OH), can be clearly observed at 567 cm-1 for 1. The platinum to nitrogen 
stretching vibration for 1 and 2, ν(Pt-N3), are located at 410 cm-1 and 408 cm-1 
on the shoulder of the DMSO vibration, δ(CSO). The out-of-plane bending 
mode of DMSO, γ(CSC), at 309 cm-1 can be used as a reference and allows 
for the normalisation of spectra. Please note that the other stronger vibrations of 
DMSO (δ(CSO) at ~380 cm-1 and γ(CSO) at ~330 cm-1) are not considered due 
to line saturation caused by the 100 µm pathlength and are therefore not true 
values.  
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Figure 4.16. SR-FIR spectra of DMSO, 1  (76 mM in DMSO) and 2  (53 mM in 
DMSO) in a 100 µm pathlength diamond window liquid cell. Spectral regions are 
cut to remove absorption of the polyethylene window in the detector and the 
spectra are smoothed (15 points). Resolution = 1 cm-1. Notations used: ν  = 
stretch, γ  = out-of-plane angle bending. The description of the pyridine mode is 
given in Wilson’s notations, as described previously. [15-16] 
 
The raw and second derivative spectra of the photodecomposition of 1 in 
DMSO (76 mM) are shown in Figure 4.17. Second derivative spectra are 
acquired to enhance the separation of overlapping peaks and exclude broad 
background features. Please note that in second derivative spectra, peak 
minimum correspond to peak maxima in the un-derivatised spectra. Rapid 
decrease of the ν(Pt-N3) vibration is observed in the first five minutes, after 
which it slows down and the peak shifts from 410 to 409 cm-1 (insignificant as 
spectra were recorded at a resolution of 1 cm-1). After 1 h and 15 min of 
irradiation, a new peak is gleaned at 419 cm-1, which continues to evolve until 
the last spectrum is recorded, 7 h 15 min later (Figure 4.17B). The ν(Pt-OH) 
vibration continues to decrease throughout irradiation, with complete removal 
observed after 7 hours 15 minutes. Furthermore, the γ(py, 4) shifts from 777 
cm-1 to 772 cm-1 during irradiation. The average peak intensities (four 
replicates) of the ν(Pt-OH) and ν(Pt-N3) vibrations during irradiation are plotted 
in Figure 4.18 (567 cm-1, 419 cm-1 and 409 cm-1  normalized second derivative). 
A near identical trend is observed for the 567 cm-1 and 409 cm-1 vibrations, 
which indicates a same rate of removal for the ν(Pt-OH) and ν(Pt-N3) vibrations 
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in terms of peak intensity and sharpness of the band. Irradiation of DMSO in 20 
µm and 100 µm pathlength liquid cells was carried out and no changes were 
observed (section 4.8, Figure S4.6). 
 
 
Figure 4.17. SR-FIR spectra (A) and second derivative spectra (B) of the 
photodecomposition of 1  in DMSO (76 mM) under 355 nm irradiation, including 
selected peak labels. A) Raw spectra are cut to highlight peaks. B) Second 
derivative (65 smoothing points, weighted tails), normalized to 309 cm-1. Arrows 
indicate increase, decrease or shift direction of the vibration during irradiation. 
Resolution = 1 cm-1. Notations used: ν  = stretch, γ  = out-of-plane angle bending. 
The description of the pyridine mode is given in Wilson’s notations, as described 
previously.[15-16] 
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Figure 4.18. Average second derivative intensities of the ν(Pt-OH) and ν(Pt-N3) 
vibrations (567, 419 and 409 cm-1) of four measurements. Standard deviations are 
depicted as error bars, relative second derivative intensities shown. 
 
The next set of experiments was carried out to study the effect of 1 on DNA by 
SR-FIR. Deoxyribonucleic acid sodium salt from calf thymus (CT-DNA) was 
used, and samples were freshly dissolved in water (15.8 mg/mL) prior to each 
measurement. The smallest spacer (5 µm) was used due to the strong 
absorption of water, allowing a spectral window between 300 – 45 cm-1. Figure 
4.19 shows the spectrum of water (MiliQ) by SR-FIR, highlighting the broad 
band peaking at ~194 cm-1 which corresponds to the restricted translation mode 
of stretching hydrogen bonds (ν(O-H!!!O)).[3,5g] A second broad feature can be 
observed at ~64 cm-1, which has been previously attributed to a β-band 
(bending of the intermolecular hydrogen bonds).[3,20] 
Multiple spectra of water, CT-DNA in water and CT-DNA + 1 were recorded in 
the dark and after exposure to irradiation (355 nm). A list of recorded spectra 
and experimental replicates is tabulated in Table 4.4. No considerable 
differences can be observed between individual spectra, as shown in Figure 
4.20, containing six selected spectra showing slight intensity differences.  
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Figure 4.19. SR-FIR spectra of water (black = fringing corrected, red = smoothed, 
65 points) in a 5 µm pathlength diamond window liquid cell. Offset between 
smoothed and raw spectra is artif icially created for clarity. Peak labels indicate 
the stretching and bending mode of intermolecular hydrogen bonding at ~194 cm-1 
and ~64 cm-1 respectively.  
New materials for anticancer imaging and therapy 
Chapter 4 Robbin R Vernooij 215 
Table 4.4. SR-FIR spectra recorded of l iquid/solution samples. CT-DNA in water 
(15.8 mg/mL), 1  (3.0 mM, 1.5 mg/mL). 
Component Irradiation , 
355 nm (min) 
Experimental 
replicates 
Total spectra 
obtained 
water - 10 27 
 5 1 4 
 30 1 4 
CT-DNA - 7 59 
 5 2 8 
 30 2 8 
CT-DNA + 1 - 2 11 
 5 1 12 
 
 
Figure 4.20. SR-FIR spectra of water, CT-DNA and CT-DNA+1  with and without 
355 nm irradiation (IRR) in a 5 µm pathlength diamond window liquid cell. Spectra 
are fringing corrected, smoothed (65 points) and normalized (SNV). A) full 
spectral region. B,C) 210 – 180 cm-1 and 70 – 60 cm-1 highlighting the minor 
differences between spectra. 
 
Principal Component Analysis (PCA) was carried out in an effort to identify any 
variation between spectra, samples and experiments. Three Principal 
Components (PCs) were selected, capturing 95% of the variance. The resulting 
PCA scores and loading plots of PC1 and PC2 are shown in Figure 4.21, 
whereas PC1 and PC2 vs. PC3 plots can be found in section 4.8, Figure S4.7. 
Spectral replicates cluster well in the score plot of PC1 vs. PC2. However, 
experimental replicates do not, as shown by the selected bold symbol labels in 
Figure 4.21A. Experimental replicates were found on opposite sites of the plots 
in all cases. The loading plots corresponding to PC1 and PC2 reveal that the 
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variation captured by the PCA is due to difference in offsets between spectra, 
mainly at ~280 cm-1 (negative in PC1, positive in PC2) and between 120 - 50 
cm-1 (Figure 4.21B). These results are further elaborated on in the discussion. 
 
Figure 4.21. PCA score and loading plots for the SR-FIR spectra of water, CT-
DNA and CT-DNA+1  with and without 355 nm irradiation (IRR) in a 5 µm 
pathlength diamond window liquid cell. A) Score plot PC1 vs. PC2, bold labels of 
water and CT-DNA highlight the variation between experimental replicates. B) 
Loading plots and peak labels of PC1 (blue), PC2 (red) and the mean spectrum of 
the data set (black dashed line) for comparison. IRR = irradiation time of 5 or 30 
minutes. 
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4.2.3 Synchrotron Radiation Infrared Microspectroscopy – Live Single Cell 
Study 
The acute myeloid leukaemia cell line, K562, was used to study the effect of 1 
on live cells by synchrotron radiation infrared microspectroscopy (SR-IRMS) in 
the mid-infrared region (3800 – 900 cm-1). Cells were treated as described in 
the experimental section and an overview of the measured samples is shown in 
Figure 4.22.  
 
Figure 4.22. Overview of K562 cell treatment and SR-IRMS measurement points 
(60 single cell spectra per point, carried out in triplicate). Drug = 1 , IRR = 
irradiation, square = no addition of 1 , circle = addition of 1 , white = cells not 
exposed to irradiation, blue = cells exposed to 350 nm irradiation.  
 
The average second derivative spectra (to enhance spectral features) of each 
time point were investigated prior to statistical analysis. As an example, 
differences between the spectra are outlined in Figure 4.23 showing the 
average second derivative spectra of cells not treated with 1 at time point 0 and 
no irradiation vs. cells treated with 1 and irradiated at time point 0, 4 h and 16 h. 
Other average spectra were omitted for clarity and will be discussed in more 
detail below. Selected peak labels are included in Figure 4.23, covering 
potential marker bands to monitor throughout the full spectral analysis (please 
note that in second derivative spectra, peak minimum correspond to peak 
maxima in the un-derivatised spectra).  
In the high wavenumber region (Figure 4.23A), there is a change in ratio to the 
νsym(CH3) vibration related to cellular lipids at 2893 cm-1 and 2875 cm-1. 
Furthermore, a decrease in intensity of lipid vibrations at 2924 cm-1 and 2852 
Cell split 
4 h drug 
Incubation 
wash 
Drug, no IRR 
Drug, IRR 
No Drug, no IRR 
No Drug, IRR 
Tbefore IRR T0 T16 h T4 h 
Measurement Points 
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cm-1 (νasym(CH3) and  νsym(CH2)) is observed four hours after irradiation, 
whereas these vibrations become equal to untreated cells after 16 hours. 
Several differences can be observed between 1800 cm-1 and 1040 cm-1 (Figure 
4.23B): the B-DNA base pairing vibration at 1716 cm-1, several of the amide I 
vibrations (1655 cm-1, 1645 cm-1 ‘water’, 1628 cm-1), the amide II vibration at 
1552 cm-1, the A-DNA and ribose vibration at 1173 cm-1 and the RNA vibrations 
at 1173 cm-1, 1124 cm-1 and 1119 cm-1.  
 
Figure 4.23. Average second derivative spectra of K562 cells by SR-IRMS 
including selected peak labels (A: 2980 – 2820 cm-1, B: 1800 – 1040 cm-1). Four 
measurement points are depicted for comparison: t ime point before irradiation, no 
drug and no irradiation vs. t ime points 0, 4 h, 16 h with treatment of 1  and 
irradiation.  
 
Pre-processing was applied to the raw spectra as outlined in the experimental 
section and outliers were removed with at least 50 spectra per time point per 
replicate remaining. Six individual PLS-DA’s were setup to discriminate between 
the different factors applied to the cell: time, drug, irradiation and combinations 
of the three. Each factor was compared vs. cells not exposed to irradiation, drug 
and time. 
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Figure 4.24. Ycv values (A) and cross validation errors (B) of the PLS-DA’s of the 
effect of t ime, irradiation and/or drug (blue) vs. no time, no irradiation and no drug 
(red). IRR = irradiation, drug = 1  and time = 4 hours. 
 
The Ycv values and cross validation errors of the PLS-DA’s are depicted in 
Figure 4.24. The largest separation between 0 and 1 for the Ycv values is 
observed for the cells affected by time, drug and irradiation. The cross 
validation errors similarly reflect this with the lowest percentage obtained for 
time, drug and irradiation, whereas larger cross validation errors are obtained 
for the independent and control factors (> 8%) on the cells. 
The regression vectors for each PLS-DA are shown in Figure 4.25. Inspection 
of the regression vectors from the PLS-DA reveal the main contributions of the 
Ycv value plots of the control factors (time, drug, irradiation and time and drug) 
to be related to the DNA vibration underlying the amide I at 1662 cm-1 and the 
symmetric phosphate vibration (νsym(PO2-)) at 1084 cm-1. The regression vector 
for the time and irradiation factor has one main additional contribution that 
stands out at 1564 cm-1 (shoulder of the amide II vibration) and two minor 
contributions from the B-DNA basepairing vibration and water from the amide I 
vibration at 1713 cm-1 and 1639 cm-1, respectively. Time, drug and irradiation 
factor, however, clearly have additional main spectral contributions in the 
regression vector. These include, νsym(CH3) at 2875 cm-1, the more prominent 
B-DNA and A-DNA basepairing vibrations at 1713 cm-1 and 1705 cm-1 
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respectively, the amide II vibration at 1558 cm-1, 1367 cm-1 on the shoulder of 
the ν(COO2-) vibration of fatty acids and amino acid side chains and the A-DNA 
and ribose vibration at 1178 cm-1. 
 
Figure 4.25. Regression vectors obtained for each PLS-DA, including selected 
peak labels. IRR = irradiation, drug = 1  and time = 4 hours. 
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4.3 Discussion 
4.3.1 Synchrotron Radiation Attenuated Total Reflection Far-Infrared 
New experimental setups for the THz/Far-IR beamline were pursued to allow for 
faster measurements and reduced sample preparation times. ATR is a 
commonly used infrared method allowing for a range of sample compositions 
(solid, liquid, film) to be measured without prior sample preparation. Prior to this 
work, only one such SR-ATR setup was known to exist, at the SOLEIL 
synchrotron in France.[21] 
Alignment of an ATR accessory (Specac golden gate ATR) was possible using 
SR and Globar infrared sources, with reference material spectra obtained using 
a bench-top ATR setup matching the SR spectra. The Specac golden gate ATR 
accessory limited the spectral range to 480 cm-1 (lowest) due to the ZnSe 
condensing optics which focus the infrared beam on the 4 mm x 4 mm ATR 
crystal. The feasibility of a SR ATR setup was tested by comparison of the 
internal Globar to the SR infrared source by varying the infrared beamspot size. 
Globar infrared sources are typically weaker in the far-infrared region (< 400 
cm-1), unfortunately, this could not be tested with this particular setup. 
Nevertheless, it showed the superiority of SR over Globar at beamspot sizes 
smaller than 2 mm. Furthermore, far-infrared capable ATR accessories typically 
do not contain condensing optics and would therefor not limit the spectral region 
and the high collimation of SR starts to become key with smaller sample areas. 
The outcome of this study enabled the follow up studies using a far-infrared 
capable ATR accessory. 
The Bruker platinum ATR accessory was used to obtain rapid collection of solid 
sample spectra of metal complexes, DNA nucleobases and malaria infected red 
blood cells. The previously measured SR-FIR spectra of 1, 2 and 3 could be 
matched with the SR-ATR-FTIR spectra. Furthermore, the photodecomposition 
using identical experimental preparations as in Chapter 3.1 was attempted. 
SR-ATR-FIR spectra of irradiated time points of 1 were limited to two time 
points (10 min and 22 h) due to time restrictions caused by extended amounts 
of time the spectrometer took to reach an adequate vacuum level to use the SR 
after samples were deposited (~3 – 5 h). This is likely caused by extended 
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periods of time (~1 h) to deposit liquid samples on the ATR followed by 
evaporation, allowing water and CO2 accumulation inside the sample chamber 
(ultimately circumvented with the out-of-vacuum sample setup). The deposition 
of samples using a mid-infrared ATR-FTIR setup as outlined in Chapter 3.1 took 
considerably less amount of time (1 – 5 min). This is due to two factors, first the 
Si-ATR accessory used in Chapter 3.1 has a cavity that allows for samples to 
be deposited effortlessly under a N2 flow on the ATR crystal, whereas the 
platinum ATR crystal is on a flat surface allowing solution to evaporate outside 
the measurable area Figure 4.7). Second, the penetration depth of far-infrared 
beam is considerably larger than in the mid-infrared by a factor of at least 2 
(depending on the refraction index of the sample and ATR crystal, Chapter 1, 
Figure 1.14). Therefore, deposition of several layers of sample was required in 
order to obtain high quality spectra. 
Initially, the effect of dissolving 1 in water, followed by evaporation prior to 
measurement showed the effect on the platinum to azide and platinum to 
hydroxide related vibrations. The changes effecting the hydroxide and azide 
vibrations are in line with our previously reported results the mid-infrared ATR 
studies of 1 in Chapter 2.1, with evident changes to the intermolecular 
interactions effecting the shifts of the main vibrations.[16] The pyridine vibrations 
in the far-infrared are combination bands with platinum to azide and platinum to 
hydroxide vibrations, such as the ν(Pt-py) (complete description: νasym(py-Pt-
py), scr(N3-Pt-N3), rot(Pt-OH) out-of-phase). Thus, in turn these vibrations are 
more significantly affected (from 257 cm-1 to 244 cm-1) than the pyridine 
vibrations in the mid-infrared region as reported in Chapter 2.1 (± 5 cm-1). 
The time points of 420 nm irradiation investigated were 10 min and 22 h. 10 min 
was selected as it showed the presence of hydroxide vibrations (ν(OHPt-OH)), as 
well as multiple azide vibrations (νasym(N3)) in the mid-infrared region (Chapter 
3.1). Whereas, 22 h was selected to investigate the final product postulated to 
be trans-[Pt(py)2(OH/H2O)2]0/1+/2+ (Chapter 3.1). Interestingly, after 10 min of 
irradiation, both the platinum to azide, ν(Pt-N3), and platinum to hydroxide, ν(Pt-
OH), vibrations split up into multiple vibrations shifting both to lower and higher 
wavenumber vibrations (ν(Pt-OH), from 559 cm-1 to 555 cm-1 and 507 cm-1, 
ν(Pt-N3) from 410 cm-1 and 406 cm-1 to 440, 419 and 384 cm-1). This confirms 
that multiple platinum species are present in the first 20 minutes of irradiation 
(after which ν(OHPt-OH) is completely removed according to mid-infrared 
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spectra). The difference in the ν(Pt-OH) vibrations (-47 cm-1) and the ν(Pt-N3) 
vibrations (+21 cm-1 and -35 cm-1), going from 0 to 10 min of irradiation, are 
substantially larger compared to the changes observed in the mid-infrared 
region (Δ cm-1 ≤ 15 cm-1, Chapter 3.1). Increasing and decreasing bond lengths, 
geometry changes and/or ligand release could result in the observed changes. 
However, only educated guesses can be made at this point, as more irradiation 
time points and accompanied computational studies have to be carried out in 
order to provide more definite results. The ν(Pt-OH) vibration at 507 cm-1 could 
be the result of a single hydroxide ligand release or substantial elongation of the 
platinum to oxygen bond length. The ν(Pt-N3) vibration at 440 cm-1 could be the 
result of single azido ligand release, in line with the increase in the mid-infrared 
for νasym(N3) for the trans-[Pt(N3)(py)2(OH/H2O)] species. The ν(Pt-N3) vibration 
at 384 cm-1 could be related to the previously observed decrease in νasym(N3) in 
the first 10 minutes, as highlighted by the principal component analysis of the 
mid-infrared spectra of the photodecomposition of 1 (Chapter 3.1). The spectra 
of 1 after 22 h of irradiation confirmed our suspected final product of 
trans-[Pt(py)2(OH/H2O)2]0/1+/2+, with one broad platinum to oxygen (water) 
vibration present at 545 cm-1, the out-of-plane pyridine bending mode at 468 
cm-1, the scissoring mode of oxygen to platinum to oxygen at 295 cm-1 and the 
platinum to nitrogen (pyridine) stretching vibration at 237 cm-1. 
The above limitations of increased system evacuation to vacuum were to be 
circumvented by the manufacture of an ATR accessory with the sample area 
remaining outside of vacuum. The modified Pike GladiATR™ single reflection, 
heated (< 300 °C) ATR was finalized in June 2017 with additional adapters 
(high-pressure and liquid cell), opening up the far-infrared field to rapid analysis 
of otherwise difficult to obtain spectra. Unfortunately, this work could not be 
progressed further within this PhD candidature. 
4.3.2 Transmission Synchrotron Radiation Far-Infrared – Liquid cell in situ 
Irradiation 
A set of new liquid cells (first users) was investigated together with a novel SR 
and pulsed laser setup to allow for irradiation of liquid samples without breaking 
vacuum. Several experimental difficulties were encountered, which needed to 
be addressed. As outlined in the results, one of the major problems met was the 
interference phenomenon called fringes caused by internal in-phase 
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reflections.[18,22] The custom built diamond windows of the liquid cells were 
wedged in order to reduce such fringing effects, whereby the out-of-phase 
reflections should not interfere, as shown in Figure 4.26. Unfortunately, fringes 
were still present and it is possible that additional fringes are introduced due to 
angled reflections. Furthermore, the infrared reflections are dependent on the 
substance in between the windows, as well as the pathlength. There is 
extensive literature reported attempting to address these artefacts, with results 
shown to completely negate these artefacts by optimising wedge angle to 
pathlength and refractive index of the measured substance.[18,23] Time, nor the 
liquid cells, allowed for such optimisations and these would be recommended to 
be carried out separately in the future by the THz/Far-IR beamline at the 
Australian Synchrotron.  
 
Figure 4.26. Schematic representation of parallel and wedged windows showing 
possible in-phase (straight) and out-of-phase (angled) reflections. The angle of 
the wedged windows is exaggerated for clarity. 
 
The fringing artefacts were not reproducible within experimental replicates. This 
could be due to leakage of the cell and/or slight differences in pathlength 
caused by the tightening of the cell. In turn, this meant that solvent spectra 
could not be used as a background reference. The fringes were corrected for as 
described in the section 4.2.2 and vacuum background (no liquid cell, no 
fringing artefact) was used to obtain absorbance spectra. While a majority of the 
fringes could be accounted for with the corrections, it is likely that other 
interferences were recorded inside or too close to the spectral part of the 
interferogram to allow for corrections. This in turn resulted in noisy baselines, 
whereby one cannot distinguish between noise and weak signal of solutes. 
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Other issues encountered were leakage of the cells inside the spectrometer and 
cracks developing in the windows of the diamond liquid cell. 
The use of water to study the photodecomposition of 1 in situ was not feasible 
due to the pathlength limitations (5 µm) when using water (due to its strong 
far-infrared absorption). This in turn, did not allow for distinguishing between 
noise and infrared absorptions of 1. Therefore, it was decided to use DMSO to 
allow higher concentrations and longer pathlengths to monitor the 
photodecomposition. The SR-FIR spectra of 1 and its synthetic precursor 2 in 
DMSO were obtained, revealing their platinum to oxygen, ν(Pt-OH), and 
platinum to nitrogen, ν(Pt-N3), stretching vibrations as well as a pyridine 
bending mode (γ(py, 4)). The ν(Pt-OH) vibration can be clearly observed at 567 
cm-1 for 1, slightly shifted compared to the SR-ATR-FIR (559 cm-1) of hydrated 1 
and SR-FIR (540 cm-1) of crystalline 1. The platinum to nitrogen stretching 
vibration of 1 and 2, ν(Pt-N3), are located at 409 cm-1 and 408 cm-1 on the 
shoulder of the DMSO vibrations. These are within 2 cm-1 of the main vibrations 
of the spectra by both transmission SR-FIR (crystalline) and SR-ATR-FIR 
(crystalline and hydrated) and could be insignificant as spectra were recorded at 
a resolution of 1 cm-1. However, the possibility of other ν(Pt-N3) vibrations 
underlying DMSO cannot be ruled out. The pyridine bending mode, γ(py, 4), 
located at 777 cm-1 and 772 cm-1 for 1 and 2 respectively, has not been 
recorded before by SR-FIR prior to this. Their corresponding solids show 
identical wavelengths for this vibration by ATR-FTIR at 777 cm-1 for 1 and 772 
cm-1 for 2 (Chapter 2.1). 
Upon irradiation of 1, γ(py, 4) shifts from 777 cm-1 to 772 cm-1, in line with the 
photodecomposition results described in Chapter 3.1 by ATR-FTIR. The 
decrease of both ν(Pt-N3) and ν(Pt-OH) of 1 in DMSO (76 mM) could be 
monitored in situ upon 355 nm irradiation. Both vibrations appeared to decrease 
rapidly in the first five minutes and no apparent difference in rate of removal 
was observed. A new peak is observed at 419 cm-1, which is a identical to one 
of the ν(Pt-N3) vibrations of 1 observed after 10 minutes of irradiation by 
SR-ATR-FTIR. In Chapter 3.1, an increase in νasym(N3) vibration of 1 is 
observed and is assigned to one of the photodecomposition intermediates, 
trans-[Pt(N3)(py)2(solvent)]. This could be a possible intermediate formed in this 
work. The work described in Chapter 3.1 monitors the photodecomposition 
based on the individual ligand vibrations rather than metal to ligand vibrations. 
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This revealed the complete removal of the ν(OHPt-OH) at a rapid rate, whereas it 
took extended times of irradiation to remove νasym(N3) completely. Both results 
are not directly comparable due to the use of different solvents, concentrations 
and irradiation wavelength and do require further investigation in order to draw 
any conclusions. However, the SR-FIR results might suggest that the hydroxido 
ligand undergoes chemical changes prior to release, which cannot be monitored 
by the ν(OHPt-OH) in the mid-infrared region. 
Further studies on 1 were attempted by investigation of its effect on DNA in the 
far-infrared region. While there are reports of dried and partly hydrated DNA 
and protein spectra in the far-infrared region that reveal potential marker bands, 
spectral reproducibility remains a problem.[4c-f,5e,24] The hydration layers around 
such biomolecules can be a used study higher-order structures. Furthermore, 
Globus et al. reported the correlation between oscillator strength and hydration 
levels of herring DNA films prepared at different water-to-DNA 
concentrations.[5e] Whilst not completely understood, the observed spectral 
bands reduce in intensity when the amount of water used to prepare the films is 
reduced. This suggests that the vibrational modes in the far-infrared region of 
DNA occur at the interface between DNA and the surrounding media.[5e] Their 
reported DNA spectra are in line with our results for CT-DNA, revealing the 
broad intermolecular hydrogen vibrations at ~194 cm-1 and ~64 cm-1. The fine 
structure of these spectra was not further investigated due to the uncertainty 
between noise caused by fringing artefacts or weak DNA vibrations. Instead, 
smoothing of spectra was carried out to obtain clean broad peaks for the 
intermolecular hydrogen stretching and bending modes of water. No apparent 
variation between water, CT-DNA or CT-DNA+1 spectra with or without 355 nm 
irradiation could be observed in the smoothed spectra. Further examination of 
the data by principal component analysis showed the reproducibility within 
spectral replicates, although no significant changes to the intermolecular 
hydrogen bond vibrations could be observed. It could be that the hydration 
layers around CT-DNA were too large in order to identify any differences even 
though very high concentrations of CT-DNA in water were used (leading to 
viscous solutions). The improvement of better liquid cells might improve the 
feasibility of such studies and could reveal exciting new ways to study the 
biochemistry of life.  
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4.3.3 Synchrotron Radiation Infrared Microspectroscopy – Live Single Cell 
Study 
Cells were treated for four hours to allow uptake of 1 into the cell, prior to 
washing away remaining 1 in the growth medium. This was chosen to reflect the 
clinical application of 1, in which cancerous areas would be irradiated locally. 
Therefore, relatively high concentrations of 1 (50 µM) were used to promote 
uptake in short times to fit within the limited amount of continuous experimental 
time that can obtained at synchrotrons. 1 is known to show rapid platinum 
accumulation in cells in the dark in just an hour.[25] Pizarro et al. reported an 
uptake of ~20 ng of platinum per 106 cells for 1, whereas ~8 ng of platinum per 
106 cells was found for cisplatin (cis-[PtCl2(NH3)2]) in the A2780 human ovarian 
carcinoma cell line. In this case, irradiation prior to removing 1 (at lower 
concentrations) resulted in a low viability of cells and an inability study the effect 
of 1 on cells that were still intact. The protocol used in this study allowed for 
plentiful viable cells at all time points regardless of the factors applied.  
Initial examination of the average second derivative spectra of the infrared data 
revealed potential marker bands to explore further by PLS-DA, including lipid, 
DNA base pairing and ribose vibrations (Figure 4.23). The effect of 1 on the 
K562 cell line was divided into three different factors to investigate by PLS-DA; 
time, drug (exposure to 1) and irradiation. Whilst measurements were obtained 
for 0, 4 and 16 h after irradiation, only 0 and 4 h were investigated in the PLS-
DA, as the majority of changes occurred in this time. 
The PLS-DA model classification performances vs. the sample prediction (Ycv 
values), revealed the best separation when all three factors were applied 
together (time, drug and irradiation). Furthermore, the cross validation error 
verifies this with the lowest value (4%) found for this model (the lower the 
percentage, the better the model). It is expected that the worst model fits are 
obtained for the three independent factors, which are expected to have little to 
no effect on the cells (controls). 
The corresponding regression vectors revealed the two main vibrations 
contributing to the separation in the PLS-DA models for the controls (time, drug, 
irradiation and time & drug). The vibration at 1662 cm-1, underlying the amide I, 
and the symmetric phosphate vibration, νsym(PO2-), at 1084 cm-1. Increased 
intensity of the symmetric phosphate vibration has been reported to occur in live 
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cell infrared studies compared to dried cells and the amount of short-lived 
phosphate containing components in metabolically active cells could account for 
this strong intensity.[26] Components such as adenine triphosphate, proteins and 
phosphorylated carbohydrates are especially prominent in active metabolic cells 
and are expected to change over time or when any other external or internal 
factor is applied, such as irradiation or drug ingestion. Therefore, it is 
challenging to relate changes to this particular vibration with confidence to any 
of the factors. The other main contribution to the controls is the vibration at 
1662 cm-1, which shows a slight increase in intensity when comparing the 
controls: time, drug and time & drug.  
More significant is the effect by irradiation and irradiation & time factors. The 
low dose of 350 nm irradiation (2.58 J cm-2) applied to the cells resulted in an 
initial increase in intensity of the 1662 cm-1 vibration upon irradiation. Upon 
including time (four hours after irradiation), this increase is accompanied by the 
increase in intensity of the shoulder of the amide II vibration at 1564 cm-1. 
Intensity increases of the amide II vibration have been previously reported in 
live cells upon exposure to UV radiation by SR-IRMS, which might be related to 
the cellular repair response and therefore increase in protein content.[7b] 
Nevertheless, the irradiation did not result in an apoptotic event as this would 
result in a significant decrease of amide I intensity.[27]  
The most noteworthy alterations were obtained when time, drug and irradiation 
are applied to the cells concurrently. Significant changes to the symmetric 
methyl vibration, νsym(CH3), at 2875 cm-1 were picked up by both the PLS-DA as 
well as the average second derivative spectra. This is indicative of alterations to 
the lipid saturation inside the cell, a potential effect of 1 that has not been 
reported before. The PLS-DA further suggest changes to the ν(COO2-) vibration 
of fatty acids and amino acid side chains at 1367 cm-1, supporting the observed 
changes on the lipid vibrations. 
Secondly, the B-DNA and A-DNA base paring vibrations at 1713 cm-1 and 1705 
cm-1 considerably increase in intensity, with the A- to B-DNA ratio increasing in 
favour of A-DNA. Furthermore, the A-DNA and ribose vibration at 1178 cm-1 in 
the regression vector suggest a shift from 1173 cm-1 as shown in the average 
second derivative spectra (Figure 4.23, 4.25). Previous studies have shown that 
1 rapidly accumulates inside tumour cells whereupon it penetrates the nucleus 
after irradiation, strongly binding to nuclear DNA. The major DNA adducts 
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formed proved capable of efficiently stalling RNA polymeraze II and in turn 
inhibit DNA transcription.[28] The observed changes to the DNA basepairing and 
A-DNA and ribose vibrations support that in these live conditions, 1 alters the 
conformational structures of DNA significantly already four hours after 
irradiation. 
Whilst the average second derivative spectra suggested possible shifts 
occurring to the RNA vibrations at ~ 1120 cm-1, this did not significantly stand 
out in the regression vector of the PLS-DA.  
Please note, that background subtraction should allow for an accurate infrared 
spectrum of intracellular material only, although, the presence of external water 
(growth medium) cannot be 100% ruled out. This has to be taken into account 
when drawing conclusions based on the amide I signal. Shifts occurring in the 
amide I vibration can normally be assigned to a result of intramolecular 
changes. However, the average spectra and PLS-DA only suggest changes in 
intensity including increase in intensity for the water bending mode at 1639 cm-1 
(Figure 4.25). Therefore, I refrain from drawing further conclusions on the strong 
signal at 1662 cm-1 without further investigation by additional experimental 
methods. 
Further studies on K562 cells with 1 were attempted at both Monash University 
and the University of Warwick to backup our observations but poor sustainability 
of the cell line did not allow for successful studies by ATR or cell viability 
studies. 
Lastly, attempts were carried out to obtain imaging maps of single cells in order 
to detect vibrational signatures of 1 (in particular the strong anti-symmetric 
azido vibration at ~2050 cm-1) at similar and elevated concentrations (up to 500 
µM for four hours) compared to the single cell spectra, however, no signal could 
be uncovered. This could be due several reasons, namely, detection limitations, 
the influence of water inside the cell and/or related to the mechanism of uptake 
and accumulation of 1 prior to irradiation. 
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4.4 Conclusion 
Attempts were undertaken to exploit the high brilliance and collimation of 
Synchrotron Radiation (SR) using infrared spectroscopy at the Australian 
Synchrotron. The development of a new beamline accessory, Synchrotron 
Radiation Attenuated Total Reflection Far-Infrared (SR-ATR-FIR), for the 
THz/Far-IR beamline was instigated and proof of concept studies provided the 
necessary evidence of SR spectral range superiority over conventional sources 
whilst allowing for rapid screening of samples. Particular to this thesis is the 
groundwork on the SR-ATR-FIR spectra of 1 and synthetic precursors, 
highlighting the in line vibrations to the transmission SR-FIR spectra as well as 
the capabilities to carry out photodecomposition studies with an out-of-vacuum 
SR-ATR-FIR system. This particular system has been funded, designed and is 
now available as of application round 3, 2017 at the Australian Synchrotron. 
New liquid diamond window cells were tested at the THz/Far-IR beamline with a 
laser source aligned to the sample chamber to allow for in situ irradiation of 
samples. Reflection artefacts of the liquid cells, referred to as fringes, hampered 
the detection of weak and low intensity vibrations in solution due to noise in the 
baselines. Nevertheless, elevated concentrations of 1 in DMSO allowed for the 
photodecomposition to be monitored by SR-FIR. Rapid rate of removal of the 
ν(Pt-OH) and ν(Pt-N3) vibrations was observed in the first five minutes, with 
similar rates of removal followed throughout 7 hours and 15 minutes. A new 
ν(Pt-N3) vibration appears overtime, which might correspond to the 
trans-[Pt(N3)(py)2(solvent)] formed throughout irradiation as described in 
Chapter 3.1. Further liquid cell work on CT-DNA and 1 was studied by 
monitoring the intermolecular hydrogen vibrations. Whilst inconclusive at this 
stage, the improvement of better liquid cells could open up the field to these 
types of studies. 
Lastly, Synchrotron Radiation Infrared Microspectroscopy (SR-IRMS) was 
carried out to study effect of 1 on live cells. With the unique microfluidic setup 
available at the Infrared Microspectroscopy beamline it is possible to study the 
effect of 1 on the K562 suspension cell line in a live state by SR-IRMS whilst 
obtaining spectra of single cells. Partial Least Square – Discriminant Analysis 
(PLS-DA) of the live single cell spectra reveals significant changes to the DNA 
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base stacking and lipid vibrations, already at 4 hours after drug treatment and 
irradiation, whilst this is not observed or to a lesser extent for the controls. The 
observed changes to the DNA basepairing, A-DNA and ribose vibrations 
support that 1 alters the conformational structures of DNA significantly and 
rapidly, in line with previous studies where rapid accumulation of platinum inside 
the nucleus is observed upon irradiation of 1.[28-29]  
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4.5 Experimental 
4.5.1 Chemicals 
All reactions were performed under nitrogen atmosphere using standard 
Schlenk techniques. Chemicals, deoxyribonucleic acid sodium salt from calf 
thymus, cell culture products and other solvents were purchased from Sigma-
Aldrich, BioScientific or ThermoFisher and used as such. 
4.5.2 Synthesis 
The synthesis of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, py = pyridine) was 
carried out as described in Chapter 2 with characterisation data in agreement 
with those reported previously.[16,30] 
4.5.3 External Illumination source 
A Rayonet RPR-200 photoreactor equipped with six 420 nm lamps (λem max: 420 
nm, spectral distribution: 390 – 460 nm, 3.6 mW cm-2) or six 350 nm lamps (λem 
max: 350 nm, spectral distribution: 300 – 400 nm, 4.3 mW cm-2) was used for 
irradiation. Solutions for 420 nm irradiation were placed in a 3 mL, 1 cm 
pathlength fluorescent quartz cuvette with a PTFE stopper. Multi well cell 
cultures plates, including their top plates (68% transmission at 350 nm) were 
irradiated for 13 minutes to reach a total of 2.58 J cm-2.  
4.5.4 The Australian Synchrotron 
The Australian synchrotron light source runs at 200 mA in top-up mode. 
4.5.5 Far-Infrared spectroscopy 
Spectra were acquired on a Bruker IFS 125/HR FT spectrometer equipped with 
a 6 µm multilayer Mylar beamsplitter and a helium-cooled Si bolometer detector, 
unless otherwise stated.  
A Specac golden gate diamond ATR accessory was used to carry out initial 
alignments and to acquire spectra of test samples (poly(1-phenylethene) and 
polytetrafluoroethylene, also known as polystyrene and Teflon™). A Bruker 
Platinum ATR accessory was used to acquire spectra of all other solids and 
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evaporated solutions of 1. Unless otherwise stated, spectra were recorded at a 
resolution of 1 cm-1, 128 interferograms co-added. 
For liquid samples, automated motorised cryostat sample holder (ST-100, Janis 
Research), holding three sample holders, was used to hold diamond window 
liquid cell holders with variable spacers (described in more details in section 
4.2.2). A Nd:YAG pulsed laser (Surelite, 355 nm, 3rd harmonic, 12.0 mW) was 
used to irradiate the samples at a 90° angle of incidence relative to the infrared 
beam. 3.5 mW transmitted through the diamond cell window onto the liquid. A 
Lakeshore model 335 cryogenic temperature controller was set to 296.5 K and 
maintained the temperature of the sample holder between 296.5 and 298.2 K 
throughout irradiation of the samples over continuous periods of irradiation. 
4.5.6 Synchrotron Infrared Microspectroscopy 
Single cell spectra were acquired on a modified Bruker V80v spectrometer with 
a narrow band MCT detector. Transmission spectra were recorded between 
3800 – 900 cm-1 with 64 interferograms co-added at a spectral resolution of 6 
cm-1. 2 µL of a cell pellet suspension (section 4.5.8) was placed on a 
microfluidic sample slide (CaF2), purposely built for hydrated sample 
measurements.[11] A top window (CaF2) is gently placed on top of the 
microfluidic slide and held stationary during measurement allowing for a fully 
hydrated state for 30 to 60 min. The aperture was set to 10 x 10 µm to cover the 
majority of the inside of the cell (12 – 16 µm). Background spectra (cell medium 
next to the live cells) were taken every 5th scan to subtract non-cellular 
contributions and account for synchrotron current and signal fluctuations. A total 
of three experimental replicates were carried out; three time points, four sets 
per time points, a minimum of 60 single cell spectra per set ≥ 2160 spectra. 
4.5.7 Cell Culture 
The acute myeloid leukaemia suspension cell line (K562) was cultured in RPMI 
1640 medium (containing L-Glutamine) supplemented with 10% (v/v) fetal 
bovine serum (FBS) and 1% (v/v) penicillin-streptomycin at 37 °C with 5% CO2. 
Cells were transported to the Australian synchrotron one week prior to the 
experiment and maintained at exponential growth (± 1 × 106 cells/mL). 
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4.5.8 Cell Treatment and Irradiation 
All cell treatment was carried out under dim light conditions to prevent unwanted 
activation of 1. All cells were pooled before each experiment out of which three 
T75 cell cultures flasks were seeded (± 0.25 × 106 cells/mL) and remaining cells 
were maintained at exponential growth in T75 cell cultures flasks until the next 
replicate experiment. The three T75 flasks were incubated for 48 hours at 37 °C 
with 5% CO2, after which two T75 flask were seeded (± 0.5 × 106 cells/mL). 1 (2 
mM stock in Mili-Q water) was added to one T75 flask at a final concentration of 
50 µM, with equal quantities of Mili-Q water added to the other flask and 
incubated for four hours at 37 °C with 5% CO2. The cells in growth media were 
centrifuged at 500 × g for five minutes, supernatant discarded and resuspended 
in fresh growth medium. Two multi well plates (6 wells ea.) were filled with 3 mL 
aliquots of re-suspended cells (three treated with 1 and three untreated) to 
undergo irradiation. Both plates were put in the photoreactor for 13 minutes 
(350 nm, 2.58 J cm-2), with one plate covered in aluminium foil to prevent 
exposure to light. The aluminium foil was removed and both multi well plates 
were placed in the incubator at 37 °C with 5% CO2 until measurement time 
points were reached (0, 4 and 16 h). Samples at each time point were 
centrifuged at 500 × g for five minutes, supernatant discarded, leaving a small 
volume of growth medium in the cell pellet and placed on the sample holder as 
described in section 4.5.6. 
4.5.9 Data Processing 
SR-ATR-FIR 
Data was cut as indicated and extended ATR correction was carried out only on 
the SR-ATR-FIR spectra of the solids of 1, 2 and 3 to correct for the artefacts 
caused by anomalous dispersion, as described previously in Chapter 2.2.[16-17] 
 
Transmission SR-FIR – Liquid cell 
Data was cut as indicated and fringing corrections were carried out by straight-
line generation in the interferogram, caused by interferences of the infrared 
beam with the surfaces of the liquid cell, when possible as outlined in the 
results. Principal Component Analysis (PCA) was carried out in MATLAB using 
PLS-Toolbox 8.2 (Eigenvector Research). Preprocessing prior to PCA: 1) data 
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was cut (350 – 45 cm-1), 2) smoothed (65 smoothing points), 3) standard normal 
variate (SNV) normalization and 5) mean centred. 
Synchrotron Infrared Microspectroscopy 
Partial Least Squares-Discriminant Analysis (PLS-DA) was carried out in 
MATLAB using the PLS_Toolbox 8.2 (Eigenvector Research). Preprocessing 
prior to PLS-DA: 1) data was cut, 3050 – 2750 cm-1 and 1800 – 1040 cm-1, 2) 
second derivative (9 smoothing points, weighted tails), 3) SNV normalization, 4) 
Pareto scaling and 5) mean centred. Separate PLS-DA’s were carried out to 
compare the individual and combined effect of three factors on the cells (1, time 
and irradiation) to that of cells not treated with 1, at time zero and no irradiation. 
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4.8 Supporting Information 
4.8.1 SR-ATR-FIR – DNA Nucleobases 
DNA nucleobases, including deoxyribose and monophosphate derivatives were 
measured by SR-ATR-FIR to record their spectra for potential metal complex 
binding studies. Figure S4.1 shows the SR-ATR-FIR spectra of thymine, 
guanine, cytosine and adenine. The spectra shown below, including the 
deoxyribose (Figure S4.2) and monophosphate derivatives (Figure S4.3), are in 
line with previously reported transmission spectra of the corresponding 
compounds.[5b-e,31] 
The peaks present in the far-infrared region mainly consist of out-of-plane ring 
deformations, torsional and lattice modes. These vibrations are extremely 
sensitive to conformational changes and can be used to monitor effect to 
geometry like hydration, isomerisation and/or binding of other molecules. For 
example, the effect of changing anions and the state (crystal or gel) of 
guanosine 5’-monophosphate disodium salt (5’-GMP) showed to have large 
effects of the far-infrared spectra, including large differences in intensities (very 
strong to weak and vice versa) and wavenumber shifts of ± 20 cm-1.[31] 
Increasing amount of rotational and lattice vibrations are observed going from 
guanine to guanosine to 5’-GMP (Figure S4.2). The crystal lattice of the 
disodium salts have a large effect on the rotational and lattice vibrations, 
resulting in multiple broad peaks with underlying features, as shown in Figure 
S4.3. 
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Figure S4.1. SR-ATR-FIR spectra of thymine, guanine, cytosine and adenine, 
including molecular structures. 
 
 
Figure S4.2. SR-ATR-FIR spectra of guanine, guanosine and guanosine 5’-
monophosphate disodium salt, including molecular structures. 
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Figure S4.3. SR-ATR-FIR spectra of 5’-AMP, 5’-CMP, 5’-GMP and 5’-TMP 
disodium salts, including molecular structures. Abbreviations used: 5’-A/C/G/TMP 
= adenosine/cytidine/guanosine/thymidine 5’-monophosphate disodium salt. 
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4.8.2 SR-ATR-FIR – Malaria Infected Red Blood Cells 
Malaria has one of the highest yearly human mortality rates in the world, with up 
to 1.2 million reported deaths per annum.[32] Continuous effort is placed on the 
development of new highly sensitive diagnostic techniques to detect low-density 
parasite infections in asymptomatic carriers (infected people without 
symptoms). Development of vibrational spectroscopic techniques has been 
highlighted in recent years as a potential diagnostic tool and to better 
understand the different stages of malaria.[33] 
SR-ATR-FTIR could allow for a fast screening method of the far-infrared spectra 
of marker molecules associated with detecting malaria, such as haemoglobin 
and haematin, containing metal to ligand vibrations in this region. Furthermore, 
screening red blood cells fixed in methanol at different stages of malaria 
infection (on glass slides or as a solution) would be a new approach to 
investigate malaria. 
The spectra obtained by SR-ATR-FTIR and molecular structures for the 
haemoglobin protein, β-haematin, haematin, haemin and protoporphyrin ix are 
shown in Figure S4.4. Starting at Haemin, the protoporphyrin ix ligand vibrations 
remain present (such as at 475 cm-1) and a strong new band is observed for the 
iron to chloride stretching vibration at 349 cm-1. Furthermore, the iron to 
nitrogen (protoporphyrin ix) stretching vibration emerges at 259 cm-1, which 
remains present throughout haematin and β-haematin at 267 cm-1 and 264 cm-1 
respectively. Haematin contains the single strong iron to oxygen (hydroxide) 
stretching vibration at 342 cm-1, whereas β-haematin contains several iron to 
oxygen (carboxylate) stretching vibrations at 383 cm-1, 361 cm-1, 343 cm-1 and 
326 cm-1. β-haematin consists of several haematin stacked dimers, as shown in 
Figure S4.4, resulting in different iron to oxygen bond lengths and angles, 
intermolecular hydrogen bonding and longer distance interactions. This results 
in the factor group splitting observed for the iron to oxygen stretching vibration, 
which is in line with previous reports.[33d,34] Furthermore, several other marker 
bands are clearly present in the spectra, namely at, 625 cm-1, 558 cm-1, 516 
cm-1, 461 cm-1, 264 cm-1, 174 cm-1 and 150 cm-1. 
The iron to oxygen stretching vibrations can be gleaned in the spectra of the 
haemoglobin protein at 348 cm-1, including other weak vibrations (Figure S4.4). 
The malaria parasite catabolizes haemoglobin into toxic haeme inside red blood 
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cells, which it sequestrates into the insoluble pigment haemozoin. β-haematin is 
the synthetic precursor of haemozoin and therefore, the observed vibrations 
could be used to detect malaria in red blood cells. 
 
Figure S4.4. SR-ATR-FIR spectra of haemoglobin, β-haematin, haematin, haemin 
and protoporphyrin ix, including selected peak labels and molecular structures 
(apart from haemoglobin). 
 
Figure S4.5. SR-ATR-FIR spectra of uninfected and infected RBC (ring or 
trophozoite phase), including selected peak labels. A) Fixed RBC in methanol 
were deposited on the ATR diamond and evaporated prior to measurement 
(average spectra of four sample replicates, with four spectral replicates each). B) 
Methanol f ixed RBC on glass microscopy slides, placed on the ATR diamond 
(each spectrum is a different sample, four spectral replicates each). 
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Methanol fixed Red Blood Cells (RBC) were kindly supplied by Prof. Leann Tilly 
from the University of Melbourne for this study and were prepared as reported 
previously.[10,35] Two different (morphological) phases of malaria parasite 
infection were studied and uninfected RBC were measured as controls. The ring 
phase (immature asexual stage of the parasite, present in circulation) and the 
trophozoite phase (later asexual stage of the parasite, still present in 
circulation), where increasing amounts of haemozoin is present going from the 
ring to the trophozoite phase.[33b] 
RBC in methanol were deposited onto the ATR crystal and evaporated using a 
gentle N2 flow. Average SR-ATR-FIR spectra (four sample replicates, four 
spectral replicates each) of the RBC are shown in Figure S4.5A, which includes 
selected peak labels. Several vibrational signatures could be obtained present 
in all three spectra, with a few vibrations only present in either the uninfected or 
infected RBC. These include the vibrations at 558 cm-1 (uninfected), 473 cm-1 
(trophozoite), 455 cm-1 (ring), 473 cm-1 (trophozoite), 413 cm-1 (uninfected and 
ring), 342 cm-1 (uninfected), 319 cm-1 (ring and trophozoite) and 257 cm-1 (ring 
and trophozoite). Interestingly, an increase in the vibration at 377 cm-1 is 
observed for the infected RBC compared to uninfected RBC. This could be due 
to increasing quantities of β-haematin present in the RBC. 
Intriguingly, the peak at 558 cm-1 of the uninfected RBC is present in the 
spectra of β-haematin (Figure S4.4), whilst this peak doesn’t stand out in either 
of the infected RBC spectra or Haemoglobin. Haemoglobin is a main 
component of RBC, however, other proteins and membrane lipids are present in 
RBC. These should be screened in the future in order to fully characterise the 
SR-ATR-FIR vibrational signature of RBC. 
Furthermore, previously fixed RBC on glass slides were measured by placing 
them facedown on the ATR crystal with spectra shown in Figure S4.5B. Each 
spectrum corresponds to a different sample, with four spectral replicates each 
sample. Spectral acquisition was limited to 700 – 200 cm-1 due to the strong 
infrared absorption of the glass slides (SiO2) below 200 cm-1. Comparable 
vibrational signatures could be obtained compared to the RBC in methanol, 
such as the matching vibrations (methanol/glass slides) at 621/620 cm-1, 
523/519 cm-1, 377/371 cm-1 present in all RBC. However, the inconsistency 
between the previously fixed RBC were too excessive to allow for spectral 
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averaging between samples (and the small amount of samples measured). 
Therefore, further investigation of spectral replicates is necessary in the future. 
Nevertheless, these results provide an outlook to a potential new area to pursue 
in SR far-infrared spectroscopy. 
4.8.3 Transmission Synchrotron Radiation Far-Infrared – Liquid cell in situ 
Irradiation 
 
Figure S4.6. SR-FIR spectra of DMSO upon 355 nm irradiation at selected time 
points using a 20 µm (A) and 100 µm (B) pathlength diamond window liquid cell. 
Beamsplitter (Mylar) and detector (polyethylene window) absorptions are cut 
(~920 – 870 cm-1 and ~740 – 650 cm-1, respectively), l ine saturations are cut 
(~380 cm-1 and ~330 cm-1) and the spectra are smoothed (15 points). 
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Figure S4.7. PCA analysis results for the SR-FIR spectra of water, CT-DNA and 
CT-DNA+1  with and without 355 nm irradiation (IRR) in a 5 µm pathlength 
diamond window liquid cell. A) PC1 vs. PC3 score plot. B) PC2 vs. PC3 score 
plot. C) Loading plot including mean spectra, including peak labels. D) 
Eigenvalues, variance captured, Root Mean Square Error of Calibration (RMSEC) 
and Root Mean Square Error of Cross Validation (RMSECV) of the Principal 
components (PC). 
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Chapter 5 
Upconverting Nanoparticles 
Chapter 5 covers the efforts made towards the development of new lanthanide-
doped upconverting nanoparticles (UCNPs) to address the low wavelength 
excitation of the earlier described photoactivatable metal-based anticancer 
prodrug candidates (Chapters 1 – 3), which currently hamper their clinical 
feasibility. This involves the preparation of a range of highly defined, narrow-
sized UCNPs by variation of doping materials, inorganic host lattices, capping 
agents and physical parameters (reaction time and temperature). Preliminary 
characterisation of UCNPs was carried out using Transmission Electron 
Microscopy (TEM), X-ray powder diffraction (XRD) and UV-Vis absorption 
spectroscopy. Attempts were made to further expand the excitation 
wavelengths of these nanoparticles to the clinically relevant optical window by 
coupling of near-infrared dyes to their surface to match wavelengths accessible 
by clinically used lasers. Lastly, a custom-made setup was build to screen the 
emission profiles of such UCNPs. 
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Figure 5.1. Graphical representation of a hexagonal upconverting nanoparticle 
excited with an NIR (red) laser, emitting visible (blue, green) and UVA (pink) l ight.  
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5.1 Introduction 
A brief outline on upconverting nanoparticles (UCNPs) is covered below, 
concentrating on the physical and (photo)chemical requirements to make them 
clinically relevant. The reader is kindly directed to Chapter 1.6 for a more 
detailed overview on UCNPs. 
 
UCNPs are well known for their anti-Stokes type upconversion (near-infrared 
excitation, visible light emission) that originates from the lanthanides doped at 
different ratios into a host lattice (e.g. NaYF4, CaF2, LiYF4) in a core or 
core/shell nanoparticle assembly.[1] They display unique optical, structural and 
chemical properties. This includes different absorption and emission 
bandwidths, different extents of water solubility, a diverse range of surface 
functionalities and varying size distributions. The challenge remains to utilise 
and improve previous results to develop the core/shell UCNPs best suited for 
their biomedical application as a drug-delivery and drug-activation system. The 
opportunity of having multiple imaging and therapeutic modalities on UCNPs 
makes them ideally suited as drug-delivery systems, allowing for possible new 
diagnostic therapy on an individual basis (theranostics). However, before that, a 
systematic and reproducible approach is much-needed for synthesising water-
dispersible UCNPs of uniform size and shape with an easy to functionalise 
surface to allow for efficient covalent binding of multiple modalities. 
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5.1.1 Physical and (Photo)Chemical Requirements 
Optimal size. Size distribution displays an important role in the uptake, 
distribution and accumulation of nanoparticles in in vivo testing.[2] ‘’Larger’’ 
nanoparticles (>100nm) are easily cleared by the reticuloendethelial system 
(RES) or mononuclear phagocytic system (MPS), thus providing a upper size 
threshold for this research in particular.[3] A lower size threshold can be set by 
taking the kidney clearance (8 nm), glomerular filtration of the blood (5 nm) and 
renal excretion (5.5 nm) cut-off pore sizes into account.[4] More recent in vivo 
studies show that UCNPs with an average size between 10 and 50 nm can still 
accumulate rapidly in the liver and spleen.[2,5] Based on these research findings, 
the ultimate aim for this project was to synthesise sub-20 nm UCNPs (this 
includes the core/shell, coating and surface functionalities). At the same time, it 
is important to increase the blood circulation half-lives in order to prevent 
premature clearance and still allow for the utilisation of the enhanced 
permeability and retention (EPR) effect of leaky tumour cells.[6] For this, several 
working strategies have already been reported. For example polyethylene glycol 
(PEG), citric acid or polyphosphoric acid incorporation on the surface of the 
UCNPs has been reported to increase blood circulation half-lives of the NPs.[7]  
 
Hexagonal Structure. Hexagonal-phase NaYF4 (β-NaYF4) crystals have been 
reported to be the most efficient host materials for upconverting lanthanide ions 
due to the low phonon energy of the crystal lattice, compared to the other 
commonly obtained cubic-phase NaYF4 (α-NaYF4).[8] It is important to 
synthesise phase-pure hexagonal UCNPs to achieve high quantum yields. 
 
Excitation band at or below 800 nm. The majority of UCNPs reported have an 
excitation band centred at 980 nm, which can in most cases be allocated to the 
peak absorption of Yb3+ ions.[1,9] However, the excitation band overlaps with the 
maximum absorption peak of water molecules (Figure 5.2). The absorption of 
980 nm light is expected to limit deep tissue penetration and induce thermal 
damage to cells and tissues.[9] Thus, UCNPs with excitation bands at or below 
800 nm will be the aim in this project to increase tissue penetration and reduce 
potential thermal damage.  
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Water-dispersible. The majority of as-synthesised UCNPs are hydrophobic. 
There are several coating strategies to render them water-dispersible, such as 
polymer, silica, phospholipid and zwitterionic coatings.[10] For this work, coating 
with octylamine-modified polyacrylic acid (OPA) polymer was used as a starting 
point as the Spiccia and Graham groups have studied it intensively.[11] OPA 
coating has shown little effect on the size and shape of UCNPs without the 
formation of UCNP aggregates.[11] 
 
 
Figure 5.2. Spectral profi les of t issue optical window. The extinction coefficient of 
water at 800 nm is about 20 times lower than that at 980 nm (Hb = haemoglobin,  
HbO2 = oxyhemoglobin). Adapted from Han et al. [12] Reprinted by permission of 
John Wiley & Sons, Inc. 2013 Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. 
 
Throughout the last decade, examples of Nd3+-doped core/shell NaYF4 UCNPs 
with absorption wavelengths around 800 nm have been reported using the 
thermal decomposition synthesis method.[12-13] Low concentrations of Nd3+ 
(doping ratio ≤ 2%) in the core are used to reduce self-quenching, whereas high 
concentrations of Nd3+ (~20%) in the shell are essential to synthesise UCNPs 
with absorption at 800 nm.[13]  
It is important to keep in mind that lasers most commonly used in clinics for 
photodynamic therapy (PDT) are pulsed dye lasers (595 nm) and diode lasers 
(ranging from 630 nm to 670 nm). Furthermore, when aiming for ultrasmall 
UCNPs, the already poor quantum yields of UCNPs will be further reduced, 
which would increase the irradiation time required for these particles to be 
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effective.[14] Clinical laser irradiation times can vary between 5-45 minutes, 
therefore, it is of importance to synthesise UCNPs with high quantum yields to 
minimise irradiation times.[15] Embedding dyes onto the UCNPs might overcome 
the above mentioned limitations, i.e. increasing quantum yields to reduce 
irradiation times, reducing UCNP sizes towards the ultimate objective of 
nanoparticle renal clearance, and broadening of the absorption spectrum for the 
use of clinical grade lasers.[16]   
 
Therefore, initial strategies involved the synthesis of hexagonal neodymium 
doped UCNPs and embedding dyes into well defined UCNPs with absorption 
peaks around 800 nm. Appropriate core/shell ratios were selected based on the 
surface functionalities. 
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5.2 Results and Discussion 
5.2.1 IR-806 
 
 
Scheme 5.1. Synthesis of IR-806. 
 
IR-806 was synthesised from a commercially available dye IR-780 following a 
slight modification from literature.[16] The reaction is shown in Scheme 5.1. 
Several batches of IR-806 (gold coloured crystals) were synthesised and stored 
in the fridge protected from light. The UV-Vis and emission spectra of IR-780 
(λabs max 790 nm, λem max 826 nm) and IR-806 (λabs max 805 nm, λem max 837 nm) 
are shown in Figure 5.3, matching the previously reported results.[16] Equipment 
limitations only allowed for emission spectra measurements up until 850 nm, but 
did not hinder the observation of the emission maxima. 
 
Figure 5.3. UV-Vis (solid) and Emission spectra (dotted, λexc i ta t ion 750 nm) of IR-
780 and IR-806. 
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5.2.2 IR-806 dye adsorption to LiYF4: Yb3+/Tm3+ nanoparticles 
For initial trials, the adsorption/attachment of IR-806 to the surface of LiYF4: 
Yb3+/Tm3+ nanoparticles was attempted. LiYF4: Yb3+/Tm3+ nanoparticles (OG39) 
have an average size of 122 ± 14 nm, λabs max at 977 nm (Yb3+), are diamond 
shaped and were synthesised by Olga Gazukin.[17] The UV-Vis spectrum in 
CHCl3 and a TEM image of OG39 are shown in Figure 5.4. The UV-Vis 
spectrum of the bare UCNPs shows the characteristic absorption profile for the 
2F7/2 → 2F5/2 transition of Yb3+.[18] 
 
Figure 5.4. OG39; A) UV-Vis spectrum in CHCl3, B) TEM image. 
 
IR-806 adsorption to OG39 (weight ratio 1:5) was carried out in CHCl3 and the 
adsorption was followed by UV-Vis spectroscopy, recording the spectra after 4 
h, 1, 4 and 7 days (Figure 5.5). A slight red shift from λabs max 805 to 810 nm was 
observed after 4 h, indicative of the interaction of IR806 and OG39, and did not 
significantly change beyond this point.  
 
Figure 5.5. UV-Vis spectra of IR-806 and IR-806 adsorption to OG39 after 4 h, 1, 
4 and 7 days. Y-axis left; Abs IR-806 and OG39 in CHCl3, y-axis right; IR-806 in 
CHCl3. 
B A 
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Following this, the IR-806 coated UCNPs were further encapsulated with 
octylamine-modified polyacrylic acid (OPA), an amphiphilic polymer, to render 
them water-dispersible. The obtained nanoparticles are green in solution 
(Figure 5.6C) and can be obtained as a green solid when lyophilised. UV-Vis 
spectra of the final materials measured in water, showed an λabs max at 805 nm 
for dye/UCNP ratio 1:50 (w/w) and a λabs max at 807 nm for all other ratios (1:25, 
1:100, 1:150 w/w) (Figure 5.6A). The UV-Vis spectrum of the nanoparticles 
were further referenced against dye-free OPA-coated OG39 nanoparticles in 
water (λabs max 922 nm) in Figure 5.6B. IR-806 is not water soluble and the UV-
Vis spectrum was therefore recorded in CHCl3.  
 
Figure 5.6. A) UV-Vis spectra of OPA coated OG39-IR-806 in water at different 
weight ratios (dye:OG39). B) UV-Vis spectra of OPA coated OG39-IR-806 (weight 
ratio 1:25) in water (LHS Abs. scale), OPA coated OG39 in water (LHS Abs. scale) 
and IR-806 in CHCl3 (RHS Abs. scale). C) OPA coated OG39-IR-806 solutions in 
water. 
A 
B C 
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807 
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805 
922 
922 
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In the absorption spectrum of the dye-loaded nanoparticles, characteristic 
absorption bands ascribable to the OPA coated nanoparticles as well as to the 
IR-806 were observed, providing clear evidence for the adsorption of IR-806 
onto LiYF4: Yb3+/Tm3+ nanoparticles. The resulting green solutions provide a 
visual proof for this. Moreover, the slight red shift in λabs max for IR-806 from 805 
nm to 810 nm is indicative of interaction between the two. 
However, previously reported studies on interaction of IR-806 with NaYF4;Yb,Er 
nanoparticles mention a Dye:UCNP ratio dependent blue shift of λabs max from 
806 to 800 nm .[16] Ratio dependent results originating in that case were carried 
out in CHCl3, on the dye samples and UCNPs simply mixed together in solution, 
whereas our UV-Vis studies were carried out in water, which may account for 
the difference in observations. Whether or not our particles behave differently to 
reported results remains unclear as changes in λabs-max in such a small range 
can be highly influenced by instrumental error (1 nm), which cannot be ruled out 
at this stage. 
Evidence for IR-806 increasing the quantum yield of the nanoparticles has yet 
to be obtained. Emission spectra could not be recorded due to the lack of and 
technical challenges with appropriate instrumental setups (refer to Chapter 
5.2.4). Collaboration should be established when these particles are pursued in 
the future. 
5.2.3 Neodymium (Nd3+) doped UCNPs 
Synthesis of Nd3+-doped UCNPs (NaYF4: Yb3+/Tm3+/Nd3+) involved a series of 
experiments to optimise the size and shape, adapting a synthetic procedure 
previously reported by Xie et al.[13] A typical reaction involves a series of steps 
as shown in Scheme 5.2. In short, the lanthanide salts (Y3+:Yb3+:Tm3+:Nd3+ = 
80.5:18:0.5:1 mol%) in methanol are added to a three-neck round-bottom flask 
containing oleic acid (capping agent) and octadecene (high boiling point 
solvent). Methanol, water traces and oxygen are removed under vacuum at 140 °C, before cooling to 50 °C and addition of the fluoride and sodium source 
(NH4F and NaOH in methanol). Evaporation of methanol is followed by an 
increase of temperature to 270 or 290 °C, at a rate of 450 °C h-1 and the 
solution was maintained at this temperature for a set time under N2 or by 
applying a flow of N2 allowing for nanoparticle formation. The resulting solution 
is then cooled to room temperature at 450 °C h-1 and the UCNPs are collected 
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by addition of ethanol. Please refer to the experimental section for a more 
detailed description of synthetic procedure. 
The size and shape of the Nd3+-doped UCNPs were tuned by varying the 
temperature and time in an effort to yield small hexagonal-phase UCNPs, 
whereby higher temperatures restrict the formation of the thermodynamically 
less stable cubic-phase but favour the formation of larger nanoparticles.[19] Size 
and uniformity control was further tested by introducing Ca(oleate)2, which has 
been reported to yield more reproducible and uniform UCNPs.[20] Table 5.1 
shows the summary of synthetic outcomes.  
 
Scheme 5.2. Synthesis of neodymium doped nanoparticles, NaYF4: 
Yb3+/Tm3+/Nd3+ (Y3+:Yb3+:Tm3+:Nd3+ = 80.5:18:0.5:1 mol%). 
 
The synthesis of NaYF4: Yb3+/Tm3+/Nd3+ (18/0.5/1 mol%) UCNPs was carried 
out at 290 °C for 1.5 h (RRV-001), during which Ca(oleate)2 was introduced to 
yield RRV-011 and a gentle N2 flow was used during the nanoparticle formation 
of RRV-017. RRV-001 UCNPs were characterised by TEM and have an 
average size of 59 ± 3.4 nm (Figure 5.7A). Addition of Ca(oleate)2 resulted in 
UCNPs (RRV-011) with an average size of 46 ± 3.1 nm and pure hexagonal-
phase (X-ray diffraction and TEM, Figure 5.7B, 5.8). The average size of the 
particles was further reduced to 39 ± 1.6 nm when nitrogen was allowed to flow 
through the reaction vessel while heating (RRV-017, Scheme 5.2, Figure 5.7C).  
New materials for anticancer imaging and therapy 
Chapter 5 Robbin R. Vernooij 260 
 
 
Figure 5.7. TEM images of NaYF4: Yb3+/Tm3+/Nd3+ (18/0.5/1 mol%) UCNPs; A) 
RRV-001, B) RRV-011, C) RRV-017. 
 
 
Figure 5.8. X-ray diffraction (A) and HR TEM (B) of NaYF4: Yb3+/Tm3+/Nd3+ UCNPs; RRV-011.  
 
Synthesis of similarly doped NaYF4: Yb3+/Tm3+/Nd3+ UCNPs was carried out at 
a maximum temperature of 270 °C, in an effort to attain smaller sized 
nanoparticles, whilst varying the reaction time at this temperature (1.5 h RRV-
003, 1.5 h RRV-007, 15 min RRV-012, 15 min RRV-013, 3h RRV-015 and 45 
min OG111). However, non-uniform mixtures of UCNPs were obtained with size 
distributions ranging between 4 – 30 nm (Figure 5.9, Table 5.1). 
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Figure 5.9. TEM images of NaYF4: Yb3+/Tm3+/Nd3+ UCNPs synthesised at 270 °C maintained 
for: A) 1.5 h, RRV-003, B) 1.5 h, RRV-007, C) 15 min, RRV-012. D) 15 min, RRV-013. E) 3 h, 
RRV-015, F) 45 min, OG111. 
 
UV-Vis spectra were recorded for all nanoparticles in n-hexane or cyclohexane 
and are identical for all (λabs max Yb 977 nm). Representative UV-Vis spectra of 
RRV-011 in cyclohexane at different UCNP/solvent weight ratios (2.5, 5, 10 
wt%) are shown in Figure 5.10. 
 
 
Figure 5.10. UV-Vis spectra of RRV-011 in cyclohexane at different UCNP/solvent weight ratios 
(wt%). 
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A variety of shape and size of neodymium doped nanoparticles was obtained by 
varying experimental conditions. Procedures carried out at 290 °C resulted in 
more uniform size distributions while reactions carried out at 270 °C resulted in 
two different sized nanoparticles in the same batch.  
Introduction of Ca2+ ions into the nanoparticle lattice decreased the size of the 
nanoparticles by approximately 12 nm and resulted in pure hexagonal 
nanoparticles, as revealed by X-ray diffraction studies. The introduction of alkali 
ions into the UCNPs is believed to introduce F- vacancies in the host matrix due 
to their lower valence. Previous reports have shown that this can potentially 
accelerate the crystal growth of UCNPs and turn it into a diffusion-controlled 
process tolerating shorter reaction times whilst maintaining a small unimodel 
size distribution of UCNPs.[20-21]  
The introduction of a N2 flow during the heating process reduced the size of the 
nanoparticles by approximately 18 nm. The N2 flow might be influencing the 
heating rate and create more stable maximum temperatures. 
Very minor changes in the experimental conditions for synthesis of these 
nanoparticles can have a large effect on the shape and size of these particles. 
Therefore, emission profiles of the nanoparticles have to be measured followed 
by optimisation of the Ln3+ ion ratios to obtain the desired emission profiles, 
before continuing the size and shape optimisation. 
It remains unclear whether the characteristic λabs max of Nd3+ is present in the 
absorption profiles of the nanoparticles (Figure 5.10). A filter changeover at 800 
nm of the spectrophotometer results in a measurement error in this region. 
Mathematical corrections were applied to correct the spectra. Nevertheless, a 
λabs max at 800 nm was not evident. Recording emission profiles under 800 nm 
excitation would reveal whether neodymium doping of the nanoparticles led to 
the desired outcome. 
5.2.4 Fluorescence Spectroscopy Setup for Upconverting Nanoparticles  
The development of custom-made equipment was endeavoured in order to 
measure emission profiles of the recently developed UCNPs. A single cell 
holder for a Cary Eclipse Fluorescence Spectrophotometer was modified to hold 
single wavelength diode lasers (class 3b). Figure 5.11 illustrates a simplified 
overview of the setup as well as a top view picture, in which diode lasers of 
different diameters could be inserted using custom cut O-rings and connected 
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to the 3 VDC power supply. The build-in monochromators of the 
spectrophotometer were turned off and covered with a detector card for NIR 
light to focus the NIR diode lasers. The power switch of the diode lasers is 
placed outside the spectrophotometer to allow for control of the laser whilst the 
spectrophotometer is closed. Initial testing was carried out using ultrasmall 
UCNPs obtained from our collaborators at Helmholtz-Zentrum Dresden-
Rossendorf, Dr. Julia Hesse and Dr. Holger Stephan. Core particles, Core/Shell 
(C/S) particles and Core/Shell particles coated with OPA of the composition: 
NaYF4: Nd3+/Yb3+/ Tm3+ (Core, 18/0.5/1 mol%) and NaYF4: Nd3+ (Shell, 20 
mol%) were used. TEM images of the core (11.71 ± 0.76 nm) and Core/Shell 
(C/S, 14.87 ± 0.61 nm) particles were taken before recording the emission 
spectra, confirming the average sizes obtained through dynamic light scattering 
measurements in n-hexane (Core: 13.78 ± 2.46 nm, C/S: 17.02 ± 2.92 nm) 
(Figure 5.12). The emission spectra, including selected peak labels, are 
depicted in Figure 5.13. Core, C/S and OPA coated C/S UCNPs exhibit 
emission peaks at 290 nm (Tm3+, 1I6 " 3H6), 346 nm (Tm3+, 1I6 " 3F4), 363 nm 
(Tm3+, 1D2 " 3H6), 452 nm (Tm3+, 4D2 " 3F4), 476 nm (Tm3+, 1G4 " 3H6), 541 
nm (impurity Er3+, 4S3/2 " 4I15/2), 652 nm (Tm3+, 1G4 " 3F4) and 804 nm (Nd3+, 
3F4/2 " 4I9/2) under 980 nm excitation (~200 mW). The emission profiles match 
those of similarly doped UCNPs reported previously, confirming the presence of 
the lanthanide dopants and cover the excitation wavelengths for both the 
platinum (Chapter 2, 3.1, 3.2) and ruthenium (Chapter 3.5, 3.6) complexes 
discussed in this thesis.[12-13] Different concentrations were used to obtain 
signal, as the emission from the water soluble UCNPs suffered from a decrease 
in intensity as expected due to the absorption of NIR light by water and the OPA 
coating. This setup does not allow for additional photophysical measurements. 
Determination of life-time or quantum yield is not possible, as diode lasers are 
continuous wave and have to be refocused after each sample, i.e. identical 
power and focus on each sample is difficult to achieve. 
This setup was developed, tested and approved initially with the use of a 
relatively weak (200 mW, 3 VDC) 980 nm diode laser (class 3b), due to 
stringent regulations regarding the use of (NIR) lasers. Approval was obtained 
over a year after synthesis of the UCNPs, whilst approval of an 800 nm laser 
could not be obtained before travel to the University of Warwick. This setup, 
however, allows for fast screening of the emission profiles under different 
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excitation wavelengths directly after synthesis and is available at Monash 
University, School of Chemistry. 
 
 
Figure 5.11. Simplif ied representation (A) and top view picture (B) of the custom 
sample and laser holder in a Cary Eclipse Fluorescence Spectrophotometer. 
A 
B 
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Figure 5.12. TEM images of NaYF4: Nd3+/Yb3+/Tm3+ (A, B Core) and NaYF4: 
Nd3+@NaYF4: Nd3+/Yb3+/Tm3+ (C, D Core/Shell) particles synthesised by Dr. Julia 
Hesse. 
 
Figure 5.13. Emission spectra including selected peak labels of NaYF4: 
Nd3+/Yb3+/Tm3+ UCNPs in n-hexane (black), NaYF4: Nd3+@NaYF4: Nd3+/Yb3+/Tm3+ 
UCNPs in n-hexane (red) and OPA coated NaYF4: Nd3+@NaYF4: Nd3+/Yb3+/Tm3+ 
UCNPs in water (blue) under 980 nm excitation (~200 mW). 
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5.3 Conclusion 
A range of NaYF4: Nd3+/Yb3+/Tm3+ upconverting nanoparticles were 
synthesised, with measurement and sampling methods optimised. 
A commercially available NIR dye, IR-780, was suitably modified to incorporate 
a carboxylate functionality (IR-806). This allowed for its coupling to LiYF4: 
Yb3+/Tm3+ upconverting nanoparticles in an effort to increase emission intensity 
and broaden the window of excitation wavelengths of these particles. 
Nanoparticles were later coated with octylamine-modified polyacrylic acid to 
render them water-dispersible. 
A range of neodymium (Nd3+) doped nanoparticles were synthesised with a 
theoretical intrinsic property of 800 nm excitation. Perfect hexagonal particles 
with a size of 46.3 ± 3.1 nm were synthesised, which were further optimised to a 
size of 39.0 ± 1.6 nm. Attempts to synthesise ultrasmall nanoparticles (< 10 nm) 
resulted in mixed population of ultrasmall and small (10 – 40 nm) nanoparticles.  
The above mentioned UCNPs would need to be studied by fluorescence 
spectroscopy before further optimisation of dye coupled, core and core-shell 
neodymium doped nanoparticles can be carried out as minor changes to the 
experimental procedure of these nanoparticles can have a large effect on their 
shape and size. Therefore, it is essential to measure the emission profiles and 
lifetimes before further size and shape optimisation. Collaboration was sought 
throughout the candidature but to no avail, thus far. 
In order to progress, the development of custom-made equipment was 
endeavoured to measure emission profiles of the neodymium doped and dye 
coupled upconverting nanoparticles in-house. A single cell holder for a Cary 
Eclipse Fluorescence Spectrophotometer was modified to hold single 
wavelength diode lasers. Due to stringent regulations, the approval of this setup 
was obtained for one 980 nm laser over a year after the particle synthesis and 
optimised core/shell neodymium doped nanoparticles from our collaborators at 
Helmholtz-Zentrum Dresden-Rossendorf were used as a proof of principle. The 
setup enabled fast screening of the emission profiles under different excitation 
wavelengths using inexpensive NIR diode lasers. However, this setup does not 
allow for photophysical measurements, such as life-times and quantum yield 
determination, due to the limitations of diode lasers. 
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5.4 Experimental 
5.4.1 Chemicals 
All reactions were performed under nitrogen atmosphere using standard 
Schlenk techniques. Chemicals and other solvents were purchased from 
Sigma-Aldrich or BioScientific and used as such. 
5.4.2 Instrumentation 
1H-NMR spectra were acquired on a Bruker DRX400 (400 MHz) spectrometer. 
Chemical shifts were referenced to the residual 1H-NMR of deuterated solvents 
in ppm (δ) and the coupling constants are given in Hz. 
 
UV-Vis spectra were acquired on a Varian Cary 5G UV-Vis-NIR 
spectrophotometer for NIR measurements and on a Varian Cary 300 BIO UV-
Vis spectrophotometer equipped with a Varian Cary temperature controller. 
 
Emission spectra were acquired on a Horiba Scientific FluoroMax4 fluorescence 
spectrophotometer. 
 
ESI MS was carried out on a Micromass Platform II coupled to an ESI source 
with a capillary voltage of 3.5 keV and cone voltage of 35 V. 
 
TEM images were acquired on a FEI Tecnai G2 T20 transmission electron 
microscope operated at an acceleration voltage of 200 kV at the Monash Centre 
for Electron Microscopy. ImageJ was used to process TEM images and 
calculate size distributions.[22] 
 
X-ray diffraction (XRD) patterns were acquired on a Philips X-ray diffractometer 
with Cu Kα radiation. 
 
DLS measurements were undertaken on a Brookhaven Instruments Corporation 
(BIC) Zetaplus Zeta Potential Analyzer and processed with BIC particle sizing 
software. 
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5.4.3 Synthesis 
IR-806 
Synthesis of IR-806 was adapted from literature.[16]  
A green solution of IR-780 (50 mg, 0.075 mmol) and 4-mercaptobenzoic acid 
(27 mg, 0.18 mmol) in DMF (5 mL) was stirred for 18 h at RT. Removal of DMF 
under reduced pressure at 50 °C resulted in a dark red residual with a green 
edge. The residue was dissolved in DCM (1 mL) and filtered through a 0.20 µm 
PTFE syringe filter followed by slow addition of diethyl ether (50 mL). Gold 
coloured crystals were collected by centrifugation, washed with diethyl ether 
over a glass frit and dried under vacuum (52 mg, 88%). 1H-NMR (400 MHz, δ in 
CDCl3, 298 K): 8.59 (d, J = 14.1 Hz, 2H), 7.97 (d, J = 8.1 Hz, 2H), 7.34 (t, J = 
8.2 Hz, 2H), 7.26 (t, J = 6.9 Hz, 4H), 7.19 (t, J = 7.4 Hz, 2H), 7.11 (d, J = 8.0 Hz, 
2H), 6.24 (d, J = 14.1 Hz, 2H), 4.10 (t, J = 7.2 Hz, 4H), 2.80 (t, J = 5.7 Hz, 4H), 
2.06 (t, J = 5.6 Hz, 2H), 2.06 (t, J = 5.6 Hz, 2H), 1.88 (sext, 7.4 Hz, 4H), 1.43 (s, 
12H), 1.04 (t, J = 7.4 Hz, 6H). ESI MS m/z (calcd.): 679.4 (679.333 [M – H + 
Na]+), 657.4 (657.351 [M]+). 
 
Calcium di((9Z)-9-octadecenoate) (Ca(oleate)2) 
NaOH (0.9 g, 22 mmol) in 100 mL methanol was added drop wise to a solution 
of CaCl2 (1.1 g, 10 mmol) and oleic acid (7.0 mL, 22 mmol) in 30 mL methanol. 
The reaction mixture was stirred at RT overnight. The white precipitate was 
washed three times with methanol, collected by centrifugation and dried under 
vacuum (2.9 g, 48%). 
 
NaYF4: Yb3+/Tm3+/Nd3+ Nanoparticles 
A range of conditions has been investigated towards the synthesis of the 
nanoparticles. Experimental details are shown in Table 5.1. In a typical 
experiment the rare earth (RE) salts, yttrium, ytterbium, thulium and neodymium 
(80.5:18:0.5:1 mol%) were transferred into a 50 or 100 mL three neck round 
bottom flask using minimal amounts of methanol. After evaporation of methanol, 
oleic acid and 1-octadecene were added followed by heating at 140 °C under 
vacuum until a clear yellow solution was formed. The resulting mixture was 
cooled to 50 °C before NH4F and NaOH (RE:NH4F:NaOH, 1:4:2.5 mol%) was 
added and stirred for 30 min. The reaction temperature was increased to 100 °C 
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to remove methanol. Upon removal of methanol, the temperature was increased 
to 270 or 290 °C at a rate of 450 °C h-1 and maintained at this temperature for a 
set time under N2. The resulting solution was cooled to room temperature at 
450 °C h-1. The resulting nanoparticles were precipitated out by addition of 
ethanol, collected by centrifugation and washed three times with ethanol 
resulting in a brown oil. The nanoparticles were redispersed in n-hexane or 
cyclohexane (~10 wt%) and stored in the fridge. 
 
NaYF4: Ca2+/Yb3+/Tm3+/Nd3+ Nanoparticles 
NaYF4: Ca2+/Yb3+/Tm3+/Nd3+ nanoparticles (80.5:10:18:0.5:1 mol%) were 
synthesised using the same procedure as NaYF4: Yb3+/Tm3+/Nd3+ nanoparticles 
where Ca(oleate)2 was added simultaneously with the RE methanol mixture to 
the round bottom flask. Experimental details are shown in Table 5.1. 
 
LiYF4: Yb3+/Tm3+ Nanoparticles 
Synthesis of LiYF4: Yb3+/Tm3+ nanoparticles was carried out in collaboration 
with Olga Gazukin (Monash University),[17] and adapted from literature.[23] 
Yttrium trifluoroacetate (856 mg, 2.00 mmol), ytterbium trifluoroacetate 
(276 mg, 0.539 mmol), thulium trifluoroacetate (5.08 mg, 0.0100 mmol) and 
lithium trifluoroacetate (300 mg, 2.50 mmol) were added to a three-necked 
round bottom flask followed by addition of oleic acid (20 mL) and 1-octadecene 
(20 mL). The mixture was heated to 110 °C at a rate of 450 °C h-1 at 1200 rpm 
under vacuum for 3 hours. The flask was placed under nitrogen and heated to 
322 °C at a rate of 450 °C h-1 and kept at the temperature for one hour before 
cooling down to RT. The resulting nanoparticles were precipitated out by 
addition of ethanol, collected by centrifugation, redispersed in minimal amounts 
of chloroform and washed three times with ethanol resulting in a yellow oil. 
Size(TEM) = 122±14 nm. λabs max Yb 977 nm. 
 
IR-806 dye adsorption to LiYF4: Yb3+/Tm3+ nanoparticles 
IR-806 (0.049 mg in 2.04 mL CHCl3) was added to a round bottom flask 
containing LiYF4: Yb3+/Tm3+ nanoparticles (6.5 mg) in 0.39 mL CHCl3. The 
reaction was stirred at RT under N2 for 2 hours before addition of 20 mL 
ethanol. The nanoparticles were collected by centrifugation and washed three 
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times with ethanol before drying under vacuum at 40 °C. The green solid was 
stored in the fridge and protected from light. 
In another batch, IR-806 (1.36 mg in 2.00 mL CHCl3) was added to a round 
bottom flask containing LiYF4: Yb3+/Tm3+ nanoparticles (6.5 mg) in 0.80 mL 
CHCl3. The reaction was stirred at RT under N2 for a week, where samples 
were taken for UV-Vis at 4 h, 1, 4 and 7 days before addition of 80 mL of 
ethanol. The nanoparticles were collected by centrifugation and washed three 
times with ethanol before drying under vacuum at 40 °C (13 mg). The green 
solid was stored in the fridge and protected from light. 
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Table 5.1. Experimental details of NaYF4: (Ca2+/) Yb3+/Tm3+/Nd3+ nanoparticle synthesis. 
Sample Scale RE Temp & Timea Yield TEM 
(nm)b 
RRV-
001 
0.4 mmol RE 
9.5 mmol OA (3 mL) 
21.9 mmol ODE (7 mL) 
1.6 mmol NH4F 
1.0 mmol NaOH 
Y(CH3CO2)3 ! xH2O 
Yb(CH3CO2)3 ! xH2O 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
290 °C 
1.5 h 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
0.17 g 58.5 ± 3.4 
nm 
RRV-
011 
0.4 mmol RE 
9.5 mmol OA (3 mL) 
21.9 mmol ODE (7 mL) 
1.6 mmol NH4F 
1.0 mmol NaOH 
Y(CH3CO2)3 ! xH2O 
Yb(CH3CO2)3 ! xH2O 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
Ca(Oleate)2 
290 °C  
1.5 h 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
0.18 g 46.3 ± 3.1 
nm 
 
RRV-
017 
0.4 mmol RE 
9.5 mmol OA (3 mL) 
21.9 mmol ODE (7 mL) 
1.6 mmol NH4F 
1.0 mmol NaOH 
Y(CH3CO2)3 ! xH2O 
Yb(CH3CO2)3 ! xH2O 
Tm(CH3CO2)3 ! xH2O 
Nd(CH3CO2)3 ! xH2O 
290 °C 
1.5 h 
450 °C h-1 heating, 
stir, N2 flow 
450 °C h-1 cooling, 
stir 
0.30 g 39.0 ± 1.6 
nm 
      
RRV-
003 
1.0 mmol RE 
10 mmol OA (3.2 mL) 
37.5 mmol ODE (7 mL) 
4.0 mmol NH4F 
2.5 mmol NaOH 
Y(CH3CO2)3 ! xH2O 
Yb(CH3CO2)3 ! xH2O 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
270 °C  
1.5 h 
450 °C h-1 heating, 
stir 
No controlled 
cooling,  
no stirring 
0.24 g ~4-12 nm 
RRV-
007 
1.0 mmol RE 
10 mmol OA (3.2 mL) 
37.5 mmol ODE (7 mL) 
4.0 mmol NH4F 
2.5 mmol NaOH 
Y(CH3CO2)3 ! xH2O 
Yb(CH3CO2)3 ! xH2O 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
270 °C 
1.5 h 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
0.10 g ~4-20 nm 
OG111 1.0 mmol RE 
10 mmol OA (3.2 mL) 
37.5 mmol ODE (7 mL) 
4.0 mmol NH4F 
2.5 mmol NaOH 
Y(CH3CO2)3 ! xH2O 
Yb(CH3CO2)3 ! xH2O 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
270 °C  
45 min 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
- ~4-40 nm 
RRV-
012 
1.0 mmol RE 
10 mmol OA (3.2 mL) 
37.5 mmol ODE (7 mL) 
4.0 mmol NH4F 
2.5 mmol NaOH 
Y(TFA)3 
Yb(Cl)3 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
270 °C  
15 min 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
0.14 g ~3-10 nm 
RRV-
013 
1.0 mmol RE 
10 mmol OA (3.2 mL) 
37.5 mmol ODE (7 mL) 
4.0 mmol NH4F 
2.5 mmol NaOH 
Y(CH3CO2)3 
Yb(Cl)3 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
270 °C  
15 min 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
0.19 g ~3-10 nm 
RRV-
015 
1.0 mmol RE 
10 mmol OA (3.2 mL) 
37.5 mmol ODE (7 mL) 
4.0 mmol NH4F 
2.5 mmol NaOH 
Y(CH3CO2)3 
Yb(Cl)3 
Tm(CH3CO2)3 ! xH2O 
Nd(CF3SO2)3 
270 °C  
3 h 
450 °C h-1 heating, 
stir 
450 °C h-1 cooling, 
stir 
0.80 g ~3-30 nm 
a stirring is set to 1200 rpm. b Average sizes were calculated using at least 100 individual 
nanoparticles when particles were uniform, ~ = indicates the range of sizes observed be TEM 
when more than one average particle size was present. 
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Octylamine-Modified Polyacrylic Acid (OPA) 
Octylamine-modified polyacrylic acid (OPA) was synthesised as described 
elsewhere.[24] 
 
OPA coating of  LiYF4: Yb3+/Tm3+ nanoparticles 
A five-fold excess of OPA (25 mg) in 5 mL CHCl3 was added to a round bottom 
flask containing LiYF4: Yb3+/Tm3+ nanoparticles (5 mg) in 1 mL CHCl3. The 
reaction mixture was stirred at RT under N2 for 2 hours followed by solvent 
removal under reduced pressure. 20 mL of water was added to the white solid, 
the pH was adjusted to ~ 9 and the mixture was sonicated until fully suspended. 
The resulting reaction mixture was filtered through a 0.2 µm PTFE syringe filter, 
spin dialysed using a 50 kDa centrifugal filters and washed three times with 
water using the same filter. The transparent concentrated solutions were stored 
in the fridge. 
 
OPA coating and IR-806 dye adsorption to LiYF4: Yb3+/Tm3+ nanoparticles 
IR-806 was attached to LiYF4: Yb3+/Tm3+ nanoparticles at different ratios and 
coated with OPA (Table 5.2). A stock solution of IR-806 (4.16 mg in 5 mL 
CHCl3) was used. IR-806 was added to a solution of LiYF4: Yb3+/Tm3+ 
nanoparticles in 15 mL CHCl3 and the resulting green mixtures were stirred at 
RT under N2 for 3 hours. An excess of OPA in 1.2 mL CHCl3 was added to the 
reaction mixture and stirred at RT under nitrogen for 2 hours followed by solvent 
removal under reduced pressure. 15 mL of water was added to the green solid, 
the pH was adjusted to ~ 9 and the mixture was sonicated until fully suspended. 
The resulting reaction mixture was filtered through a 0.2 µm PTFE syringe filter, 
spin dialysed using a 50 kDa centrifugal filter and washed three times with 
water using the same filter. Note that the filtrate of sample 1 and 2 was slightly 
green after the final third wash. The green concentrated solutions were stored in 
the fridge and protected from light.  
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Table 5.2. Experimental details of OPA coating and IR-806 dye adsorption to LiYF4: Yb3+/Tm3+ 
nanoparticles. 
Sample Ratio (NP:IR-806) NP (mg) IR-806 (mg) OPA (mg) 
1 25:1 5.91 0.24 24 
2 50:1 7.48 0.15 31 
3 100:1 12.46 0.12 52 
4 150:1 5.96 0.04 25 
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Chapter 6 
Conclusion and Future Perspectives 
The requirement for more effective anticancer drugs is clear, and new classes 
of metal-based photoactivatable prodrugs might provide the necessary means 
to overcome the current drawbacks, on account of their novel mechanism(s) of 
action. However, a viable and improved chemotherapeutic agent is very rarely 
revealed in the first round of discovery. Studying the mechanisms of action can 
provide invaluable information for the development of more potent prodrugs and 
yield experimental evidence on how to modify screened candidates. 
Vibrational spectroscopic approaches were used throughout this thesis to study 
the photophysical and photochemical properties of metal-based 
photoactivatable anticancer prodrugs, centred around the potent diazido Pt(IV) 
prodrug candidate. These techniques reasserted the excellent capabilities of 
vibrational spectroscopy to study such prodrugs whilst being non-destructive 
and label-free. 
In this thesis, the comprehensive vibrational spectroscopic screening of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, py = pyridine) followed by the 
subsequent mechanism of action studies of 1 have been described (Chapter 2 
and Chapter 3.1, 3.2 respectively). Alike methodologies were applied to study a 
series of ruthenium CO releasing complexes (Chapter 3.5, 3.6). The 
high-brilliance of synchrotron radiation was exploited by infrared spectroscopy 
further examining the photoactivation and in vitro activity of 1 (Chapter 4). 
Finally, the preparation of upconverting nanoparticles (UCNPs) was examined 
towards their potential application in combination with photoactivatable prodrug 
candidates (Chapter 5). 
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The work presented in this thesis can be summarised based on the previously 
noted research objectives in Chapter 1.7. Where appropriate, further work is 
also suggested. 
 
1. Explore the vibrational fingerprint of the photoactivatable Pt(IV) prodrug 
candidate, trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1, py = pyridine), with a 
series of vibrational spectroscopic techniques as the essential first step 
towards monitoring the photoactivation pathways. 
 
The ligand (pyridine, hydroxide and azide) and Pt-ligand vibrations of 1 were 
recorded by Attenuated Total Reflection Fourier Transform Infrared (ATR-FTIR), 
Raman and transmission synchrotron radiation far-infrared (SR-FIR) and were 
assigned by comparison to the synthetic precursors trans-[Pt(N3)2(py)2] and 
trans-[PtCl2(py)2] (Chapter 2). Assignments of vibrational modes were aided by 
Density Functional Theory (DFT) calculations, with experimental data consistent 
with the predicted values. Notably, are the strong platinum to oxygen stretching 
vibrations, ν(OHPt-OH) (540 cm-1) and the platinum to nitrogen stretching 
vibrations, ν(Pt-N3) (415 – 395 cm−1) by SR-FIR, which are likewise Raman 
active. Furthermore, multiple strong anti-symmetric azido stretching vibrations, 
νasym(N3) (2048 cm-1 and 2033 cm-1) and a sharp hydroxido stretching vibration, 
ν(OHPt-OH) (3551 cm-1) were observed by ATR-FTIR after the deposition of 1 in 
water (2 mM).  
 
This essential first step allowed for translation of the described methodologies 
into further application in photodecomposition and photoreaction studies. 
 
2. Translation of the vibrational signatures to support photodecomposition 
and photoinduced binding studies of 1 and subsequently apply these 
methods to other metal-based PACT candidates. 
 
New insights into the mechanism of action of 1 were elucidated by a 
combination of ATR-FTIR, transient electronic absorption spectroscopy (TEAS) 
and UV-Vis spectroscopy (Chapter 3.1, 3.2). Following the selected results in 
Figure 6.1, a multistep mechanism could be assigned to the 
photodecomposition of 1 in water upon 420 nm irradiation. Principal Component 
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Analysis (PCA) correlated the removal of ν(OHPt-OH) at 3550 cm-1 to a -10 cm-1 
decrease to νasym(N3), prior to an increase of 21 cm-1 upon complete 
disappearance of ν(OHPt-OH). At the same time, the formation of a new broad 
δ(OHPt-OH/OH2) vibration at 1381 cm-1 and 1334 cm-1 correlates to the single 
νasym(N3) vibration at 2044 cm-1, with gradual increase of δ(OHPt-OH/OH2) until 
νasym(N3) is completely removed. Additional HPLC and Multi Curve Resolution 
Alternating Least Squares (MCR-ALS) on ATR-FTIR and UV-Vis spectra 
suggested the formation of a trans-[Pt(N3)(py)2(OH/H2O)] intermediate and a 
final product, trans-[Pt(py)2(OH/H2O)2]. Studies carried out in acetonitrile for 1 
and its synthetic precursor trans-[Pt(N3)2(py)2] showed similar 
photodecomposition pathways with analogous intermediate species, verified by 
the pure components obtained with MCR-ALS. TEAS to study the fast 
photomechanics of 1 provided a plausible switching mechanism where the 
excited state complex has access to a dissociative 3MC state only when it is 
vibrationally hot. Consecutively, 1 gets trapped in a vibrationally cool state 
resulting in a long-lived absorption (>> 2 ns). Extending on reactivity of 1 were 
the photoinduced reactions in the presence of the DNA nucleotide, 5’-guanosine 
monophosphate (5’-GMP). These studies revealed the faster removal of 
ν(OHPt-OH) compared to the photodecomposition (≤ 5 min vs. 20 min) and 
increased hydrogen bonding between the hydroxide ligands of 1 and 5’-GMP 
and/or water prior to irradiation. HPLC separation of the photoproducts allowed 
for the mass spectrometry and ATR-FTIR characterisation. Aided by frequency 
calculations of DFT optimised photoproducts, marker bands for the major 
photoproducts trans-[Pt(N3)(py)2(5’-GMP)] and trans-[Pt(py)2(5’-GMP)2] were 
deduced and marker bands at 1772 cm-1, for example, could be used to follow 
the formation of the latter product in the reaction mixture by ATR-FTIR. 
 
Successful translation of the ATR-FTIR methodology to study the steady state 
photodecomposition showed evidence of subsequent azido dissociation from 
platinum, which suggests that at least one hydroxyl radical is formed in the 
reduction of Pt(IV) to Pt(II) under such conditions. TEAS revealed several 
characteristics of the complicated fast photodynamics. However, TEAS is blind 
to the formation of photoproducts, thus paving the way for more comprehensive 
ultrafast photodynamic studies (transient vibrational spectroscopy) in 
combination with DFT calculations. The optimisation of singlet and triplet 
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excited state structures by TD-DFT via vertical excitation of the corresponding 
ground states could provide essential information on excited state energies, 
which can potentially be measured with transient infrared spectroscopy, 
focussing on the azido and hydroxido ligand vibrations. The photoinduced 
reactions with 5’-GMP can contribute to understanding the chemical basis for 
the mechanism of action of 1 with DNA bases. This could be followed up with 
studies using short oligonucleotides as a DNA model to complement previous 
DNA binding studies of 1, opening up the option to detect the interactions of 
released ligands as potential azide anions or radicals. 
 
 
Figure 6.1 Summary of the photodecomposition pathway of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) derived from ATR-FTIR and UV-Vis 
spectroscopy complemented by PCA and MCR-ALS analysis as outl ined in 
Chapter 2, 3.1 and 3.2. Only selected ATR-FTIR vibrations are shown for clarity. 
Notations used: ν  = stretch, δ  = in-plane angle bending, x  = complete removal of 
vibration, MeCN = acetonitri le. The description of the pyridine mode is given in 
Wilson’s notations, as described previously in Chapter 2. 
 
Likewise, the methods described above for ATR-FTIR and UV-Vis spectroscopy 
were essential for the exploration of the fundamental understanding of the 
photodecarbonylation of a series of ruthenium complexes of the formula 
[RuLCl2(CO)2] (L = 4,4′-dimethyl-2,2′-bipyridine, 4′-methyl-2,2′-bipyridine-4-
carboxylic acid or 2,2′-bipyridine-4,4′-dicarboxylic acid). Decarbonylation of the 
first CO ligand in acetonitrile occurred on a rapid time-scale (k1 ≫ 3 min−1), to 
an extent that the steady state UV-Vis spectroscopy did not allow for 
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determination of the influence of the electron-donating/withdrawing groups 
attached to the bipyridine ligand by MCR-ALS. Subsequent release of the 
second CO ligand proved to be substantially slower (k2 = 0.099 – 0.17 min−1) 
exposing the reduction in rates caused by the electron withdrawing carboxyl 
substituents on bipyridine. These groups increase the absorption wavelength 
maxima, thus potentially enabling more ‘’biologically friendly’’ longer-wavelength 
excitation (red – near-infrared). However, careful consideration is required when 
using acetonitrile, as the rate of CO release was found to be significantly slower 
in aqueous media using identical protocols (k1 = 0.46 – 2.0 min−1, k2 = 0.026 – 
0.035 min−1), once more emphasising results obtained with organic solvents 
might be an incomplete model for biological applications. 
 
3. Methodological plus instrumental development and utilisation of 
synchrotron based infrared techniques to study metal-based PACT 
candidates, outlined by 1, in an effort trying to overcome the limitations of 
bench-top infrared equipment. 
 
Synchrotron based infrared studies were undertaken to acquire otherwise 
difficult to obtain spectra of far-infrared metal to ligand vibrations and mid-
infrared live cells with unprecedented signal-to-noise levels. The results 
obtained with transmission SR-FIR outlined in Chapter 2 and the maintained 
focus on the mechanism of action of 1 instigated the combination of ATR and 
SR-FIR. A custom built in vacuo Synchrotron Radiation Attenuated Total 
Reflection Far-Infrared (SR-ATR-FIR) setup was developed, which significantly 
reduced the turnover time between samples, from ~30 min – 2 h, to 5 – 10 min, 
of which the majority of the time now consisted of pumping down to ≤ 10-4 mbar 
rather than sample preparation. SR-ATR-FIR spectra for 1 and its synthetic 
precursors were directly compared to the transmission SR-FIR spectra and are 
in good agreement. The in vacuo setup and limited beamtime restricted a full 
study, as described in Chapter 3.1, due to extended amounts of time to reach 
adequate vacuum level to use SR after samples were deposited on the ATR 
crystal. This could eventually be circumvented with the out-of-vacuum SR-ATR-
FIR setup, but this setup was not completed prior to the end of PhD 
candidature. Nevertheless, the development of a new beamline accessory, 
funded, built and available for use by all synchrotron applicants as of round 3, 
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2017 at the THz/Far-Infrared beamline (Australian Synchrotron), is a reflection 
of the efforts made throughout this thesis. 
Testing of new diamond window liquid cells for the in situ irradiation of samples 
by transmission SR-FIR revealed reflection artefacts, which hampered the 
detection of weak and low intensity vibrations in solution due to noise in the 
baselines. Elevated concentrations of 1 in dimethyl sulfoxide (DMSO, 76 mM) 
did allow for in situ photodecomposition to be carried out under 355 nm 
irradiation. The decrease of both the ν(Pt-N3) at 559 cm-1 and ν(Pt-OH) at 409 
cm-1 occurred rapidly in the first five minutes and no apparent difference in rate 
of removal was observed. A new peak was observed at 419 cm-1, which is 
identical to one of the ν(Pt-N3) vibrations of 1 observed after 10 minutes of 
irradiation by SR-ATR-FTIR. In Chapter 3.1, an increase in νasym(N3) vibration of 
1 was assigned to one of the photodecomposition intermediates, 
[Pt(N3)(py)2(solvent)]. This could be a possible intermediate formed in this work. 
Live cell studies of 1 on acute myeloid leukaemia cells (K562) by Synchrotron 
Radiation Infrared Microspectroscopy (SR-IRMS) revealed significant changes 
to the DNA base stacking and lipid vibrations, already at 4 hours after drug 
treatment and irradiation. This was not observed or to a lesser extent for the 
controls. The observed changes to the DNA basepairing, A-DNA and ribose 
vibrations support the proposition that 1 alters the conformational structures of 
DNA significantly and rapidly, in line with previous studies in which rapid 
accumulation of platinum inside the nucleus is observed upon irradiation of 1. 
 
The apparent next study should be photodecomposition studies by out-of-
vacuum SR-ATR-FIR, to allow for substantial complementary evidence of the 
outlined mechanism of action by mid-infrared ATR-FTIR in Figure 6.1. 
Furthermore, the results outlined in Chapter 3 are not directly comparable to the 
transmission SR-FIR studies due to use of different solvents, concentrations 
and irradiation wavelength and do require further investigation in order to draw 
any conclusions. However, the SR-FIR results might suggest that the hydroxido 
ligands undergo chemical changes prior to release, which cannot be monitored 
by the ν(OHPt-OH) in the mid-infrared region. Therefore, further optimisation of 
the diamond window liquid cell is essential, also highlighted by the work carried 
out on CT-DNA, suffering from irreproducibility. The artefacts could potentially 
be overcome by the development of algorithms that can correct for the fringes in 
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the case of pattern recognition and/or in combination of reducing the fringing 
effects by systematic increase/decrease of the angles between the windows. 
Additional cell study attempts were carried out at both Monash University and 
the University of Warwick in order to complement the obtained results of 1 in 
K562 cells by SR-IRMS. However, poor sustainability of the cell line did not 
allow for successful studies by ATR-FTIR or cell viability studies. At the same 
time, cell studies on different cell lines are of interest to compare reported 
antiproliferative activities to the observed vibrational changes in an effort to 
identify possible intracellular targets of 1. Raman spectroscopy, infrared 
microspectroscopy, ATR-FTIR and Atomic Force Microscopy IR are potentially 
powerful techniques to carry out such studies. 
 
4. Synthesis and optimisation of UCNPs as a platform for addressing the 
wavelength activation of PACT candidates to a clinically-relevant 
window. 
 
Current clinically available light sources commonly include photodynamic 
therapy lasers ranging from red to near-infrared wavelengths. Optimum 
penetration depths into tissue can be achieved using approx. 800 nm light. 
Thus, a range of lanthanide-doped UCNPs were synthesised to allow for visible 
light emission matching the absorbance of photoactivatable metal-based 
complexes. Emphasis was placed on the clinical relevance of UCNPs by 
targeting water-dispersible, ultrasmall (< 10 nm to reduce spleen and liver 
accumulation), hexagonal shaped (highest quantum yields) nanoparticles that 
allow for 800 nm excitation. Perfect hexagonal UCNPs were obtained at a 
smallest size of 39.0 ± 1.6 nm; mixed populations of 10 – 40 nm UCNPs were 
obtained when attempting to go ultrasmall sizes (< 10 nm). Both neodymium 
doping and coupling of a near-infrared dye to the nanoparticles afforded water-
dispersible UCNPs theoretically capable of 800 nm excitation and UV and blue 
light emission. Minor changes to the synthesis procedures have a large effect 
on the resulting shape and size. Therefore, confirming the theoretical emission 
with experimental proof was essential. In the absence of available equipment, 
an in-house setup was developed to measure the emission of UCNPs using 
diode lasers and experimental emission wavelengths of thulium (290 nm, 346 
nm, 363 nm, 452 nm, 476 nm, 541 nm and 652 nm) and neodymium (804 nm). 
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Previous reported studies, as outlined in Chapter 1.6, revealed the retained in 
vitro and in vivo antiproliferative activity of diazido Pt(IV) complexes when 
incorporated onto UCNPs, allowing for near-infrared activation of the prodrugs. 
However, the in vivo effectiveness of nanoparticles has mainly been hampered 
by accumulation of UCNPs in the liver and spleen. Therefore, continued effort is 
essential to address the factors effecting accumulation, such as size and 
surface (charge) modifications. 
